Gene expression in biological conditions

Information

  • Patent Application
  • 20040038917
  • Publication Number
    20040038917
  • Date Filed
    March 11, 2003
    21 years ago
  • Date Published
    February 26, 2004
    20 years ago
Abstract
The present invention relates to a method of determining the presence or absence of a biological condition in animal tissue, wherein the expression of genes in normal tissue and tissue from the biological condition is examined and correlated to standards. The invention further relates to the treatment of the biological condition and an assay for determining the condition. More particularly the invention concerns gene expression in epithelial tissue, such as urianry bladder under both normal and abnormal conditions.
Description


TECHNICAL FIELD OF THE INVENTION

[0001] The present invention relates to a method of determining the presence or absence of a biological condition in animal tissue, wherein the expression of genes in normal tissue and tissue from the biological condition is examined and correlated to standards. The invention further relates to the treatment of the biological condition and an assay for determining the condition.



BACKGROUND

[0002] The building of large databases containing human genome sequences is the basis for studies of gene expressions in various tissues during normal physiological and pathological conditions. Constantly (constitutively) expressed sequences as well as sequences whose expression is altered during disease processes are important for our understanding of cellular properties, and for the identification of candidate genes for future therapeutic intervention. As the number of known genes and ESTs build up in the databases, array-based simultaneous screening of thousands of genes is necessary to obtain a profile of transcriptional behaviour, and to identify key genes that either alone or in combination with other genes, control various aspects of cellular life. One cellular behaviour that has been a mystery for many years is the malignant behaviour of cancer cells. It is now known that for example defects in DNA repair can lead to cancer but the cancer-creating mechanism in heterozygous individuals is still largely unknown as is the malignant cell's ability to repeat cell cycles to avoid apoptosis to escape the immune system to invade and metastasize and to escape therapy. There are indications in these areas and excellent progress has been made, buth the myriad of genes interacting with each other in a highly complex multidimensional network is making the road to insight long and contorted.


[0003] Similar appearing tumors—morphologically, histochemically, microscopically—can be profoundly different. They can have different invasive and metastasizing properties, as well as respond differently to therapy. There is thus a need in the art for methods which distinguish tumors and tissues on factors different than those currently in clinical use.


[0004] The malignant transformation from normal tissue to cancer is believed to be a multistep process, in which tumorsuppressor genes, that normally repress cancer growth show reduced gene expression and in which other genes that encode tumor promoting proteins (oncogenes) show an increased expression level. Several tumor suppressor genes have been identified up till now, as e.g. p16, Rb, p53 (Nesrin Ozbren and Wafik S. El-Deiry, Introduction to cancer genes and growth control, In: DNA alterations in cancer, genetic and epigenetic changes, Eaton publishing, Melanie Ehrlich (ed) p. 1-43, 2000.; and references therein). They are usually identified by their lack of expression or their mutation in cancer tissue.


[0005] Other examinations have shown this downregulation of transcripts to be partly due to loss of genomic material (loss of heterozygosity), partly to methylation of promo-torregions, and partly due to unknown factors (Nesrin Ozbren and Wafik S. El-Deiry, Introduction to cancer genes and growth control, In: DNA alterations in cancer, genetic and epigenetic changes, Eaton publishing, Melanie Ehrlich (ed) p. 1-43, 2000.; and references therein).


[0006] Several oncogenes are known, e.g. cyclinD1/PRAD1/BCL1, FGFs, c-MYC, BCL-2 all of which are genes that are amplified in cancer showing an increased level of transcript (Nesrin Özören and Wafik S. El-Deiry, Introduction to cancer genes and growth control, In: DNA alterations in cancer, genetic and epigenetic changes, Eaton publishing, Melanie Ehrlich (ed) p. 1-43, 2000.; and references therein). Many of these genes are related to cell growth and directs the tumor cells to uninhibited growth. Others may be related to tissue degradation as they e.g. encode enzymes that break down the surrounding connective tissue.



SUMMARY OF THE INVENTION

[0007] In one aspect the present invention relates to a method of determining the presence or absence of a biological condition in animal tissue comprising


[0008] collecting a sample comprising cells from the tissue and/or expression products from the cells,


[0009] assaying a first expression level of at least one gene from a first gene group, wherein the gene from the first gene group is selected from genes expressed in normal tissue cells in an amount higher than expression in biological condition cells, and/or


[0010] assaying a second expression level of at least one gene from a second gene group, wherein the second gene group is selected from genes expressed in normal tissue cells in an amount lower than expression in biological condition cells,


[0011] correlating the first expression level to a standard expression level for normal tissue, and/or the second expression level to a standard expression level for biological condition cells to determine the presence or absence of a biological condition in the animal tissue.


[0012] Animal tissue may be tissue from any animal, preferably from a mammal, such as a horse, a cow, a dog, a cat, and more preferably the tissue is human tissue. The biological condition may be any condition exhibiting gene expression different from normal tissue. In particular the biological condition relates to a malignant or premalignant condition, such as a tumor or cancer.


[0013] Furthermore, the invention relates to a method of determining the stage of a biological condition in animal tissue,


[0014] comprising collecting a sample comprising cells from the tissue,


[0015] assaying the expression of at least a first stage gene from a first stage gene group and at least a second stage gene from a second stage gene group, wherein at least one of said genes is expressed in said first stage of the condition in a higher amount than in said second stage, and the other gene is expressed in said first stage of the condition in a lower amount than in said second stage of the condition,


[0016] correlating the expression level of the at least two genes to a standard level of expression determining the stage of the condition.


[0017] Thereby, it is possible to determine the biological condition in more details, such as determination of a stage and/or a grade of a tumor.


[0018] The methods above may be used for determining single gene expressions, however the invention also relates to a method of determining an expression pattern of a cell sample, comprising:


[0019] collecting sample comprising bladder cells and/or expression products from bladder cells,


[0020] determining the expression level of at least one gene in the sample, wherein at least one gene belongs to a first group of genes, said gene from the first gene group being expressed in a higher amount in normal tissue than in biological condition cells, and wherein at least one other gene belongs to a second group of genes, said gene from the second gene group being expressed in a lower amount in normal tissue than in biological condition cells, and the difference between the expression level of the first gene group in normal cells and biological condition cells being at least two-fold, obtaining an expression pattern of the bladder cell sample.


[0021] Gene expression patterns may rely on one or a few genes, but more preferred gene expression patterns relies on expression from multiple genes, whereby a combined information from several genes is obtained.


[0022] Further, the invention relates to a method of determining an expression pattern of a bladder cell sample independent of the proportion of submucosal, muscle, or connective tissue cells present, comprising:


[0023] determining the expression of one or more genes in a sample comprising cells, wherein the one or more genes exclude genes which are expressed in the submucosal, muscle, or connective tissue, whereby a pattern of expression is formed for the sample which is independent of the proportion of submucosal, muscle, or connective tissue cells in the sample.


[0024] The expression pattern may be used in a method according to this information, and accordingly, the invention also relates to a method of determining the presence or absence of a biological condition in human bladder tissue comprising,


[0025] collecting a sample comprising cells from the tissue,


[0026] determining an expression pattern of the cells as defined above,


[0027] correlating the determined expression pattern to a standard pattern,


[0028] determining the presence or absence of the biological condition in said tissue.


[0029] as well as a method for determining the stage of a biological condition in animal tissue, comprising


[0030] collecting a sample comprising cells from the tissue,


[0031] determining an expression pattern of the cells as defined above,


[0032] correlating the determined expression, pattern to a standard pattern,


[0033] determining the stage of the biological condition is said tissue.


[0034] The invention further relates to a method for reducing cell tumorigenicity or malignancy of a cell, said method comprising


[0035] contacting a tumor cell with at least one peptide expressed by at least one gene selected from genes being expressed in an amount at least two-fold higher in normal cells than the amount expressed in said tumor cell, or


[0036] comprising


[0037] obtaining at least one gene selected from genes being expressed in an amount at least two-fold higher in normal cells than the amount expressed in said tumor cell,


[0038] introducing said at least one gene into the tumor cell in a manner allowing expression of said gene(s), or


[0039] obtaining at least one nucleotide probe capable of hybridising with at least one gene of a tumor cell, said at least one gene being selected from genes being expressed in an amount one-fold lower in normal cells than the amount expressed in said tumor cell, and


[0040] introducing said at least one nucleotide probe into the tumor cell in a manner allowing the probe to hybridise to the at least one gene, thereby inhibiting expression of said at least one gene.


[0041] In a further aspect the invention relates to a method for producing antibodies against an expression product of a cell from a biological tissue, said method comprising the steps of


[0042] obtaining expression product(s) from at least one gene said gene being expressed as defined above,


[0043] immunising a mammal with said expression product(s) obtaining antibodies against the expression product.


[0044] The antibodies produced may be used for producing a pharmaceutical composition. Further, the invention relates to a vaccine capable of eliciting an immune response against at least one expression product from at least one gene said gene being expressed as defined above.


[0045] The invention furthermore relates to the use of any of the methods discussed above for producing an assay for diagnosing a biological condition in animal tissue.


[0046] Also, the invention relates to the use of a peptide as defined above as an expression product and/or the use of a gene as defined above and/or the use of a probe as defined above for preparation of a pharmaceutical composition for the treatment of a biological condition in animal tissue.


[0047] In yet a further aspect the invention relates to an assay for determining the presence or absence of a biological condition in animal tissue, comprising


[0048] at least one first marker capable of detecting a first expression level of at least one gene from a first gene group, wherein the gene from the first gene group is selected from genes expressed in normal tissue cells in an amount higher than expression in biological condition cells, and/or


[0049] at least one second marker capable of detecting a second expression level of at least one gene from a second gene group, wherein the second gene group is selected from genes expressed in normal tissue cells in an amount lower than expression in biological condition cells.


[0050] In another aspect the invention relates to an assay for determining an expression pattern of a bladder cell, comprising at least a first marker and and/or a second marker, wherein the first marker is capable of detecting a gene from a first gene group as defined above, and the second marker is capable of detecting a gene from a second gene group as defined above.







DRAWINGS

[0051] FIGS. 1-4. Describes genes that were only present (P) in normal urothelium and absent (A) from the other four samples (samples 1, 2, 3, 4, 5 scored as P, A, A, A, A), genes that were present in normal and superficial tumors and absent from the others (PP,AAA) etcetera. These genes could for example encode tumor inhibitors, or stage specific genes.


[0052]
FIG. 5. Genes that are decreased (D) in tumors compared with normal urothelium (P,D,D,D,D). These could encode tumor inhibitors.


[0053]
FIG. 6. Genes that are increased >3 fold in all tumor compared to normal. Encode Tumor associated proteins.


[0054]
FIG. 7. Genes that are scored as PPPPA but decreased in all tumors and finally absent in the most malignant solid tumor.


[0055]
FIG. 8. Genes that lose expression in the muscle invasive tumors, PPPAA.


[0056]
FIG. 9. Genes that re lost in slightly invasive tumors, PPAAA


[0057]
FIG. 10. Genes that are increased in expression level in all tumors, APPPP. Tumor specific genes.


[0058]
FIG. 11. Genes that are turned on in all invasive tumors, AAPPP.


[0059]
FIG. 12. Genes that are associated with muscle invasive tumors. AAAPP.


[0060]
FIG. 13. Genes that identify solid tumors only AAAAP.


[0061]
FIG. 14. Genes that identify mixed tumors solid/papillom of invasive type. AAAPA.


[0062]
FIG. 15. Genes that identify T1 tumors. AAPAA


[0063]
FIG. 16. Genes that identoify superficial tumors APAAA


[0064]
FIG. 17 shows the absolute level (called average difference) of appr. 18,000 Expressed Sequence Tags.


[0065]
FIG. 18 shows western blots based on antibodies raised against synthetic peptides selected from the EST sequence.







DETAILED DESCRIPTION OF THE INVENTION

[0066] Samples


[0067] The samples according to the present invention may be any tissue sample, it is however often preferred to conduct the methods according to the invention on epithelial tissue, such as epithelial tissue from the bladder. In particular the epithelial tissue may be mucosa.


[0068] The sample may be obtained by any suitable manner known to the man skilled in the art, such as a biopsy of the tissue, or a superficial sample scraped from the tissue. The sample may be prepared by forming a cell suspension made from the tissue, or by obtaining an extract from the tissue.


[0069] In one embodiment it is preferred that the sample comprises substantially only cells from said tissue, such as substantially only cells from mucosa of the bladder.


[0070] Biological Condition


[0071] The methods according to the invention may be used for determining any biological condition, wherein said condition leads to a change in the expression of at least one gene, and preferably a change in a variety of genes.


[0072] Thus, the biological condition may be any malignant or premalignant condition, in particular in bladder, such as a tumor or an adenocarcinoma, a carcinoma, a teratoma, a sarcoma, and/or a lymphoma, and/or carcinoma-in-situ, and/or dysplasia-in-situ.


[0073] Single Gene Expression Contra Expression Pattern


[0074] The expression level may be determined as single gene approaches, i.e. wherein the determination of expression from one or two or a few genes is conducted. It is preferred that expression from at least one gene from a first (normal) group is determined, said first gene group representing genes being expressed at a higher level in normal tissue, i.e. so-called suppressors, in combination with determination of expression of at least one gene from a second group, said second group representing genes being expressed at a higher level in tissue from the biological condition than in normal tissue, i.e. so-called oncogenes. However, determination of the expression of a single gene whether belonging to the first group or second group is within the scope of the present invention. In this case it is preferred that the single gene is selected among genes having a high change in expression level from normal cells to biological condition cells.


[0075] Another approach is determination of an expression pattern from a variety of genes, wherein the determination of the biological condition in the tissue relies on information from a variety of gene expression, i.e. rather on the combination of expressed genes than on the information from single genes.


[0076] Bladder Tumors


[0077] The following data presented herein relates to bladder tumors, and therefore the description has focused on the gene expression level as one way of identifying genes that lose or gain function in cancer tissue. Genes showing a remarkable downregulation (or complete loss) or upregulation (gene expression gained de novo) of the expression level—measured as the mRNA transcript, during the malignant progression in bladder from normal mucosa through Ta superficial tumors to T1, slightly invasive tumors, to T2, T3 and T4 which have spread to muscle or even further into lymph nodes or other organs are within the scope of the invention, as well as genes gaining importance during the differentiation from normal towards malignancy.


[0078] Gene Groups


[0079] The present invention relates to a variety of genes identified either by an EST identification number and/or by a gene identification number. Both type of identification numbers relates to identification numbers of UniGene database, NCBI, build 18.


[0080] The various genes have been identified using Affymetrix arrays of the following product numbers:


[0081] HU35K SubA 900 184


[0082] HU35K SubB 900 185


[0083] First Gene Group


[0084] The first gene group relates to at least one, such as at least two, for example at least three, such as at least four, such as at least five, such as more than six genes being expressed in normal tissue cells in an amount higher than expression in biological condition cells. The term “normal tissue cells” relates to cells from the same type of tissue that is examined with respect to the biological condition in question. Thus, with respect to bladder tumors, the normal tissue relates to bladder tissue, in particular to normal bladder mucosa.


[0085] The first gene group therefore relates to genes being downregulated in tumors, such genes being expected to serve as tumor suppressor genes, and they are of importance as predictive markers for the disease as loss of one or more of these may signal a poor outcome or an aggressive disease course. Furthermore, they may be important targets for therapy as restoring their expression level, e.g. by gene therapy, or substitution with those peptide products or small molecules with a similar biological effect may suppress the malignant growth.


[0086] For a bladder tissue sample a gene from the first gene group is preferably selected individually from genes comprising a sequence as identified below by EST
1AA131127_atzo16a05.r1 Stratagene colon (#937204) Homo sapiens cDNAclone 587024 5′ similar to SW: CATX_BOVIN P05689 CATHEPSIN;.AA372630_s_atEST84548 Colon adenocarcinoma IV Homo sapiens cDNA 5′end.AA434329_atzw24g07.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 770268 5′ similar to contains element TAR1 repetitive element;.C01409_s_atHUMGS0008391, Human Gene Signature, 3′-directed cDNAsequence.RC_AA256485_atzr81e12.s1 Soares NhHMPu S1 Homo sapiens cDNA clone682126 3′.RC_AA290679_atzt19f03.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 713597 3′ similar to TR: E92665 E92665 AP56;.RC_AA429655_atzw71d04.s1 Soares testis NHT Homo sapiens cDNA clone781639 3′.RC_AA452410_atzx31f03.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 788093 3′.RC_AA461174_atzx70c04.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 796806 3′.RC_AA491463_atab01d12.s1 Stratagene fetal retina 937202 Homo sapiens cDNAclone 839543 3′.RC_AA025434_atze84f10.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 365707 3′.RC_AA026030_atze84d01.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 365665 3′ similar to PIR: A48764 A48764 calpain;.RC_AA054321_szl68c01.s1 Stratagene colon (#937204) Homo sapiens cDNAatclone 509760 3′.RC_AA099820_atzk87c05.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 489800 3′.RC_AA161043_atzo74g11.s1 Stratagene pancreas (#937208) Homo sapiens cDNA clone 592676 3′.RC_AA215379_atzr97c07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 683628 3′.RC_H09281_atyl98f11.s1 Homo sapiens cDNA clone 46316 3′.RC_H18836_atym45d10.s1 Homo sapiens cDNA clone 51262 3′.RC_H52937_atyq76e12.s1 Homo sapiens cDNA clone 201742 3′ similar togb: J02982 GLYCOPHORIN B PRECURSOR (HUMAN);.RC_H69547_atyr89e02.s1 Homo sapiens cDNA clone 212474 3′.RC_H95039_atyv20a05.s1 Homo sapiens cDNA clone 243248 3′.RC_N21687_atyx63h03.s1 Soares melanocyte 2NbHM Homo sapiens cDNAclone 266453 3′.RC_N54841_atyv73b09.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 248345 3′.RC_N59622_atyv74b06.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 248435 3′.RC_N66312_atyz38a06.s1 Homo sapiens cDNA clone 285298 3′.RC_N90717_atza90a10.s1 Soares fetal lung NbHL19W Homo sapiens cDNAclone 299802 3′.RC_R22189_atyh26a02.s1 Homo sapiens cDNA clone 130826 3′.RC_R53457_atyg83e10.s1 Homo sapiens cDNA clone 39835 3′.RC_T53389_s_atya88f04.s1 Homo sapiens cDNA clone 68767 3′.RC_W86375_s_atzh55a02.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 415946 3′.RC_Z38289_atH. sapiens partial cDNA sequence; clone c-05e04.


[0087] or a sequence as identified below
2RC_AA621122_ataf34f04.s1 Soares total fetus Nb2HF8 9wHomo sapiens cDNA clone 1033567 3′.RC_AA129216_atzn84b03.s1 Stratagene lung carcinoma937218 Homo sapiens cDNA clone 564845 3′.RC_AA133214_szk97h05.s1 Soares pregnantatuterus NbHPU Homo sapiens cDNA clone 490809 3′.RC_H99675_atyx35c02.s1 Homo sapienscDNA clone 263714 3′.RC_R87160_atyq31h10.s1 Homo sapiens cDNA clone197443 3′.


[0088] or a sequence as identified below
3RC_AA429904_atzw66d03.s1 Soares testis NHTHomo sapiens cDNA clone 781157 3′.


[0089] or a sequence as identified below
4RC_AA460273_atzx67f05.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 796545 3′.RC_AA490930_ataa46e04.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 823998 3′.RC_AA418072_atzv97g08.s1 Soares NhHMPu S1 Homo sapiens cDNA clone767774 3′.RC_H61476_s_atyr17e08.s1 Homo sapiens cDNA clone 205574 3′.RC_H16209_atyl28d11.s1 Homo sapiens cDNA clone 159573 3′.RC_N93816_atzb63f11.s1 Soares fetal lung NbHL19W Homo sapiens cDNAclone 308301 3′.RC_H17550_atym41h05.s1 Homo sapiens cDNA clone 50842 3′.RC_N36835_atyy35f02.s1 Homo sapiens cDNA clone 273243 3′.RC_T35289_atEST82492 Homo sapiens cDNA 3′ end similar to None.RC_AA447977_szw82e09.s1 Soares testis NHT Homo sapiens cDNA cloneat782728 3′.RC_AA160879_atzo62h06.s1 Stratagene pancreas (#937208) Homo sapiens cDNA clone 591515 3′.RC_W45051_atzc21g08.s1 Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone 323006 3′.RC_AA040699_atzk48g04.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 486102 3′.RC_R63734_atyi15g05.s1 Homo sapiens cDNA clone 139352 3′.RC_T61475_atyc06h08.s1 Homo sapiens cDNA clone 79935 3′.H23847_atyn71d04.r1 Homo sapiens cDNA clone 173863 5′.RC_AA482014_atzu98d05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 746025 3′ similar to TR: G414993 G414993 CENTRIN.;.RC_AA143323_szo37d04.s1 Stratagene endothelial cell 937223 Homo sapiens atcDNA clone 589063 3′ similar to gb: M60483_rna1 PROTEINPHOSPHATASE PP2A-ALPHA, CATALYTIC SUBUNIT (HUMAN);.R55902_atyg92d05.r1 Homo sapiens cDNA clone 41017 5′.RC_AA035638_atzk28a05.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 471824 3′.AA263146_atPMY0511 KG1a Lambda Zap Express cDNA Library Homo sapiens cDNA 5′.RC_W19222_atzb89h05.s1 Soares senescent fibroblasts NbHSF Homo sapiens cDNA clone 310809 3′ similar to contains Alu repetitive element;contains element L1 repetitive element;.RC_AA262276_atzs25f07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 686245 3′.H61361_s_atyu41b03.r1 Homo sapiens cDNA clone 236333 5′.RC_R10657_s_atyf31e11.s1 Homo sapiens cDNA clone 128492 3′.RC_AA227261_atzr22h04.s1 Stratagene NT2 neuronal precursor 937230 Homosapiens cDNA clone 664183 3′.RC_AA477641_atzu37b12.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 740159 3′.RC_T70596_atyd15f10.s1 Homo sapiens cDNA clone 108331 3′.R31641_atyh69e02.r1 Homo sapiens cDNA clone 135002 5′.RC_N62855_atyz83c04.s1 Homo sapiens cDNA clone 289638 3′.RC_AA279695_atzs92d10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 704947 3′.RC_H95071_s_atyv20f02.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 243291 3′.RC_N54385_atyv39f05.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone 245121 3′.H15314_atym28c02.r1 Homo sapiens cDNA clone 49413 5′.RC_AA151435_atzl43h11.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 504741 3′.RC_F01568_atH. sapiens partial cDNA sequence; clone c-06g08.


[0090] or a sequence as identified below
5RC_AA451685_atzx44c03.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 789316 3′.RC_W44745_atzb98a11.s1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 320828 3′.AA482319_f_atab15c03.r1 Stratagene lung (#937210) Homo sapiens cDNAclone 840868 5′.RC_AA155820_atzo47a08.s1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone 590006 3′.H51340_atyo30c06.r1 Homo sapiens cDNA clone 179434 5′.RC_H09594_atyl97b11.s1 Homo sapiens cDNA clone 46276 3′.RC_N29764_atyw91b09.s1 Homo sapiens cDNA clone 259577 3′.R80048_atyi91e08.r1 Homo sapiens cDNA clone 146630 5′.AC000115_cds1WUGSC: H_GS188P18.1a gene extracted from Human BACatclone GS188P18AA203222_atzx56e01.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 446520 5′ similar to contains element MER17 repetitiveelement;.RC_AA100437_atzn59e02.s1 Stratagene muscle 937209 Homo sapiens cDNAclone 562490 3′.RC_T51990_atyb29e01.s1 Homo sapiens cDNA clone 72600 3′.AA491114_ataa46e04.r1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 823998 5′.RC_R39869_atyf63b06.s1 Homo sapiens cDNA clone 26725 3′.RC_AA394071_atzt52g01.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 726000 3′ similar to SW: ADG_MOUSE P22892 GAMMA-ADAPTIN;.RC_AA196790_atzq60b06.s1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 645971 3′.AA465000_s_atzx80b07.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 810037 5′.RC_R39923_atyf51d10.s1 Homo sapiens cDNA clone 25662 3′.RC_R91819_atyp99c05.s1 Homo sapiens cDNA clone 195560 3′ similar tocontains MER1 repetitive element;.AA484982_ataa39b02.r1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 815595 5′.AA036900_atzk29e11.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 471980 5′.RC_AA449951_atzx38a10.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 788730 3′.RC_Z40233_atH. sapiens partial cDNA sequence; clone c-1wg05.RC_AA166810_atzo87a05.s1 Stratagene ovarian cancer (#937219) Homo sapiens cDNA clone 593840 3′.RC_H06746_atyl83h08.s1 Homo sapiens cDNA clone 44847 3′.AA046674_atzf12d12.r1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 376727 5′.RC_AA450118_atzx42e09.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 789160 3′.RC_AA486410_atab36b12.s1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 842879 3′.RC_AA026417_atze92g08.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 366494 3′.RC_AA125808_atzl29e12.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 503374 3′.RC_AA243721_atzr68f11.s1 Soares NhHMPu S1 Homo sapiens cDNA clone668589 3′.RC_AA452131_atzx15d06.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 786539 3′.RC_N29345_atyw85c10.s1 Homo sapiens cDNA clone 259026 3′.RC_Z39191_atH. sapiens partial cDNA sequence; clone c-13c12.RC_AA156187_atzo47c04.s1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone 590022 3′ similar to contains Alu repetitive element;.RC_AA157340_atzo42h04.s1 Stratagene endothelial cell 937223 Homo sapiens cDNA clone 589591 3′.RC_AA343514_atEST49299 Gall bladder I Homo sapiens cDNA 3′ end.RC_AA482224_fab15c03.s1 Stratagene lung (#937210) Homo sapiens cDNAatclone 840868 3′.RC_AA053021_atzl72f02.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 510171 3′.RC_AA279420_atzs85d09.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 704273 3′ similar to TR: G974805 G974805 T08A11.2;.RC_AA477252_atzu29h10.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 739459 3′.RC_N31597_s_atyy20b11.s1 Homo sapiens cDNA clone 271773 3′.U31875_atHuman Hep27 protein mRNA, complete cds.RC_F04611_atH. sapiens partial cDNA sequence; clone c-zse11.AA263032_s_atPMY0335 KG1a Lambda Zap Express cDNA Library Homo sapiens cDNA 5′.AA447052_atzw86b06.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 783827 5′ similar to TR: G595950 G595950 PROTEIN N-TERMINAL ASPARAGINE AMIDOHYDROLASE.;RC_AA056247_atzf62c02.s1 Soares retina N2b4HR Homo sapiens cDNA clone381506 3′ similar to contains Alu repetitive element;.RC_AA156532_atzo34b05.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 588753 3′.RC_AA456039_ataa03d01.s1 Soares NhHMPu S1 Homo sapiens cDNA clone812161 3′.RC_AA461444_atzx68b01.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 796585 3′.RC_AA033974_atzi05c10.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 429906 3′.RC_AA034365_atzf02b10.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 375739 3′ similar to gb: J05096_rna1 SODIUM/POTASSIUM-TRANSPORTING ATPASE ALPHA-1 CHAIN(HUMAN); contains Alu repetitive element;.RC_N22115_s_atyw32a09.s1 Homo sapiens cDNA clone 253912 3′.RC_W04698_atzb94b05.s1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 320433 3′.AA126592_atzl17g05.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 502232 5′.AA428172 _f_atzw32b06.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 770963 5′.C01790_atHUMGS0003746, Human Gene Signature, 3′-directed cDNAsequence.RC_AA017146_atze41a07.s1 Soares retina N2b4HR Homo sapiens cDNA clone361524 3′ similar to contains element PTR7 repetitive element;.RC_AA236037_atzs05g08.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 684350 3′.RC_AA026270_atze97f07.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 366949 3′.RC_AA233837_atzr47f06.s1 Soares NhHMPu S1 Homo sapiens cDNA clone666563 3′.RC_H60595_s_atyr41h02.s1 Homo sapiens cDNA clone 207891 3′.RC_N66388_atyz39f01.s1 Homo sapiens cDNA clone 285433 3′.RC_N91023_atzb41a09.s1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 306136 3′.RC_W80354_atzh49a02.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 415370 3′.RC_T51995_atyb29e09.s1 Homo sapiens cDNA clone 72616 3′.RC_AA463637_atzx98h04.s1 Soares NhHMPu S1 Homo sapiens cDNA clone811831 3′.RC_AA161085_atzo62h09.s1 Stratagene pancreas (#937208) Homo sapiens cDNA clone 591521 3′ similar to SW: PPAP_RAT P20646 PRO-STATIC ACID PHOSPHATASE PRECURSOR;.RC_AA489101_ataa56h11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 824997 3′.RC_AA255464_atzr83b02.s1 Soares NhHMPu S1 Homo sapiens cDNA clone682251 3′.RC_AA609614_ataf15f12.s1 Soares testis NHT Homo sapiens cDNA clone1031759 3′.L32832_s_atHomo sapiens zinc finger homeodomain protein (ATBF1-A)mRNA, complete cds.AA464051_s_atzx86d04.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 810631 5′.RC_Z39652_atH. sapiens partial cDNA sequence; clone c-1fg03.AB002321_atHuman mRNA for KIAA0323 gene, partial cds.RC_D59981_s_atHuman fetal brain cDNA 3′-end GEN-079C04.RC_AA027954_atzk05c12.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 469654 3′.RC_AA115559_atzl07b12.s1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 491615 3′.L02547_atHomo sapiens (clone pZ50-19) cleavage stimulation factor50 kDa subunit, complete cdsRC_AA256996_atzr81h11.s1 Soares NhHMPu S1 Homo sapiens cDNA clone682149 3′.RC_AA450373_atzx05h06.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 785627 3′.RC_N71875_atyz34f07.s1 Homo sapiens cDNA clone 284965 3′.AA431505_atzw76e03.r1 Soares testis NHT Homo sapiens cDNA clone782140 5′.U77942_atHuman syntaxin 7 mRNA, complete cds.RC_AA393876_szv64h10.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAatclone 758467 3′.W16686_atzb08f12.r1 Soares fetal lung NbHL19W Homo sapiens cDNAclone 301487 5′.RC_AA287388_atzs50f04.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 700927 3′.RC_F02397_s_atH. sapiens partial cDNA sequence; clone c-0xh11.AA247679_athfe0045.seq.F Human fetal heart, Lambda ZAP Express Homosapiens cDNA 5′.RC_AA282791_atzs91c05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 704840 3′.AA504744_ataa63f03.r1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 825629 5′.RC_AA149987_atzo03d03.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 566597 3′.RC_AA262485_atzs17h07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 685501 3′.AA436536_atzv08g07.r1 Soares NhHMPu S1 Homo sapiens cDNA clone753084 5′.RC_AA037828_atzf03g09.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 375904 3′.RC_AA255628_atzs31g06.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 686842 3′.AA418098_atzv94b04.r1 Soares NhHMPu S1 Homo sapiens cDNA clone767407 5′.RC_N21380_atyx54c04.s1 Homo sapiens cDNA clone 265542 3′.AA459542_s_atzx89d08.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 810927 5′ similar to TR: G608025 G608025 ANKYRIN G.;.RC_AA464180_atzx83f04.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 810367 3′ similar to gb: M38188 OVARIAN GRANULOSACELL 13.0 KD PROTEIN HGR74 (HUMAN);.RC_AA143726_atzo67g06.s1 Stratagene pancreas (#937208) Homo sapiens cDNA clone 591994 3′ similar to TR: G530823 G530823 EPIDERMALGROWTH FACTOR RECEPTOR KINASE SUBSTRATE.;.RC_N38930_atyy43e04.s1 Homo sapiens cDNA clone 274014 3′.H27242_atyl63h11.r1 Homo sapiens cDNA clone 162981 5′ similar toSP: GCN5_YEAST Q03330 TRANSCRIPTIONAL ACTIVATOR;.RC_AA002088_atzh85g03.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 428116 3′.D31313_s_atHuman fetal-lung cDNA 5′-end sequence.RC_R40702_atyf73f10.s1 Homo sapiens cDNA clone 27969 3′.RC_AA405543_atzw39c01.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 772416 3′.RC_AA284143_atzs47c07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 700620 3′.RC_AA158234_atzo76b01.s1 Stratagene pancreas (#937208) Homo sapiens cDNA clone 592777 3′.R66920_atyi25f09.r1 Homo sapiens cDNA clone 140297 5′ similar to containsAlu repetitive element;.RC_AA034189_atzi06h12.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 430055 3′.AA147510_s_atzl50c12.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 505366 5′.RC_N48715_atyy75h02.s1 Homo sapiens cDNA clone 279411 3′.AA489299_atab35g04.r1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 842838 5′.RC_AA242799_atzr65f06.s1 Soares NhHMPu S1 Homo sapiens cDNA clone668291 3′ similar to SW: SPO8_YEAST P41833 TRANSCRIPTIONALREGULATOR SPO8. [1];.AA091412_s_atll2053.seq.F Fetal heart, Lambda ZAP Express Homo sapiens cDNA 5′.RC_H70554_atyr91a03.s1 Homo sapiens cDNA clone 212620 3′.RC_AA256208_atzr80a08.s1 Soares NhHMPu S1 Homo sapiens cDNA clone681974 3′.RC_R64660_atyi22a10.s1 Homo sapiens cDNA clone 139962 3′.RC_AA135185_atzo27a05.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 588080 3′.AA442428_atzv70f08.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 759015 5′ similar to SW: YB72_YEAST P38137 HYPOTHETICAL60.5 KD PROTEIN IN PDB1-ABD1 INTERGENICREGION.;.RC_AA293719_atzt55h03.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 726293 3′.RC_AA287131_atzt20g02.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 713714 3′ similar to TR: E124071 E124071 NAD+−ISOCITRATE DEHYDROGENASE;.AB002387_atHuman mRNA for KIAA0389 gene, complete cds.RC_N50550_atyy89f05.s1 Homo sapiens cDNA clone 280737 3′.


[0091] or a sequence as identified below
6RC_AA599501_atag23g12.s1 Jia bone marrow stroma Homo sapiens cDNA clone 1071238 3′.RC_AA443923_atzv51a02.s1 Soares testis NHT Homo sapienscDNA clone 757130 3′.R82598_s_atyj19b12.r1 Homo sapiens cDNA clone 149183 5′.


[0092] or a sequence as identified below
7RC_AA402000_atzu55b03.s1 Soares ovary tumor NbHOTHomo sapiens cDNA clone 741869 3′ similar toTR: G452270 G452270 2-19 PROTEINPRECURSOR.;.


[0093] or a sequence as identified below
8RC_T40767_atya11a06.s1 Homo sapiens cDNAclone 61138 3′.RC_AA426454_szv61f08.s1 Soares testisatNHT Homo sapiens cDNA clone758151 3′ similar to contains elementTAR1 repetitive element;.RC_AA057620_atzf15h06.s1 Soares fetal heart NbHH19WHomo sapiens cDNA clone 377051 3′.RC_AA398197_atzt59a08.s1 Soares testis NHT Homo sapienscDNA clone 726614 3′.RC_N63332_atyz33d11.s1 Homo sapiens cDNA clone284853 3′ similar to containsAlu repetitive element;.RC_H58692_s_atyr20g08.s1 Homo sapiens cDNA clone205886 3′ similar to SP: FTDH_RAT P28037FORMYLTETRAHYDROFOLATEDEHYDROGENASE;.


[0094] or a sequence as identified below
9zo76b01.s1 Stratagene pancreas (#937208) Homo sapiens RC_AA158234_atcDNA clone 592777 3′.yo61a11.s1 Homo sapiens cDNA clone 182396 3′.RC_H42123_atH. sapiens partial cDNA sequence; clone c-13f02.RC_Z39200_atyx63h03.s1 Soares melanocyte 2NbHM Homo sapiens cDNARC_N21687_atclone 266453 3′.Homo sapiens mRNA for uroplakin II.Y13645_atzb86b03.s1 Soares senescent fibroblasts NbHSF Homo sapiens RC_N98461_atcDNA clone 310445 3′.zd99d10.s1 Soares fetal heart NbHH19W Homo sapiens RC_W92449_atcDNA clone 357619 3′.H. sapiens partial cDNA sequence; clone c-13c12.RC_Z39191_atzl29e12.s1 Soares pregnant uterus NbHPU Homo sapiens RC_AA125808_atcDNA clone 503374 3′.ya11a06.s1 Homo sapiens cDNA clone 61138 3′.RC_T40767_atyb29c05.s1 Homo sapiens cDNA clone 72584 3′.RC_T51972_atzs58b06.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA286862_atIMAGE: 701651 3′.yw91b09.s1 Homo sapiens cDNA clone 259577 3′.RC_N29764_atzw32b06.r1 Soares ovary tumor NbHOT Homo sapiens cDNAAA428172_f_atclone 770963 5′.yj35d05.s1 Homo sapiens cDNA clone 150729 3′.RC_H02265_atzb98a11.s1 Soares parathyroid tumor NbHPA Homo sapiens RC_W44745_atcDNA clone 320828 3′.yp99c05.s1 Homo sapiens cDNA clone 195560 3′ similar toRC_R91819_atcontains MER1 repetitive element;.zx84d05.r1 Soares ovary tumor NbHOT Homo sapiens cDNAAA464468_atclone 810441 5′.zp78e01.s1 Stratagene HeLa cell s3 937216 Homo sapiens RC_AA188647_atcDNA clone 626328 3′ similar to TR: G998813 G998813 TIF1.[1];.zu57g11.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA405832_atclone 742148 3′ similar to TR: G780241 G780241 AU-BINDING PROTEIN/ENOYL-COA HYDRATASE.;.zc13b12.s1 Soares parathyroid tumor NbHPA Homo sapiens RC_W37778_f_atcDNA clone 322175 3′ similar to contains LTR2.t3 LTR2 repetitiveelement;.Homo sapiens breast cancer-specific protein 1 (BCSG1)AF010126_atmRNA, complete cds.yx83a05.r1 Homo sapiens cDNA clone 268304 5′.N36432_atzr74c04.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA236533_s_at669126 3′ similar to gb: S69002 ECOTROPIC VIRUS INTEGRATION1 SITE PROTEIN (HUMAN);.zt55e05.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA293163_atclone 726272 3′.zq60b06.s1 Stratagene neuroepithelium (#937231) HomoRC_AA196790_atsapiens cDNA clone 645971 3′.zr53g12.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA253220_at667174 3′.zn59e02.s1 Stratagene muscle 937209 Homo sapiens cDNARC_AA100437_atclone 562490 3′.zt28d03.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA293300_s_atclone 714437 3′.H. sapiens partial cDNA sequence; clone c-1fg03.RC_Z39652_atHuman glutathione transferase M2 (GSTM2) mRNA, completeM63509_s_atcdsH. sapiens partial cDNA sequence; clone c-1ke11.RC_Z39842_atyx78e10.s1 Homo sapiens cDNA clone 267882 3′.RC_N23319_atzs78d11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA278817_atIMAGE: 703605 3′.Homo sapiens mRNA in the region near the btk gene involvedL20773_atin a-gamma-globulinemiayi44h05.s1 Soares placenta Nb2HP Homo sapiens cDNARC_R69276_atclone 142137 3′.H. sapiens partial cDNA sequence; clone c-15d02.RC_F02641_atzw03a04.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA424791_at768174 3′ similar to contains Alu repetitive element;.yf63b06.s1 Homo sapiens cDNA clone 26725 3′.RC_R39869_atab15c03.s1 Stratagene lung (#937210) Homo sapiens cDNARC_AA482224_f_atclone 840868 3′.ze76f02.s1 Soares fetal heart NbHH19W Homo sapiens RC_AA025277_atcDNA clone 364923 3′ similar to contains Alu repetitive element;contains element LTR4 repetitive element;.ab15c03.r1 Stratagene lung (#937210) Homo sapiens cDNAAA482319_f_atclone 840868 5′.ze47b04.s1 Soares retina N2b4HR Homo sapiens cDNA cloneRC_AA001045_at362095 3′.zo10f03.s1 Stratagene neuroepithelium NT2RAMI 937234RC_AA130645_s_atHomo sapiens cDNA clone 567293 3′ similar toSW: NI2M_BOVIN Q02369 NADH-UBIQUINONE OXIDORE-DUCTASE B22 SUBUNIT;.zt37c02.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA291659_atclone 724514 3′.zk72d02.r1 Soares pregnant uterus NbHPU Homo sapiens AA046768_atcDNA clone 488355 5′.yl81e01.r1 Homo sapiens cDNA clone 44466 5′.H07011_atzt54g04.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA293533_i_atclone 726198 3′ similar to gb: J05158 CARBOXYPEPTIDASEN 83 KD CHAIN (HUMAN);.zn63g10.s1 Stratagene HeLa cell s3 937216 Homo sapiens RC_AA100649_atcDNA clone 562914 3′ similar to SW: LCFA_ECOLI P29212LONG-CHAIN-FATTY-ACID-COA LIGASE;.ze41a07.s1 Soares retina N2b4HR Homo sapiens cDNA cloneRC_AA017146_at361524 3′ similar to contains element PTR7 repetitiveelement;.zp40g07.s1 Stratagene muscle 937209 Homo sapiens cDNARC_AA180054_atclone 611964 3′.PMY0335 KG1a Lambda Zap Express cDNA Library HomoAA263032_s_atsapiens cDNA 5′.zd46f07.r1 Soares fetal heart NbHH19W Homo sapiens W69310_atcDNA clone 343717 5′.zr05e02.s1 Stratagene NT2 neuronal precursor 937230 HomoRC_AA219653_atsapiens cDNA clone 650618 3′.aa91c07.s1 Stratagene fetal retina 937202 Homo sapiens RC_AA457235_atcDNA clone 838668 3′.aa16h10.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA455967_at813475 3′.yx51a09.r1 Homo sapiens cDNA clone 265240 5′.N27670_atza65e02.s1 Homo sapiens cDNA clone 297434 3′.RC_N80152_atyi22a10.s1 Homo sapiens cDNA clone 139962 3′.RC_R64660_atzo64g03.s1 Stratagene pancreas (#937208) Homo sapiens RC_AA147218_s_atcDNA clone 591700 3′.HUMGS0007818, Human Gene Signature, 3′-directed cDNAC01139_atsequence.PMY0691 KG1a Lambda Zap Express cDNA Library HomoAA285284_atsapiens cDNA 5′.zx44c03.s1 Soares total fetus Nb2HF8 9w Homo sapiens RC_AA451685_atcDNA clone 789316 3′.zx56e01.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiens AA203222_atcDNA clone 446520 5′ similar to contains elementMER17 repetitive element;.zt52g01.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA394071_atclone 726000 3′ similar to SW: ADG_MOUSE P22892 GAMMA-ADAPTIN;.zv17e07.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA479096_at753924 3′.zo34b05.s1 Stratagene colon (#937204) Homo sapiens cDNARC_AA156532_atclone 588753 3′.H. sapiens partial cDNA sequence; clone c-1wg05.RC_Z40233_atseq2490 Homo sapiens cDNA clone 3HFLSK20-87 3′.RC_T03927_atEST186294 Colon carcinoma (HCC) cell line II Homo sapiens AA314457_atcDNA 5′ end.yy89f05.s1 Homo sapiens cDNA clone 280737 3′.RC_N50550_atzp88f04.s1 Stratagene HeLa cell s3 937216 Homo sapiens RC_AA191524_atcDNA clone 627295 3′.yw90b12.s1 Homo sapiens cDNA clone 259487 3′.RC_N29740_atyy75h02.s1 Homo sapiens cDNA clone 279411 3′.RC_N48715_atzx98h04.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA463637_at811831 3′.zw38a06.s1 Soares total fetus Nb2HF8 9w Homo sapiens RC_AA404487_atcDNA clone 772306 3′.ym26a10.s1 Homo sapiens cDNA clone 49155 3′.RC_H16666_atzv24d11.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA406197_at754581 3′.yl97b11.s1 Homo sapiens cDNA clone 46276 3′.RC_H09594_atzo62h09.s1 Stratagene pancreas (#937208) Homo sapiens RC_AA161085_atcDNA clone 591521 3′ similar to SW: PPAP_RAT P20646PROSTATIC ACID PHOSPHATASE PRECURSOR;.zx15d06.s1 Soares total fetus Nb2HF8 9w Homo sapiens RC_AA452131_atcDNA clone 786539 3′.zt54g04.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA293533_f_atclone 726198 3′ similar to gb: J05158 CARBOXYPEPTIDASEN 83 KD CHAIN (HUMAN);.zt59a08.s1 Soares testis NHT Homo sapiens cDNA cloneRC_AA398197_at726614 3′.zx86d04.r1 Soares ovary tumor NbHOT Homo sapiens cDNAAA464051_s_atclone 810631 5′.yb29e01.s1 Homo sapiens cDNA clone 72600 3′.RC_T51990_atzr54a11.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA236356_at667196 3′.zd92a04.r1 Soares fetal heart NbHH19W Homo sapiens W92678_atcDNA clone 356910 5′ similar to contains element LTR3 repetitiveelement;.yz33d11.s1 Homo sapiens cDNA clone 284853 3′ similar toRC_N63332_atcontains Alu repetitive element;.Human aorta cDNA 5′-end GEN-259H09.C16281_s_atzu29h10.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA477252_atclone 739459 3′.yw20e07.r1 Homo sapiens cDNA clone 252804 5′.H88035_s_atHuman mRNA for KIAA0389 gene, complete cds.AB002387_atyg45h12.s1 Homo sapiens cDNA clone 35838 3′.RC_R45698_atzr75g11.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA236542_at669284 3′.EST89388 Small intestine I Homo sapiens cDNA 5′ end similarAA376875_atto monoamine oxidase A.yg15g06.s1 Homo sapiens cDNA clone 32365 3′.RC_R43365_atyl83h08.s1 Homo sapiens cDNA clone 44847 3′.RC_H06746_atzr47f06.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA233837_at666563 3′.zf15h06.s1 Soares fetal heart NbHH19W Homo sapiens RC_AA057620_atcDNA clone 377051 3′.zx42e09.s1 Soares total fetus Nb2HF8 9w Homo sapiens RC_AA450118_atcDNA clone 789160 3′.ae37b10.s1 Gessler Wilms tumor Homo sapiens cDNA cloneRC_AA598872_at897979 3′.zl52g06.s1 Soares pregnant uterus NbHPU Homo sapiens RC_AA147646_s_atcDNA clone 505594 3′.zb94b05.s1 Soares parathyroid tumor NbHPA Homo sapiens RC_W04698_atcDNA clone 320433 3′.yv39c06.s1 Homo sapiens cDNA clone 245098 3′.RC_N54365_atzr80a08.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA256208_at681974 3′.zk62g01.r1 Soares pregnant uterus NbHPU Homo sapiens AA046593_atcDNA clone 487440 5′.zh85g03.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens RC_AA002088_atcDNA clone 428116 3′.zr81c12.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA256273_at682102 3′.aa46e04.r1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneAA491114_atIMAGE: 823998 5′.zt55h03.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA293719_atclone 726293 3′.zl84c04.s1 Stratagene colon (#937204) Homo sapiens cDNARC_AA086005_atclone 511302 3′.zw44a07.s1 Soares total fetus Nb2HF8 9w Homo sapiens RC_AA479885_atcDNA clone 772884 3′.zv70f08.r1 Soares total fetus Nb2HF8 9w Homo sapiens AA442428_atcDNA clone 759015 5′ similar to SW: YB72_YEAST P38137HYPOTHETICAL 60.5 KD PROTEIN IN PDB1-ABD1 INTERGENICREGION.;.ab36b12.s1 Stratagene HeLa cell s3 937216 Homo sapiens RC_AA486410_atcDNA clone 842879 3′.yf89f02.r1 Homo sapiens cDNA clone 29665 5′.R15268_atzw86a10.s1 Soares total fetus Nb2HF8 9w Homo sapiens RC_AA443658_atcDNA clone 783834 3′ similar to TR: G438639 G438639 LAMINB RECEPTOR. [1];.ym39b01.s1 Homo sapiens cDNA clone 50559 3′.RC_H16790_atzx80b07.r1 Soares ovary tumor NbHOT Homo sapiens cDNAAA465000_s_atclone 810037 5′.yy43e04.s1 Homo sapiens cDNA clone 274014 3′.RC_N38930_atHuman mRNA for KIAA0323 gene, partial cds.AB002321_atH. sapiens partial cDNA sequence; clone c-0qb09.RC_Z38810_atWUGSC: H_GS188P18.1a gene extracted from Human BACAC000115_cds1_atclone GS188P18zr83b02.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA255464_at682251 3′.zs31g06.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA255628_atIMAGE: 686842 3′.yr91a03.s1 Homo sapiens cDNA clone 212620 3′.RC_H70554_atEST180743 Jurkat T-cells V Homo sapiens cDMA 5′ end.AA309880_atyg21a08.s1 Homo sapiens cDMA clone 32940 3′.RC_R43812_atzv47a04.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA425636_atclone 756750 3′.yz39f01.s1 Homo sapiens cDNA clone 285433 3′.RC_N66388_atzs85d09.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA279420_atIMAGE: 704273 3′ similar to TR: G974805 G974805 T08A11.2;.zi05c10.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens RC_AA033974_atcDNA clone 429906 3′.Homo sapiens sodium bicarbonate cotransporter (HNBC1)AF007216_atmRNA, complete cds.aa56h11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA489101_atIMAGE: 824997 3′.Human aorta cDNA 5′-end GEN-286G10.D79601_f_atyw70f05.s1 Homo sapiens cDNA clone 257601 3′.RC_N30856_atHomo sapiens clk2 mRNA, complete cdsL29218_s_atzo67g06.s1 Stratagene pancreas (#937208) Homo sapiens RC_AA143726_atcDNA clone 591994 3′ similar to TR: G530823 G530823 EPIDERMALGROWTH FACTOR RECEPTOR KINASE SUBSTRATE.;.zl17g05.r1 Soares pregnant uterus NbHPU Homo sapiens AA126592_atcDNA clone 502232 5′.H. sapiens partial cDNA sequence; clone c-0xh11.RC_F02397_s_atzs27d03.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA252765_atIMAGE: 686405 3′.zc36a04.s1 Soares senescent fibroblasts NbHSF Homo sapiens RC_W46846_atcDNA clone 324366 3′.zo27a05.s1 Stratagene colon (#937204) Homo sapiens cDNARC_AA135185_atclone 588080 3′.yf73f10.s1 Homo sapiens cDNA clone 27969 3′.RC_R40702_atyv36d12.s1 Homo sapiens cDNA clone 244823 3′.RC_N52565_atzc06a02.s1 Soares parathyroid tumor NbHPA Homo sapiens RC_W32506_s_atcDNA clone 321482 3′.zr85c04.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA255539_at682470 3′.zx38a10.s1 Soares total fetus Nb2HF8 9w Homo sapiens RC_AA449951_atcDNA clone 788730 3′.cchn2404.seq.F Fetal heart, Lambda ZAP Express HomoAA091278_atsapiens cDNA 5′.zs05g08.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA236037_atIMAGE: 684350 3′.II2053.seq.F Fetal heart, Lambda ZAP Express Homo sapiens AA091412_s_atcDNA 5′.zf12b09.r1 Soares fetal heart NbHH19W Homo sapiens AA046865_atcDNA clone 376697 5′.EST27743 Cerebellum II Homo sapiens cDNA 5′ end.AA324825_atzx79d09.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA454840_s_atclone 809969 3′.zh49a02.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens RC_W80354_atcDNA clone 415370 3′.zt65c03.s1 Soares testis NHT Homo sapiens cDNA cloneRC_AA402484_at727204 3′.15h10 Human retina cDNA randomly primed sublibrary HomoW26883_atsapiens cDNA.zs17h07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA262485_atIMAGE: 685501 3′.zw39c01.s1 Soares total fetus Nb2HF8 9w Homo sapiens RC_AA405543_atcDNA clone 772416 3′.yx54c04.s1 Homo sapiens cDNA clone 265542 3′.RC_N21380_atzn77a05.s1 Stratagene NT2 neuronal precursor 937230 HomoRC_AA121360_s_atsapiens cDNA clone 564176 3′.Homo sapiens zinc finger homeodomain protein (ATBF1-A)L32832_s_atmRNA, complete cds.Human fetal-lung cDNA 5′-end sequence.D31313_s_atym45b05.r1 Homo sapiens cDNA clone 51043 5′ similar toH18718_atcontains Alu repetitive element;.zf03g09.s1 Soares fetal heart NbHH19W Homo sapiens RC_AA037828_atcDNA clone 375904 3′.yi04c10.s1 Homo sapiens cDNA clone 138258 3′.RC_R67996_atze92g08.s1 Soares fetal heart NbHH19W Homo sapiens RC_AA026417_atcDNA clone 366494 3′.H. sapiens partial cDNA sequence; clone c-33a10.RC_F11115_atyf21e07.s1 Homo sapiens cDNA clone 127524 3′.RC_R08871_atzr12e05.s1 Stratagene hNT neuron (#937233) Homo sapiens RC_AA224324_atcDNA clone 648608 3′.zt50c01.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA399226_atclone 725760 3′.yi25f09.r1 Homo sapiens cDNA clone 140297 5′ similar toR66920_atcontains Alu repetitive element;.zx81a05.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA464240_s_atclone 810128 3′.zv08g07.r1 Soares NhHMPu S1 Homo sapiens cDNA cloneAA436536_at753084 5′.yz34f07.s1 Homo sapiens cDNA clone 284965 3′.RC_N71875_atzk10b03.s1 Soares pregnant uterus NbHPU Homo sapiens RC_AA029288_atcDNA clone 470093 3′ similar to PIR: H45193 H45193 zincfinger protein ZNF65;.yl63h11.r1 Homo sapiens cDNA clone 162981 5′ similar toH27242_atSP: GCN5_YEAST Q03330 TRANSCRIPTIONAL ACTIVATOR;.Human cytochrome P450 PCN3 gene, complete cdsJ04813_s_ataa32h08.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA465093_atIMAGE: 815007 3′.zs91c05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA282791_atIMAGE: 704840 3′.zx83f04.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA464180_atclone 810367 3′ similar to gb: M38188 OVARIAN GRANULOSACELL 13.0 KD PROTEIN HGR74 (HUMAN);.zo03d03.s1 Stratagene colon (#937204) Homo sapiens cDNARC_AA149987_atclone 566597 3′.zr82h09.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA256680_at682241 3′.zl50c12.r1 Soares pregnant uterus NbHPU Homo sapiens AA147510_s_atcDNA clone 505366 5′.yi80c10.r1 Homo sapiens cDNA clone 145554 5′.R78119_atH. sapiens partial cDNA sequence; clone c-0ac03.RC_Z38407_s_atzs58f12.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA287107_s_atIMAGE: 701711 3′.zs57e07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA287042_atIMAGE: 701604 3′.ab35g04.r1 Stratagene HeLa cell s3 937216 Homo sapiens AA489299_atcDNA clone 842838 5′.aa63f03.r1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneAA504744_atIMAGE: 825629 5′.zu47g07.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA402622_atclone 741180 3′.zw55e10.s1 Soares total fetus Nb2HF8 9w Homo sapiens RC_AA436628_atcDNA clone 773994 3′.zt02a10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA282138_atIMAGE: 711930 3′.zk75a04.r1 Soares pregnant uterus NbHPU Homo sapiens AA045870_atcDNA clone 488622 5′.zv94b04.r1 Soares NhHMPu S1 Homo sapiens cDNA cloneAA418098_at767407 5′.zr65f06.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA242799_at668291 3′ similar to SW: SPO8_YEAST P41833 TRANSCRIPTIONALREGULATOR SPO8.[1];.af12f04.s1 Soares testis NHT Homo sapiens cDNA cloneRC_AA609210_at1031455 3′.zo13e11.s1 Stratagene colon (#937204) Homo sapiens cDNARC_AA133469_atclone 586796 3′.yh25b11.r1 Homo sapiens cDNA clone 130749 5′.R22139_atEST176117 Colon carcinoma (Caco-2) cell line II Homo sapiens AA305116_atcDNA 5′ end.zk05c12.s1 Soares pregnant uterus NbHPU Homo sapiens RC_AA027954_atcDNA clone 469654 3′.zk29e11.r1 Soares pregnant uterus NbHPU Homo sapiens AA036900_atcDNA clone 471980 5′.ze92d07.s1 Soares fetal heart NbHH19W Homo sapiens RC_AA026397_atcDNA clone 366445 3′.Human fetal brain cDNA 3′-end GEN-079C04.RC_D59981_s_atzs47c07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA284143_atIMAGE: 700620 3′.zb08f12.r1 Soares fetal lung NbHL19W Homo sapiens cDNAW16686_atclone 301487 5′.yw28c11.r1 Homo sapiens cDNA clone 253556 5′.H89575_s_atzs07g11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA251003_atIMAGE: 684548 3′.zs84h09.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA279408_atIMAGE: 704225 3′.zt07g10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA281760_atIMAGE: 712482 3′ similar to TR: G808826 G808826 HYPOTHETICAL25.7 KD PROTEIN.;.Human mRNA for KIAA0383 gene, partial cds.AB002381_atzx89d08.r1 Soares ovary tumor NbHOT Homo sapiens cDNAAA459542_s_atclone 810927 5′ similar to TR: G608025 G608025 ANKYRING.;.zl07b12.s1 Soares pregnant uterus NbHPU Homo sapiens RC_AA115559_atcDNA clone 491615 3′.ye36a05.r1 Homo sapiens cDNA clone 119792 5′.T94506_atHuman fetal brain cDNA 5′-end GEN-404F02.D55869_s_atHomo sapiens (clone pZ50-19) cleavage stimulation factorL02547_at50 kDa subunit, complete cdsHuman syntaxin 7 mRNA, complete cds.U77942_atzw76e03.r1 Soares testis NHT Homo sapiens cDNA cloneAA431505_at782140 5′.zr38c08.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA194045_at665678 3′.ze78f05.s1 Soares fetal heart NbHH19W Homo sapiens RC_AA025104_atcDNA clone 365121 3′.zr65e09.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA242822_at668296 3′.zs50f04.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA287388_atIMAGE: 700927 3′.hfe0045.seq.F Human fetal heart, Lambda ZAP Express HomoAA247679_atsapiens cDNA 5′.ab41e08.s1 Stratagene HeLa cell s3 937216 Homo sapiens RC_AA489383_atcDNA clone 843398 3′.zu81a08.s1 Soares testis NHT Homo sapiens cDNA cloneRC_AA621188_at744374 3′.ab35a01.s1 Stratagene HeLa cell s3 937216 Homo sapiens RC_AA486182_atcDNA clone 842760 3′.zv64h01.s1 Soares total fetus Nb2HF8 9w Homo sapiens RC_AA393876_s_atcDNA clone 758467 3′.zi06h12.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiens RC_AA034189_atcDNA clone 430055 3′.ze79b09.s1 Soares fetal heart NbHH19W Homo sapiens RC_AA024866_atcDNA clone 365177 3′.zx05h06.s1 Soares total fetus Nb2HF8 9w Homo sapiens RC_AA450373_atcDNA clone 785627 3′.yz78d07.r1 Homo sapiens cDNA clone 289165 5′.N78483_atzs94d07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA281245_atIMAGE: 705133 3′.zc45b12.r1 Soares senescent fibroblasts NbHSF Homo sapiens W52431_atcDNA clone 325247 5′ similar to SW: WDNM_RATP14730 WDNM1 PROTEIN. [2] PIR: S07807;.zw84f01.s1 Soares total fetus Nb2HF8 9w Homo sapiens RC_AA446597_atcDNA clone 783673 3′.zr81h11.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA256996_at682149 3′.H. sapiens gene for cytokeratin 20X73501_atzt20g02.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA287131_atclone 713714 3′ similar to TR: E124071 E124071 NAD+-ISOCITRATE DEHYDROGENASE;.


[0095] In a preferred embodiment genes from the first gene group is preferably selected individually from genes comprising a sequence as identified below by EST
10RC_N23319_atyx78e10.s1 Homo sapiens cDNA clone 267882 3′.RC_R43812_atyg21a08.s1 Homo sapiens cDNA clone 32940 3′.RC_W37778_f_atzc13b12.s1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 322175 3′ similar to contains LTR2.t3 LTR2 repetitiveelement;.RC_AA001045_atze47b04.s1 Soares retina N2b4HR Homo sapiens cDNA clone362095 3′.RC_AA086005_atzl84c04.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 511302 3′.RC_AA191524_atzp88f04.s1 Stratagene HeLa cell s3 937216 Homo sapiens cDNA clone 627295 3′.RC_AA219653_atzr05e02.s1 Stratagene NT2 neuronal precursor 937230 Homosapiens cDNA clone 650618 3′.RC_AA252765_atzs27d03.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 686405 3′.RC_AA293300_szt28d03.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 714437 3′.RC_AA405832_atzu57g11.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 742148 3′ similar to TR: G780241 G780241 AU-BINDINGPROTEIN/ENOYL-COA HYDRATASE.;.X73501_atH. sapiens gene for cytokeratin 20AA046768_atzk72d02.r1 Soares pregnant uterus NbHPU Homo sapiens cDNA clone 488355 5′.AA314457_atEST186294 Colon carcinoma (HCC) cell line II Homo sapiens cDNA 5′ end.AA324825_atEST27743 Cerebellum II Homo sapiens cDNA 5′ end.


[0096] In another embodiment a gene from the first gene group is selected individually from genes comprising a sequence as identified below by EST
11Human mRNA for KIAA0372 gene, complete cds.AB002370_atHomo sapiens purinergic receptor P2Y5 mRNA, completeAF000546_atcds.yo70c03.r1 Homo sapiens cDNA clone 183268 5′.H43922_atyp17b05.r1 Homo sapiens cDNA clone 187665 5′ similarH44269_atto contains Alu repetitive element;.yw23e08.r1 Homo sapiens cDNA clone 253094 5′.H88706_s_atHomo sapiens epoxide hydrolase (EPHX) gene, completeL25880_s_atcdsyw36d01.r1 Homo sapiens cDNA clone 254305 5′.N81162_atH. sapiens partial cDNA sequence; clone c-3ec07.RC_F10381_s_atEST00018 HE6W Homo sapiens cDNA cloneRC_H54558_atHE6WCR108 3′.yr20g08.s1 Homo sapiens cDNA clone 205886 3′ similarRC_H58692_s_atto SP: FTDH_RAT P28037 FORMYLTETRAHYDROFOLATEDEHYDROGENASE;.yx28d06.s1 Homo sapiens cDNA clone 263051 3′.RC_N20047_atyv28e04.s1 Homo sapiens cDNA clone 244062 3′.RC_N38810_atyg51h01.s1 Homo sapiens cDNA clone 36305 3′.RC_R46497_atyj76a08.s1 Homo sapiens cDNA clone 154646 3′.RC_R55001_atEST10130 Homo sapiens cDNA 3′ end similar to None.RC_T29986_s_atEST12901 Homo sapiens cDNA 3′ end similar to None.RC_T30214_atya01c07.s2 Homo sapiens cDNA clone 60204 3′.RC_T40438_atzc37f06.s1 Soares senescent fibroblasts NbHSF HomoRC_W51910_atsapiens cDNA clone 324515 3′.zd71f09.s1 Soares fetal heart NbHH19W Homo sapiensRC_W73949_atcDNA clone 346121 3′.zh55a02.s1 Soares fetal liver spleen 1NFLS S1 HomoRC_W86375_s_atsapiens cDNA clone 415946 3′.H. sapiens partial cDNA sequence; clone c-05e04.RC_Z38289_atH. sapiens partial cDNA sequence; clone c-0qb04.RC_Z38807_s_atH. sapiens partial cDNA sequence; clone c-1ed10.RC_Z39599_atze74h03.s1 Soares fetal heart NbHH19W Homo sapiensRC_AA025351_atcDNA clone 364757 3′ similar to contains OFR.t1OFR repetitive element;.zl01f04.s1 Soares pregnant uterus NbHPU Homo sapiensRC_AA136474_atcDNA clone 491071 3′.zk99b02.s1 Soares pregnant uterus NbHPU Homo sapiensRC_AA136611_atcDNA clone 490923 3′.zr48f07.s1 Soares NhHMPu S1 Homo sapiens cDNARC_AA233375_atclone 666661 3′.zt36c05.s1 Soares ovary tumor NbHOT Homo sapiensRC_AA235621_s_atcDNA clone 724424 3′.zr72g02.s1 Soares NhHMPu S1 Homo sapiens cDNARC_AA253331_atclone 668978 3′.zv64a10.s1 Soares total fetus Nb2HF8 9w Homo sapiensRC_AA393793_atcDNA clone 758394 3′.zv04a05.s1 Soares NhHMPu S1 Homo sapiens cDNARC_AA419547_atclone 752624 3′.zu27d11.s1 Soares ovary tumor NbHOT Homo sapiensRC_AA421100_atcDNA clone 739221 3′.zw87f06.s1 Soares total fetus Nb2HF8 9w Homo sapiensRC_AA443277_atcDNA clone 783971 3′.zw84c05.s1 Soares total fetus Nb2HF8 9w Homo sapiensRC_AA446570_atcDNA clone 783656 3′.zw93c01.s1 Soares total fetus Nb2HF8 9w Homo sapiensRC_AA447123_atcDNA clone 784512 3′.zx06g09.s1 Soares total fetus Nb2HF8 9w Homo sapiensRC_AA449343_atcDNA clone 785728 3′.aa03a08.s1 Soares NhHMPu S1 Homo sapiens cDNARC_AA456016_atclone 812150 3′.zv21f04.s1 Soares NhHMPu S1 Homo sapiens cDNARC_AA479299_atclone 754303 3′.zv17d09.s1 Soares NhHMPu S1 Homo sapiens cDNARC_AA479350_atclone 753905 3′ similar to contains element TAR1 TAR1repetitive element;.Human leukemogenic homolog protein (MEIS1) mRNA,U85707_atcomplete cdsHuman multispanning membrane protein mRNA, completeU94831_atcds. /gb = U94831 /ntype = RNA38c8 Human retina cDNA randomly primed sublibraryW27827_atHomo sapiens cDNA.zd85a12.r1 Soares fetal heart NbHH19W Homo sapiensW81301_atcDNA clone 347422 5′.H. sapiens mRNA for putative progesterone bindingY12711_atproteinzm15c08.r1 Stratagene pancreas (#937208) Homo sapiensAA074407_atcDNA clone 525710 5′.yy1646.seq.F Fetal heart, Lambda ZAP Express HomoAA091017_atsapiens cDNA 5′.l7134.seq.F Fetal heart, Lambda ZAP Express HomoAA104023_atsapiens cDNA 5′.zo95d05.r1 Stratagene ovarian cancer (#937219) HomoAA171913_atsapiens cDNA clone 594633 5′.zr32h05.r1 Soares NhHMPu S1 Homo sapiens cDNAAA195678_atclone 665145 5′.zr55e05.r1 Soares NhHMPu S1 Homo sapiens cDNAAA227678_atclone 667328 5′.csg0306.seq.F Human fetal heart, Lambda ZAP ExpressAA247204_atHomo sapiens cDNA 5′.zv18b05.r1 Soares NhHMPu S1 Homo sapiens cDNAAA479995_atclone 753969 5′.


[0097] In one preferred embodiment a gene from the first gene group is selected individually from genes comprising a sequence as identified below by EST
12AF000546_atHomo sapiens purinergic receptorP2Y5 mRNA, complete cds.L25880_s_atHomo sapiens epoxide hydrolase(EPHX) gene, complete cdsRC_N20047_atyx28d06.s1 Homo sapiens cDNA clone 263051 3′.RC_W51910_atzc37f06.s1 Soares senescent fibroblastsNbHSF Homo sapienscDNA clone 324515 3′.RC_W86375_s_atzh55a02.s1 Soares fetal liverspleen 1NFLS S1 Homo sapienscDNA clone 415946 3′.RC_Z38289_atH. sapiens partial cDNA sequence; clone c-05e04.RC_Z38807_s_atH. sapiens partial cDNA sequence; clone c-0qb04.RC_AA393793_atzv64a10.s1 Soares total fetus Nb2HF8 9wHomo sapiens cDNA clone 758394 3′.RC_AA446570_atzw84c05.s1 Soares total fetus Nb2HF8 9wHomo sapiens cDNA clone 783656 3′.RC_AA456016_ataa03a08.s1 Soares NhHMPu S1 Homo sapienscDNA clone 812150 3′.RC_AA479350_atzv17d09.s1 Soares NhHMPu S1 Homo sapienscDNA clone 753905 3′ similar to containselement TAR1 TAR1 repetitive element;.


[0098] In yet another embodiment a gene from the first gene group is selected individually from genes comprising a sequence as identified below by EST
13yl26e06.s1 Homo sapiens cDNA clone 159394 3′.RC_H14633_atyz74d02.s1 Homo sapiens cDNA clone 288771 3′.RC_N62506_atza74g10.s1 Homo sapiens cDNA clone 298338 3′.RC_N70481_atza57b06.s1 Homo sapiens cDNA clone 296627 3′.RC_N73988_atya88g06.s1 Homo sapiens cDNA clone 68794 3′.RC_T53404_atH. sapiens partial cDNA sequence; clone c-01a09.RC_Z38149_atH. sapiens partial cDNA sequence; clone c-0rb11.RC_Z38849_atzc03h03.s1 Soares parathyroid tumor NbHPA Homo sapiensRC_AA037409_atcDNA clone 321269 3′.zn18b04.s1 Stratagene neuroepithelium NT2RAMI 937234RC_AA084318_atHomo sapiens cDNA clone 547759 3′.zk94d04.s1 Soares pregnant uterus NbHPU Homo sapiensRC_AA126419_atcDNA clone 490471 3′.zm24d04.s1 Stratagene pancreas (#937208) Homo sapiensRC_AA128407_atcDNA clone 526567 3′.zp02e08.s1 Stratagene ovarian cancer (#937219) Homo sapiensRC_AA173430_atcDNA clone 595238 3′.zt58d03.s1 Soares testis NHT Homo sapiens cDNA cloneRC_AA398104_at726533 3′.zt50e07.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA399414_atclone 725796 3′.zw72f05.s1 Soares testis NHT Homo sapiens cDNA cloneRC_AA431479_at781761 3′.zv08e05.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA436471_at753056 3′.zx05e10.s1 Soares total fetus Nb2HF8 9w Homo sapiensRC_AA449455_atcDNA clone 785610 3′ similar to contains Alu repetitive element;.zx88d07.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA458899_atclone 810829 3′.zx98g09.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA463630_s_at811840 3′.aa54d11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA489009_atIMAGE: 824757 3′.zc11f08.r1 Soares parathyroid tumor NbHPA Homo sapiensW37319_atcDNA clone 322023 5′.


[0099] In a preferred embodiment a gene from the first gene group is selected individually from genes comprising a sequence as identified below by EST
14N75611_s_atyw37b04.r1 Homo sapiens cDNA clone 254383 5′.RC_H20769_atyn64a06.s1 Homo sapiens cDNA clone 173170 3′.RC_R54822_atyg87f06.s1 Homo sapiens cDNA clone 40364 3′.RC_AA058357_szl67e01.s1 Stratagene colon (#937204) Homo sapiens cDNAatclone 509688 3′ similar to TR: G189087 G189087 NONSPECIFICCROSSREACTING ANTIGEN.;.RC_AA086487_atzn53a05.s1 Stratagene muscle 937209 Homo sapiens cDNAclone 561872 3′ similar to contains Alu repetitive element;.RC_AA456289_ataa13e06.s1 Soares NhHMPu S1 Homo sapiens cDNA clone813154 3′.RC_AA609539_ataf14g11.s1 Soares testis NHT Homo sapiens cDNA clone1031684 3′.


[0100] In another embodiment a gene from the first gene group is selected individually from genes comprising a sequence as identified below by EST
15N24990_s_atyx16e10.r1 Homo sapiens cDNA clone 261930 5′.R11267_atyf41e08.r1 Homo sapiens cDNA clone 129446 5′ similar toSP: A46661 A46661 LEUKOTRIENE B4 OMEGA-HYDROXYLASE, P-450LTB OMEGA = CYTOCHROME P-450SUPERFAMILY MEMBER-;.RC_H52937_atyq76e12.s1 Homo sapiens cDNA clone 201742 3′ similar togb: J02982 GLYCOPHORIN B PRECURSOR (HUMAN);.RC_H69547_atyr89e02.s1 Homo sapiens cDNA clone 212474 3′.RC_H70047_atyu73c12.s1 Homo sapiens cDNA clone 239446 3′.RC_N24879_atyx99c11.s1 Homo sapiens cDNA clone 269876 3′.RC_N66312_atyz38a06.s1 Homo sapiens cDNA clone 285298 3′.RC_R22189_atyh26a02.s1 Homo sapiens cDNA clone 130826 3′.RC_R45582_atyg44f05.s1 Homo sapiens cDNA clone 35270 3′.RC_R53457_atyg83e10.s1 Homo sapiens cDNA clone 39835 3′.RC_R70903_atyi49g10.s1 Homo sapiens cDNA clone 142626 3′.RC_AA054321_szl68c01.s1 Stratagene colon (#937204) Homo sapiens cDNAatclone 509760 3′.RC_AA099820_atzk87c05.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 489800 3′.RC_AA127238_atzl17g05.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 502232 3′.RC_AA147224_atzo64h02.s1 Stratagene pancreas (#937208) Homo sapienscDNA clone 591699 3′.RC_AA192765_atzq12e02.s1 Stratagene muscle 937209 Homo sapiens cDNAclone 629498 3′.RC_AA195718_atzr33d07.s1 Soares NhHMPu S1 Homo sapiens cDNA clone665197 3′.RC_AA232114_szr28b08.s1 Stratagene NT2 neuronal precursor 937230 Homoatsapiens cDNA clone 664695 3′ similar to gb: L05779 SOLUBLEEPOXIDE HYDROLASE (HUMAN);.RC_AA281770_atzt07h12.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 712487 3′.RC_AA430209_atzw59e03.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 774364 3′ similar to TR: G1199667 G1199667 PROTEINKINASE C-BINDING PROTEIN ENIGMA;.RC_AA452410_atzx31f03.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 788093 3′.RC_AA485115_ataa39g12.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 815686 3′.AA099391_s_atzk85e12.r1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 489646 5′.AA131127_atzo16a05.r1 Stratagene colon (#937204) Homo sapiens cDNAclone 587024 5′ similar to SW: CATX_BOVIN P05689 CATHEPSIN;.AA173505_atzp02c06.r1 Stratagene ovarian cancer (#937219) Homo sapienscDNA clone 595210 5′ similar to SW: QRI2_YEAST P43124 HYPOTHETICAL46.1 KD PROTEIN IN PHO2-POL3 INTERGENICREGION. [1];.AA291786_s_atzt39b07.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 724693 5′.AA402971_s_atzu53f10.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 741739 5′.


[0101] In yet another embodiment a gene from the first gene group is selected individually from genes comprising a sequence as identified below by EST
16D84239_atHuman mRNA for lgG Fc binding protein, complete cdsRC_N54841_atyv73b09.s1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone248345 3′.RC_T53389_s_atya88f04.s1 Homo sapiens cDNA clone 68767 3′.RC_T98227_atye30d12.s1 Homo sapiens cDNA clone 119255 3′.RC_AA215379_atzr97c07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 683628 3′.RC_AA256485_atzr81e12.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 682126 3′.RC_AA290679_atzt19f03.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 713597 3′ similar to TR: E92665 E92665 AP56;.RC_AA425309_atzw46c01.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 773088 3′.RC_AA429655_atzw71d04.s1 Soares testis NHT Homo sapiens cDNA clone 781639 3′.RC_AA456981_ataa90h11.s1 Stratagene fetal retina 937202 Homo sapiens cDNAclone 838629 3′ similar to contains Alu repetitive element;.RC_AA461174_atzx70c04.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 796806 3′.W61377_atzd27g09.r1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 341920 5′.


[0102] Second Gene Group


[0103] Genes that are up-regulated (or gained de novo) during the malignant progression of bladder cancer from normal tissue through Ta, T1, T2, T3 and T4 is also within the scope of the invention. These genes are potential oncogenes and may be those genes that create or enhance the malignant growth of the cells. The expression level of these genes may serve as predictive markers for the disease course and treatment response, as a high level may signal an aggressive disease course, and they may serve as targets for therapy, as blocking these genes by e.g. anti-sense therapy, or by biochemical means could inhibit, or slow the tumor growth. Such upregulated (or gained de novo) genes, oncogenes, may be classified according to the present invention as genes belonging to second genes group.


[0104] With respect to bladder tumors genes belonging to the second gene group at least one, such as at least two, for example at least three, such as at least four, such as at least five, such as more than six genes are being expressed and are preferably selected individually from genes comprising a sequence as identified below by EST
17RC_AA116036_atzm79a11.s1 Stratagene neuroepithelium(#937231) Homo sapienscDNA clone 531836 3′.RC_AA101562_atzn76c11.s1 Stratagene NT2 neuronal precursor937230 Homo sapiens cDNA clone 5641163′ similar to contains Alu repetitive element;.RC_H20269_atyn53b04.s1 Homo sapiens cDNA clone 172111 3′.RC_Z40715_atH. sapiens partial cDNA sequence; clone c-2ea12.


[0105] or a sequence as described below
18AA402119_atzu55d04.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 741895 5′ similar to TR: G397579 G397579 LL5 MRNA. ;.RC_AA102581_atzn42d02.s1 Stratagene endothelial cell 937223 Homo sapienscDNA clone 550083 3′.RC_H14089_atym62c07.s1 Homo sapiens cDNA clone 163500 3′.RC_R46079_f_atyg49c02.s1 Homo sapiens cDNA clone 36133 3′.RC_R67918_atyi25g01.s1 Homo sapiens cDNA clone 140304 3′.RC_W15360_atzc17d10.s1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 322579 3′ similar to PIR: S39983 S39983 eps8 protein -mouse;.AA082171_atzn42g07.r1 Stratagene endothelial cell 937223 Homo sapienscDNA clone 550140 5′.AA425593_atzw48f02.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 773307 5′.F15201_atH. sapiens partial cDNA sequence.H15219_atym30f02.r1 Homo sapiens cDNA clone 49693 5′.R60368_atyh04b02.r1 Homo sapiens cDNA clone 42052 5′.R86859_atym86a02.r1 Homo sapiens cDNA clone 165770 5′.RC_AA045342_atzk59g01.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 487152 3′.RC_AA171985_atzo98g05.s1 Stratagene ovarian cancer (#937219) Homo sapienscDNA clone 594968 3′.T63174_s_atyc04e08.r1 Homo sapiens cDNA clone 79718 5′ similar to containsAlu repetitive element;.U90268_atHuman Krit1 mRNA, complete cds.X14787_atHuman mRNA for thrombospondinRC_AA196991_szq10a10.s1 Stratagene muscle 937209 Homo sapiens cDNAatclone 629274 3′ similar to TR: G1049074 G1049074 VASOPRESSIN-ACTIVATED CALCIUM-MOBILIZING PROTEIN. ;.RC_F02470_atH. sapiens partial cDNA sequence; clone c-10c01.RC_F08899_atH. sapiens partial cDNA sequence; clone c-2uc10.RC_H15259_atym30c10.s1 Homo sapiens cDNA clone 49795 3′.RC_H52133_atyo44d04.s1 Homo sapiens cDNA clone 180775 3′.RC_R17059_atyf45a10.s2 Homo sapiens cDNA clone 129786 3′.RC_R45292_atyg46b01.s1 Homo sapiens cDNA clone 35626 3′.


[0106] or a sequence as described below
19C01360_atHUMGS0008341, Human Gene Signature, 3′-directed cDNAsequence.D80002_atHuman mRNA for KIAA0180 gene, partial cdsRC_AA149586_atzl39e03.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 504316 3′.RC_H68772_atyr83f01.s1 Homo sapiens cDNA clone 211897 3′.RC_N30806_atyw65f02.s1 Homo sapiens cDNA clone 257115 3′.RC_N63143_atyz37c12.s1 Homo sapiens cDNA clone 285238 3′.RC_R33146_atyh81f02.s1 Homo sapiens cDNA clone 136155 3′ similar to containsAlu repetitive element;.RC_R46206_atyj53d08.s1 Homo sapiens cDNA clone 152463 3′.RC_R49731_s_atyg71e10.s1 Homo sapiens cDNA clone 38554 3′.AA043223_atzk55g12.r1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 486790 5′.AB002346_atHuman mRNA for KIAA0348 gene, complete cds.D81608_atHuman fetal brain cDNA 5′-end GEN-177B09.M83670_s_atHuman carbonic anhydrase IV mRNA, complete cdsN28843_atyx59d10.r1 Homo sapiens cDNA clone 266035 5′.RC_AA149044_atzl45d09.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 504881 3′.RC_AA258130_atzs35f03.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 687197 3′.RC_AA281743_rzt06h05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneatIMAGE: 712377 3′.RC_AA406338_atzv10f06.s1 Soares NhHMPu S1 Homo sapiens cDNA clone753251 3′.RC_AA424524_atzv90g02.s1 Soares NhHMPu S1 Homo sapiens cDNA clone767090 3′.RC_AA435840_atzt80b08.s1 Soares testis NHT Homo sapiens cDNA clone728631 3′.RC_AA027823_atzk05c04.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 469638 3′.RC_AA084138_atzn17a03.s1 Stratagene neuroepithelium NT2RAMI 937234 Homosapiens cDNA clone 547660 3′.RC_AA135406_atzo28e08.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 588230 3′.RC_AA148923_atzl27g11.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 503204 3′.RC_H98653_atyx12h06.s1 Homo sapiens cDNA clone 261563 3′.RC_N30077_atyw81g11.s1 Homo sapiens cDNA clone 258692 3′.RC_R40166_atyf70a09.s1 Homo sapiens cDNA clone 27448 3′.RC_T90374_atyd43e03.s1 Homo sapiens cDNA clone 111004 3′ similar toSP: POL2_MOUSE P11369 RETROVIRUS-RELATED POL POLYPROTEIN;.RC_Z38182_atH. sapiens partial cDNA sequence; clone c-02a08.


[0107] or a sequence as described below
20RC_AA054726_atZk68e06.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 488002 3′.RC_AA206042_atZq77f02.s1 Stratagene hNT neuron (#937233) Homo sapienscDNA clone 647643 3′ similar to contains element MSR1 repetitiveelement;.RC_R98735_atYr31g12.s1 Homo sapiens cDNA clone 206950 3′.AA115572_s_atZl05d11.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 491445 5′ similar to TR: G895845 G895845 PUTATIVEP64 CLCP PROTEIN. ;.AA430979_atPMY0789 KG1a Lambda Zap Express cDNA Library Homo sapienscDNA 5′.AA489287_atab36e04.r1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 842910 5′.D82226_s_atsimilar to TAT-binding protein-2.H49499_s_atyq20g10.r1 Soares fetal liver spleen 1NFLS Homo sapienscDNA clone 274386 5′.M11844_atHuman prealbumin gene, complete cds.RC_AA026388_atze92c03.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 366436 3′.RC_AA044601_atzk55d05.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 486729 3′.RC_AA182030_atzp57a03.s1 Stratagene endothelial cell 937223 Homo sapienscDNA clone 624268 3′.RC_AA233451_atzr30b02.s1 Stratagene NT2 neuronal precursor 937230 Homosapiens cDNA clone 664875 3′.RC_AA236493_atzr75c10.s1 Soares NhHMPu S1 Homo sapiens cDNA clone669234 3′.RC_AA401098_fzu50g01.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 741456 3′ similar to contains Alu repetitive element;contains element THR repetitive element;.RC_AA441818_atzw62f01.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 774649 3′.RC_AA478109_atzt89d04.s1 Soares testis NHT Homo sapiens cDNA clone729511 3′.RC_AA481430_atzv06g11.s1 Soares NhHMPu S1 Homo sapiens cDNA clone752900 3′.RC_AA488878_ataa55f02.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 824859 3′.RC_AA599032_atae41h03.s1 Gessler Wilms tumor Homo sapiens cDNA clone898421 3′.S73288_atsmall proline-rich protein SPRK [human, odontogenic keratocysts,mRNA Partial, 317 nt].U87459_atHuman autoimmunogenic cancer/testis antigen NY-ESO-1mRNA, complete cdsU88047_atHuman DNA binding protein homolog (DRX) mRNA, partial cdsRC_AA063574_atze25f03.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 360029 3′ similar to gb: X52104 P68 PROTEIN (HUMAN);.RC_AA132524_atzo20c04.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 587430 3′ similar to contains Alu repetitive element;.RC_F09317_atH. sapiens partial cDNA sequence; clone c-2zh11.RC_H12863_atyj14b12.s1 Homo sapiens cDNA clone 148703 3′.RC_N33927_s_atyv25e09.s1 Homo sapiens cDNA clone 243784 3′.RC_R08189_atyf18f03.s1 Homo sapiens cDNA clone 127229 3′.RC_R39191_s_atyc89c12.s1 Homo sapiens cDNA clone 23345 3′.RC_T82323_atAS322 Homo sapiens cDNA clone AS322 3′.RC_T90746_atyd41f10.s1 Homo sapiens cDNA clone 110827 3′.RC_Z39338_atH. sapiens partial cDNA sequence; clone c-17f11.


[0108] or a sequence as described below
21AA011479_atzi01b10.r1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 429499 5′.AA314779_atEST186601 Colon carcinoma (HCC) cell line II Homo sapienscDNA 5′ end,RC_AA084640_atzn20d05.s1 Stratagene neuroepithelium NT2RAMI 937234 Homosapiens cDNA clone 547977 3′.RC_AA121534_atzk89d11.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 490005 3′ similar to gb: X79535 TUBULIN BETA-2CHAIN (HUMAN);.RC_AA131047_szo16f05.s1 Stratagene colon (#937204) Homo sapiens cDNAatclone 587073 3′.RC_AA461549_atzx62b09.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 796025 3′.RC_AA491465_atab04a05.s1 Stratagene fetal retina 937202 Homo sapiens cDNAclone 839792 3′.RC_AA496936_atae32d03.s1 Gessler Wilms tumor Homo sapiens cDNA clone897509 3′.RC_AA598689_atae49a08.s1 Stratagene lung carcinoma 937218 Homo sapienscDNA clone 950198 3′.W26392_at30g3 Human retina cDNA randomly primed sublibrary Homosapiens cDNA,RC_AA004887_atzh90g01.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 428592 3′.RC_AA135153_atzo24g02.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 587858 3′.RC_AA197311_szq50e09.s1 Stratagene neuroepithelium (#937231) Homo sapiensatcDNA clone 645064 3′ similar to gb: M24283 INTERCELLULARADHESION MOLECULE-1 PRECURSOR (HUMAN);.RC_H80622_atyu77b06.s1 Homo sapiens cDNA clone 239795 3′.RC_N64436_atza33a09.s1 Homo sapiens cDNA clone 294328 3′.RC_N67583_atyz42c02.s1 Homo sapiens cDNA clone 285698 3′.RC_R38678_atyc89d05.s1 Homo sapiens cDNA clone 23443 3′.RC_R56066_s_atyg91d08.s1 Homo sapiens cDNA clone 40992 3′.RC_R59292_atyh16a10.s1 Homo sapiens cDNA clone 37689 3′.RC_T24099_atseq2287 Homo sapiens cDNA clone Cot250Ft-b4HB3MA-8 3′.AA150364_atzl07b03.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 491597 5′.AA174185_atPTH207 HTCDL1 Homo sapiens cDNA 5′/3′.AA452353_i_atzx15d05.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 786537 5′.AB002316_atHuman mRNA for KIAA0318 gene, partial cds,H86858_atys72d05.r1 Homo sapiens cDNA clone 220329 5′.M93119_s_atHuman zinc-finger DNA-binding motifs (IA-1) mRNA, completecdsR72037_atyj86c09.r1 Homo sapiens cDNA clone 155632 5′.RC_AA004274_atzh97f02.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 429243 3′ similar to contains element MER22 repetitiveelement;.RC_AA004415_atzh89b04.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 428431 3′.RC_AA007160_at13cDNA30A-3, seq Soares infant brain 1NIB Homo sapienscDNA clone HY18-3 3′.RC_AA053660_atzl74e07.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 510372 3′ similar to contains Alu repetitive element;.RC_AA252603_atzs14a11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 685148 3′.RC_AA411944_atzu03h01.s1 Soares testis NHT Homo sapiens cDNA clone730801 3′.RC_AA412700_atzu12g03.s1 Soares testis NHT Homo sapiens cDNA clone731668 3′.RC_AA430032_atzw65f05.s1 Soares testis NHT Homo sapiens cDNA clone781089 3′.RC_AA430368_atzw20f06.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 769859 3′.RC_AA434113_atzw24b11.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 770205 3′ similar to contains element TAR1 repetitive element;.RC_AA441791_atzw62c02.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 774626 3′.RC_AA449419_atzx05b03.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 785549 3′.RC_AA449914_atzx37g02.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 788690 3′.RC_D59847_atHuman fetal brain cDNA 3′-end GEN-070G07,T95813_f_atye45f10.r1 Homo sapiens cDNA clone 120715 5′ similar togb: V00493_rna1 HEMOGLOBIN ALPHA CHAIN (HUMAN);.W80846_atzd83f05.r1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 347265 5′ similar to SW: SYB2_XENLA P47193SYNAPTOBREVIN 2;.RC_AA031360_szk16f07.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAatclone 470725 3′.RC_AA063624_atze87h05.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 366009 3′ similar to TR: G300372 G300372 CELLGROWTH REGULATING NUCLEOLAR PROTEIN,;;RC_AA076238_atzm19e04.s1 Stratagene pancreas (#937208) Homo sapienscDNA clone 526110 3′ similar to contains Alu repetitive element;.RC_AA076350_atzm91a02.s1 Stratagene ovarian cancer (#937219) Homo sapienscDNA clone 545258 3′.RC_AA101983_atzk87c02.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 489794 3′.RC_AA151245_atzl40f12.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 504431 3′.RC_AA164252_fzq46f06.s1 Stratagene hNT neuron (#937233) Homo sapiensatcDNA clone 632771 3′.RC_AA167006_atzo86b08.s1 Stratagene ovarian cancer (#937219) Homo sapienscDNA clone 593751 3′.RC_AA206225_atzq56g08.s1 Stratagene neuroepithelium (#937231) Homo sapienscDNA clone 645662 3′.RC_D62834_atHuman aorta cDNA 3′-end GEN-330D04,RC_D80981_atHuman fetal brain cDNA 3′-end GEN-121E12,RC_H16772_atym34g02.s1 Homo sapiens cDNA clone 50227 3′.RC_N62522_atyz74f08.s1 Homo sapiens cDNA clone 288807 3′.RC_N68222_atyz56e12.s1 Homo sapiens cDNA clone 287086 3′.RC_T10316_s_atseq1014 Homo sapiens cDNA clone b4HB3MA-COT8-HAP-Ft266 3′.RC_W37382_atzc12c07.s1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 322092 3′.RC_W60582_atzd25e10.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 341706 3′ similar to gb: M38188 OVARIAN GRANULOSACELL 13.0 KD PROTEIN HGR74 (HUMAN);.RC_W84768_atzh53d03.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 415781 3′ similar to contains L1, b1 L1 repetitiveelement;.


[0109] or a sequence as described below
22RC_AA176164_izp23h11.s1 Stratagene neuroepithelium (#937231) Homoatsapiens cDNA clone 610341 3′.W52431_atzc45b12.r1 Soares senescent fibroblasts NbHSF Homo sapienscDNA clone 325247 5′ similar to SW: WDNM_RAT P14730WDNM1 PROTEIN, [2] PIR: S07807;.RC_AA019641_atze62g03.s1 Soares retina N2b4HR Homo sapiens cDNA clone363604 3′ similar to contains element L1 repetitive element;.RC_H13696_atyj09e04.s1 Homo sapiens cDNA clone 148254 3′.RC_N22404_atyw37h03.s1 Homo sapiens cDNA clone 254453 3′.RC_R07501_atye97f06.s1 Homo sapiens cDNA clone 125699 3′.C14412_s_atHuman fetal brain cDNA 5′-end GEN-055A09,RC_AA236455_szr75g02.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneat669266 3′.RC_AA417030_atzu04e07.s1 Soares testis NHT Homo sapiens cDNA clone730884 3′.RC_F10945_atH. sapiens partial cDNA sequence; clone c-3mb07,RC_N29319_atyw84a11.s1 Homo sapiens cDNA clone 258908 3′.RC_N68038_f_atyz53a12.s1 Homo sapiens cDNA clone 286750 3′.


[0110] or a sequence as described below
23RC_AA417030_atzu04e07.s1 Soares testis NHT Homo sapiens cDNA clone730884 3′.RC_AA608545_atae53d05.s1 Stratagene lung carcinoma 937218 Homo sapienscDNA clone 950601 3′.RC_H09261_aty198c12.s1 Homo sapiens cDNA clone 46410 3′ similar to containsAlu repetitive element; contains MSR1 repetitive element;.RC_N68871_atza23h07.s1 Homo sapiens cDNA clone 293437 3′ similar tocontains Alu repetitive element;.AA129196_atzn29d08.r1 Stratagene neuroepithelium NT2RAMI 937234 Homosapiens cDNA clone 548847 5′ similar to SW: NU1M_MOUSEP03888 NADH-UBIQUINONE OXIDOREDUCTASE CHAIN 1;.RC_AA620553ae58g12.s1 Stratagene lung carcinoma 937218 Homo sapienss_atcDNA clone 951142 3′.RC_F10779_atH. sapiens partial cDNA sequence; clone c-3jg08.RC_F10945_atH. sapiens partial cDNA sequence; clone c-3mb07.RC_H65650_atyr72d10.s1 Homo sapiens cDNA clone 210835 3′.RC_N68038_f_atyz53a12.s1 Homo sapiens cDNA clone 286750 3′.


[0111] or a sequence as described below
24RC_AA417030_atzu04e07.s1 Soares testis NHT Homo sapienscDNA clone 730884 3′.RC_AA608545_atae53d05.s1 Stratagene lung carcinoma 937218Homo sapiens cDNA clone 950601 3′.RC_F10945_atH. sapiens partial cDNA sequence; clone c-3mb07.RC_N68038_f_atyz53a12.s1 Homo sapiens cDNA clone 286750 3′.


[0112] In one embodiment the genes belonging to the second gene group are preferably selected individually from genes comprising sequences as identified below by EST
25AB000221_atHomo sapiens mRNA for CC chemokine, complete cds.RC_D60296_atHuman fetal brain cDNA 3′-end GEN-097D06.RC_D60813_atHuman fetal brain cDNA 3′-end GEN-132E11.RC_R49708_s_atYg71a11.s1 Homo sapiens cDNA clone 38542 3′.RC_Z38182_atH. sapiens partial cDNA sequence; clone c-02a08.RC_AA456821_atAa38e07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 815556 3′.RC_AA608545_atae53d05.s1 Stratagene lung carcinoma 937218 Homo sapienscDNA clone 950601 3′.RC_AA620553_sae58g12.s1 Stratagene lung carcinoma 937218 Homo sapiensatcDNA clone 951142 3′.AA095119_atcp3087.seq.F Fetal heart, Lambda ZAP Express Homo sapienscDNA 5′.


[0113] In another embodiment genes from the second gene group are selected individually from genes comprising sequences as identified below by EST
26M63180_atHuman threonyl-tRNA synthetase mRNA, completecdsN89563_s_atHFBEST-40 Human fetal brain QBoqin2 Homosapiens cDNA.RC_D80198_atHuman fetal brain cDNA 3′-end GEN-045C11.RC_F01986_f_atH. sapiens partial cDNA sequence; clone c-0kf11.RC_H18997_atyn51g07.s1 Homo sapiens cDNA clone 171996 3′.RC_AA101562_atzn76c11.s1 Stratagene NT2 neuronal precursor937230 Homo sapiens cDNA clone 564116 3′similar to contains Alu repetitive element;.


[0114] In yet another embodiment genes from the second gene group are selected individually from genes comprising sequences as identified below by EST.
27RC_H20269_atyn53b04.s1 Homo sapiens cDNA clone 172111 3′.RC_Z40715_atH. sapiens partial cDNA sequence; clone c-2ea12.RC_AA116036_atzm79a11.s1 Stratagene neuroepithelium (#937231)Homo sapiens cDNA clone 531836 3′.RC_AA133250_atzn92a08.s1 Stratagene lung carcinoma 937218Homo sapiens cDNA clone 565622 3′.


[0115] In a further embodiment genes from the second gene group are selected individually from genes comprising sequences as identified below by EST.
28RC_R00083_atye73c08.s1 Homo sapiens cDNA clone 123374 3′.RC_R71391_atyj80e01.s1 Homo sapiens cDNA clone 155064 3′.RC_T23991_atseq2147 Homo sapiens cDNA clone NHB3MK-9 3′.RC_T79196_atyd70f06.s1 Homo sapiens cDNA clone 113603 3′ similar tocontains Alu repetitive element;.RC_AA130596_atzo26a09.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 587992 3′.RC_AA459310_rzx89d06.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 810923 3′.RC_AA490965_ataa48f12.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 824207 3′.U88047_atHuman DNA binding protein homolog (DRX) mRNA, partial cdsX56807_atHuman DSC2 mRNA for desmocollins type 2a and 2bAA011479_atzi01b10.r1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 429499 5′.AA296821_atEST112387 Aorta endothelial cells Homo sapiens cDNA 5′ end.


[0116] In a preferred embodiment genes from the second gene group are selected individually from genes comprising sequences as identified below by EST.
29RC_AA054726_atzk68e06.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 488002 3′.RC_AA206042_atzq77f02.s1 Stratagene hNT neuron (#937233) Homo sapienscDNA clone 647643 3′ similar to contains element MSR1 repetitiveelement;.RC_R98735_atyr31g12.s1 Homo sapiens cDNA clone 206950 3′.AA115572_s_atzl05d11.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 491445 5′ similar to TR: G895845 G895845 PUTATIVEP64 CLCP PROTEIN, ;.AA430979_atPMY0789 KG1a Lambda Zap Express cDNA Library Homo sapienscDNA 5′.AA489287_atab36e04.r1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 842910 5′.D82226_s_atsimilar to TAT-binding protein-2.H49499_s_atyq20g10.r1 Soares fetal liver spleen 1NFLS Homo sapienscDNA clone 274386 5′.M11844_atHuman prealbumin gene, complete cds.RC_AA026388_atze92c03.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 366436 3′.RC_AA044601_atzk55d05.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 486729 3′.RC_AA182030_atzp57a03.s1 Stratagene endothelial cell 937223 Homo sapienscDNA clone 624268 3′.RC_AA233451_atzr30b02.s1 Stratagene NT2 neuronal precursor 937230 Homosapiens cDNA clone 664875 3′.RC_AA236493_atzr75c10.s1 Soares NhHMPu S1 Homo sapiens cDNA clone669234 3′.RC_AA401098_fzu50g01.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 741456 3′ similar to contains Alu repetitive element;contains element THR repetitive element;.RC_AA441818_atzw62f01.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 774649 3′.RC_AA478109_atzt89d04.s1 Soares testis NHT Homo sapiens cDNA clone729511 3′.RC_AA481430_atzv06g11.s1 Soares NhHMPu S1 Homo sapiens cDNA clone752900 3′.RC_AA488878_ataa55f02.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 824859 3′.RC_AA599032_atae41h03.s1 Gessler Wilms tumor Homo sapiens cDNA clone898421 3′.S73288_atsmall proline-rich protein SPRK [human, odontogenic keratocysts.mRNA Partial, 317 nt].U87459_atHuman autoimmunogenic cancer/testis antigen NY-ESO-1mRNA, complete cdsU88047_atHuman DNA binding protein homolog (DRX) mRNA, partial cdsRC_AA063574_atze25f03.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 360029 3′ similar to gb: X52104 P68 PROTEIN (HUMAN);.RC_AA132524_atzo20c04.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 587430 3′ similar to contains Alu repetitive element;.RC_F09317_atH. sapiens partial cDNA sequence; clone c-2zh11.RC_H12863_atyj14b12.s1 Homo sapiens cDNA clone 148703 3′.RC_N33927_s_atyv25e09.s1 Homo sapiens cDNA clone 243784 3′.RC_R08189_atyf18f03.s1 Homo sapiens cDNA clone 127229 3′.RC_R39191_s_atyc89c12.s1 Homo sapiens cDNA clone 23345 3′.RC_T82323_atAS322 Homo sapiens cDNA clone AS322 3′.RC_T90746_atyd41f10.s1 Homo sapiens cDNA clone 110827 3′.RC_Z39338_atH. sapiens partial cDNA sequence; clone c-17f11.AA011479_atzi01b10.r1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 429499 5′.AA314779_atEST186601 Colon carcinoma (HCC) cell line II Homo sapienscDNA 5′ end.RC_AA084640_atzn20d05.s1 Stratagene neuroepithelium NT2RAMI 937234 Homosapiens cDNA clone 547977 3′.RC_AA121534_atzk89d11.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 490005 3′ similar to gb: X79535 TUBULIN BETA-2CHAIN (HUMAN);.RC_AA131047_szo16f05.s1 Stratagene colon (#937204) Homo sapiens cDNAatclone 587073 3′.RC_AA461549_atzx62b09.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 796025 3′.RC_AA491465_atab04a05.s1 Stratagene fetal retina 937202 Homo sapiens cDNAclone 839792 3′.RC_AA496936_atae32d03.s1 Gessler Wilms tumor Homo sapiens cDNA clone897509 3′.RC_AA598689_atae49a08.s1 Stratagene lung carcinoma 937218 Homo sapienscDNA clone 950198 3′.W26392_at30g3 Human retina cDNA randomly primed sublibrary Homosapiens cDNA.RC_AA004887_atzh90g01.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 428592 3′.RC_AA135153_atzo24g02.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 587858 3′.RC_AA197311_szq50e09.s1 Stratagene neuroepithelium (#937231) Homo sapiensatcDNA clone 645064 3′ similar to gb: M24283 INTERCELLULARADHESION MOLECULE-1 PRECURSOR (HUMAN);.RC_H80622_atyu77b06.s1 Homo sapiens cDNA clone 239795 3′.RC_N64436_atza33a09.s1 Homo sapiens cDNA clone 294328 3′.RC_N67583_atyz42c02.s1 Homo sapiens cDNA clone 285698 3′.RC_R38678_atyc89d05.s1 Homo sapiens cDNA clone 23443 3′.RC_R56066_s_atyg91d08.s1 Homo sapiens cDNA clone 40992 3′.RC_R59292_atyh16a10.s1 Homo sapiens cDNA clone 37689 3′.RC_T24099_atseq2287 Homo sapiens cDNA clone Cot250Ft-b4HB3MA-8 3′.AA150364_atzl07b03.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 491597 5′.AA174185_atPTH207 HTCDL1 Homo sapiens cDNA 5′/3′.AA452353_i_atzx15d05.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 786537 5′.AB002316_atHuman mRNA for KIAA0318 gene, partial cds.H86858_atys72d05.r1 Homo sapiens cDNA clone 220329 5′.M93119_s_atHuman zinc-finger DNA-binding motifs (IA-1) mRNA, completecdsR72037_atyj86c09.r1 Homo sapiens cDNA clone 155632 5′.RC_AA004274_atzh97f02.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 429243 3′ similar to contains element MER22 repetitiveelement;.RC_AA004415_atzh89b04.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 428431 3′.RC_AA007160_at13cDNA30A-3, seq Soares infant brain 1NIB Homo sapienscDNA clone HY18-3 3′.RC_AA053660_atzl74e07.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 510372 3′ similar to contains Alu repetitive element;.RC_AA252603_atzs14a11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 685148 3′.RC_AA411944_atzu03h01.s1 Soares testis NHT Homo sapiens cDNA clone730801 3′.RC_AA412700_atzu12g03.s1 Soares testis NHT Homo sapiens cDNA clone731668 3′.RC_AA430032_atzw65f05.s1 Soares testis NHT Homo sapiens cDNA clone781089 3′.RC_AA430368_atzw20f06.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 769859 3′.RC_AA434113_atzw24b11.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 770205 3′ similar to contains element TAR1 repetitive element;.RC_AA441791_atzw62c02.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 774626 3′.RC_AA449419_atzx05b03.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 785549 3′.RC_AA449914_atzx37g02.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 788690 3′.RC_D59847_atHuman fetal brain cDNA 3′-end GEN-070G07.T95813_f_atye45f10.r1 Homo sapiens cDNA clone 120715 5′ similar togb: V00493_rna1 HEMOGLOBIN ALPHA CHAIN (HUMAN);.W80846_atzd83f05.r1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 347265 5′ similar to SW: SYB2_XENLA P47193SYNAPTOBREVIN 2;.RC_AA031360_szk16f07.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAatclone 470725 3′.RC_AA063624_atze87h05.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 366009 3′ similar to TR: G300372 G300372 CELLGROWTH REGULATING NUCLEOLAR PROTEIN,;.RC_AA076238_atzm19e04.s1 Stratagene pancreas (#937208) Homo sapienscDNA clone 526110 3′ similar to contains Alu repetitive element;.RC_AA076350_atzm91a02.s1 Stratagene ovarian cancer (#937219) Homo sapienscDNA clone 545258 3′.RC_AA101983_atzk87c02.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 489794 3′.RC_AA151245_atzl40f12.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 504431 3′.RC_AA164252_fzq46f06.s1 Stratagene hNT neuron (#937233) Homo sapiensatcDNA clone 632771 3′.RC_AA167006_atzo86b08.s1 Stratagene ovarian cancer (#937219) Homo sapienscDNA clone 593751 3′.RC_AA206225_atzq56g08.s1 Stratagene neuroepithelium (#937231) Homo sapienscDNA clone 645662 3′.RC_D62834_atHuman aorta cDNA 3′-end GEN-330D04.RC_D80981_atHuman fetal brain cDNA 3′-end GEN-121E12.RC_H16772_atym34g02.s1 Homo sapiens cDNA clone 50227 3′.RC_N62522_atyz74f08.s1 Homo sapiens cDNA clone 288807 3′.RC_N68222_atyz56e12.s1 Homo sapiens cDNA clone 287086 3′.RC_T10316_s_atseq1014 Homo sapiens cDNA clone b4HB3MA-COT8-HAP-Ft266 3′.RC_W37382_atzc12c07.s1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 322092 3′.RC_W60582_atzd25e10.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 341706 3′ similar to gb: M38188 OVARIAN GRANULOSACELL 13,0 KD PROTEIN HGR74 (HUMAN);.RC_W84768_atzh53d03.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 415781 3′ similar to contains L1,b1 L1 repetitiveelement


[0117] In a preferred embodiment genes from the second gene group are selected individually from genes comprising sequences as identified below by EST.
30AA011479_atzi01b10.r1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 429499 5′.AA314779_atEST186601 Colon carcinoma (HCC) cell line II Homo sapienscDNA 5′ end.RC_AA084640_atzn20d05.s1 Stratagene neuroepithelium NT2RAMI 937234 Homosapiens cDNA clone 547977 3′.RC_AA121534_atzk89d11.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 490005 3′ similar to gb: X79535 TUBULIN BETA-2CHAIN (HUMAN);.RC_AA131047_szo16f05.s1 Stratagene colon (#937204) Homo sapiens cDNAatclone 587073 3′.RC_AA461549_atzx62b09.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 796025 3′.RC_AA491465_atab04a05.s1 Stratagene fetal retina 937202 Homo sapiens cDNAclone 839792 3′.RC_AA496936_atae32d03.s1 Gessler Wilms tumor Homo sapiens cDNA clone897509 3′.RC_AA598689_atae49a08.s1 Stratagene lung carcinoma 937218 Homo sapienscDNA clone 950198 3′.W26392_at30g3 Human retina cDNA randomly primed sublibrary Homosapiens cDNA.RC_AA004887_atzh90g01.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 428592 3′.RC_AA135153_atzo24g02.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 587858 3′.RC_AA197311_szq50e09.s1 Stratagene neuroepithelium (#937231) Homo sapiensatcDNA clone 645064 3′ similar to gb: M24283 INTERCELLULARADHESION MOLECULE-1 PRECURSOR (HUMAN);.RC_H80622_atyu77b06.s1 Homo sapiens cDNA clone 239795 3′.RC_N64436_atza33a09.s1 Homo sapiens cDNA clone 294328 3′.RC_N67583_atyz42c02.s1 Homo sapiens cDNA clone 285698 3′.RC_R38678_atyc89d05.s1 Homo sapiens cDNA clone 23443 3′.RC_R56066_s_atyg91d08.s1 Homo sapiens cDNA clone 40992 3′.RC_R59292_atyh16a10.s1 Homo sapiens cDNA clone 37689 3′.RC_T24099_atseq2287 Homo sapiens cDNA clone Cot250Ft-b4HB3MA-8 3′.AA150364_atzl07b03.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 491597 5′.AA174185_atPTH207 HTCDL1 Homo sapiens cDNA 5′/3′.AA452353_i_atzx15d05.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 786537 5′.AB002316_atHuman mRNA for KIAA0318 gene, partial cds.H86858_atys72d05.r1 Homo sapiens cDNA clone 220329 5′.M93119_s_atHuman zinc-finger DNA-binding motifs (IA-1) mRNA, completecdsR72037_atyj86c09.r1 Homo sapiens cDNA clone 155632 5′.RC_AA004274_atzh97f02.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 429243 3′ similar to contains element MER22 repetitiveelement;.RC_AA004415_atzh89b04.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 428431 3′.RC_AA007160_at13cDNA30A-3,seq Soares infant brain 1NIB Homo sapienscDNA clone HY18-3 3′.RC_AA053660_atzl74e07.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 510372 3′ similar to contains Alu repetitive element;.RC_AA252603_atzs14a11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 685148 3′.RC_AA411944_atzu03h01.s1 Soares testis NHT Homo sapiens cDNA clone730801 3′.RC_AA412700_atzu12g03.s1 Soares testis NHT Homo sapiens cDNA clone731668 3′.RC_AA430032_atzw65f05.s1 Soares testis NHT Homo sapiens cDNA clone781089 3′.RC_AA430368_atzw20f06.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 769859 3′.RC_AA434113_atzw24b11.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 770205 3′ similar to contains element TAR1 repetitive element;.RC_AA441791_atzw62c02.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 774626 3′.RC_AA449419_atzx05b03.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 785549 3′.RC_AA449914_atzx37g02.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 788690 3′.RC_D59847_atHuman fetal brain cDNA 3′-end GEN-070G07.T95813_f_atye45f10.r1 Homo sapiens cDNA clone 120715 5′ similar togb: V00493_rna1 HEMOGLOBIN ALPHA CHAIN (HUMAN);.W80846_atzd83f05.r1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 347265 5′ similar to SW: SYB2_XENLA P47193SYNAPTOBREVIN 2;.RC_AA031360_szk16f07.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAatclone 470725 3′.RC_AA063624_atze87h05.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 366009 3′ similar to TR: G300372 G300372 CELLGROWTH REGULATING NUCLEOLAR PROTEIN, ;.RC_AA076238_atzm19e04.s1 Stratagene pancreas (#937208) Homo sapienscDNA clone 526110 3′ similar to contains Alu repetitive element;.RC_AA076350_atzm91a02.s1 Stratagene ovarian cancer (#937219) Homo sapienscDNA clone 545258 3′.RC_AA101983_atzk87c02.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 489794 3′.RC_AA151245_atzl40f12.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 504431 3′.RC_AA164252_fzq46f06.s1 Stratagene hNT neuron (#937233) Homo sapiensatcDNA clone 632771 3′.RC_AA167006_atzo86b08.s1 Stratagene ovarian cancer (#937219) Homo sapienscDNA clone 593751 3′.RC_AA206225_atzq56g08.s1 Stratagene neuroepithelium (#937231) Homo sapienscDNA clone 645662 3′.RC_D62834_atHuman aorta cDNA 3′-end GEN-330D04.RC_D80981_atHuman fetal brain cDNA 3′-end GEN-121E12.RC_H16772_atym34g02.s1 Homo sapiens cDNA clone 50227 3′.RC_N62522_atyz74f08.s1 Homo sapiens cDNA clone 288807 3′.RC_N68222_atyz56e12.s1 Homo sapiens cDNA clone 287086 3′.RC_T10316_s_atseq1014 Homo sapiens cDNA clone b4HB3MA-COT8-HAP-Ft266 3′.RC_W37382_atzc12c07.s1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 322092 3′.RC_W60582_atzd25e10.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 341706 3′ similar to gb: M38188 OVARIAN GRANULOSACELL 13.0 KD PROTEIN HGR74 (HUMAN);.RC_W84768_atzh53d03.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 415781 3′ similar to contains L1, b1 L1 repetitiveelement;.


[0118] In a preferred embodiment genes from the second gene group are selected individually from genes comprising sequences as identified below by EST.
31AA203639_atzx58c10.r1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 446706 5′ similar to contains Alu repetitive element;.M11844_atHuman prealbumin gene, complete cds.RC_AA206042_atzq77f02.s1 Stratagene hNT neuron (#937233) Homo sapienscDNA clone 647643 3′ similar to contains element MSR1 repetitiveelement;.RC_N51097_atyz03e04.s1 Homo sapiens cDNA clone 281982 3′.RC_H05527_atyl70f08.s1 Soares infant brain 1NIB Homo sapiens cDNA clone43327 3′.AA115572_s_atzl05d11.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 491445 5′ similar to TR: G895845 G895845 PUTATIVEP64 CLCP PROTEIN.;.RC_H12863_atyj14b12.s1 Homo sapiens cDNA clone 148703 3′.AA489287_atab36e04.r1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 842910 5′.RC_T96383_atye49h07.s1 Homo sapiens cDNA clone 121117 3′.RC_H56453_atyq98g12.s1 Homo sapiens cDNA clone 203878 3′.RC_AA152194_atzl03h01.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 491281 3′.RC_Z38520_atH. sapiens partial cDNA sequence; clone c-0ed05.RC_R38944_atyd06g09.s1 Homo sapiens cDNA clone 25061 3′ similar to containsAlu repetitive element;.RC_AA133926_atzo16e11.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 587084 3′.RC_N69908_f_atza68f06.s1 Homo sapiens cDNA clone 297731 3′ similar togb: X59244 ZINC FINGER PROTEIN 43 (HUMAN);.RC_AA151945_atzo02c02.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 566498 3′ similar to contains Alu repetitive element;.S83308_atSOX5 = Sry-related HMG box gene {alternatively spliced} [human.testis, mRNA, 1473 nt]RC_AA406570_atzv11b06.s1 Soares NhHMPu S1 Homo sapiens cDNA clone753299 3′.RC_AA058314_atzl67g04.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 509718 3′ similar to contains Alu repetitive element;contains element PTR5 repetitive element;.RC_R98735_atyr31g12.s1 Homo sapiens cDNA clone 206950 3′.


[0119] In a preferred embodiment genes from the second gene group are selected individually from genes comprising sequences as identified below by EST.
32RC_AA054726_atzk68e06.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 488002 3′,RC_AA206042_atzq77f02.s1 Stratagene hNT neuron (#937233) Homo sapienscDNA clone 647643 3′ similar to contains element MSR1 repetitiveelement;,RC_R98735_atyr31g12.s1 Homo sapiens cDNA clone 206950 3′,AA115572_s_atzl05d11.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 491445 5′ similar to TR: G895845 G895845 PUTATIVEP64 CLCP PROTEIN,;,AA430979_atPMY0789 KG1a Lambda Zap Express cDNA Library Homo sapienscDNA 5′,AA489287_atab36e04.r1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 842910 5′,D82226_s_atsimilar to TAT-binding protein-2,H49499_s_atyq20g10.r1 Soares fetal liver spleen 1NFLS Homo sapienscDNA clone 274386 5′,M11844_atHuman prealbumin gene, complete cds,RC_AA026388_atze92c03.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 366436 3′,RC_AA044601_atzk55d05.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 486729 3′,RC_AA182030_atzp57a03.s1 Stratagene endothelial cell 937223 Homo sapienscDNA clone 624268 3′,RC_AA233451_atzr30b02.s1 Stratagene NT2 neuronal precursor 937230 Homosapiens cDNA clone 664875 3′,RC_AA236493_atzr75c10.s1 Soares NhHMPu S1 Homo sapiens cDNA clone669234 3′,RC_AA401098_fzu50g01.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 741456 3′ similar to contains Alu repetitive element;contains element THR repetitive element;,RC_AA441818_atzw62f01.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 774649 3′,RC_AA478109_atzt89d04.s1 Soares testis NHT Homo sapiens cDNA clone729511 3′,RC_AA481430_atzv06g11.s1 Soares NhHMPu S1 Homo sapiens cDNA clone752900 3′,RC_AA488878_ataa55f02.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 824859 3′,RC_AA599032_atae41h03.s1 Gessler Wilms tumor Homo sapiens cDNA clone898421 3′,S73288_atsmall proline-rich protein SPRK [human, odontogenic kerato-cysts, mRNA Partial, 317 nt],U87459_atHuman autoimmunogenic cancer/testis antigen NY-ESO-1mRNA, complete cdsU88047_atHuman DNA binding protein homolog (DRX) mRNA, partial cdsRC_AA063574_atze25f03.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 360029 3′ similar to gb: X52104 P68 PROTEIN (HUMAN);,RC_AA132524_atzo20c04.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 587430 3′ similar to contains Alu repetitive element;,RC_F09317_atH. sapiens partial cDNA sequence; clone c-2zh11,RC_H12863_atyj14b12.s1 Homo sapiens cDNA clone 148703 3′,RC_N33927_s_atyv25e09.s1 Homo sapiens cDNA clone 243784 3′,RC_R08189_atyf18f03.s1 Homo sapiens cDNA clone 127229 3′,RC_R39191_s_atyc89c12.s1 Homo sapiens cDNA clone 23345 3′,RC_T82323_atAS322 Homo sapiens cDNA clone AS322 3′,RC_T90746_atyd41f10.s1 Homo sapiens cDNA clone 110827 3′,RC_Z39338_atH. sapiens partial cDNA sequence; clone c-17f11,


[0120] In one embodiment genes from the second gene group are selected individually from genes comprising sequences as identified below by EST.
33D80002_atHuman mRNA for KIAA0180 gene, partial cdsD82418_atsimilar to none.N28843_atyx59d10.r1 Homo sapiens cDNA clone 266035 5′.RC_F02541_atH. sapiens partial cDNA sequence; clone c-12c11.RC_N30806_atyw65f02.s1 Homo sapiens cDNA clone 257115 3′.RC_R33146_atyh81f02.s1 Homo sapiens cDNA clone 136155 3′ similar tocontains Alu repetitive element;.RC_R40166_atyf70a09.s1 Homo sapiens cDNA clone 27448 3′.RC_R65998_atyi23g09.s1 Homo sapiens cDNA clone 140128 3′.RC_AA027823_atzk05c04.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 469638 3′.RC_AA084138_atzn17a03.s1 Stratagene neuroepithelium NT2RAMI 937234 Homosapiens cDNA clone 547660 3′.RC_AA223902_atzr13a10.s1 Stratagene hNT neuron (#937233) Homo sapienscDNA clone 648666 3′.RC_AA424524_atzv90g02.s1 Soares NhHMPu S1 Homo sapiens cDNA clone767090 3′.RC_AA505136_ataa65d11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 825813 3′.AA043223_atzk55g12.r1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 486790 5′.


[0121] In a preferred embodiment genes from the second gene group are selected individually from genes comprising sequences as identified below by EST
34C01360_atHUMGS0008341, Human Gene Signature, 3′-directed cDNAsequence,D80002_atHuman mRNA for KIAA0180 gene, partial cdsRC_AA149586_atzl39e03.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 504316 3′,RC_H68772_atyr83f01.s1 Homo sapiens cDNA clone 211897 3′,RC_N30806_atyw65f02.s1 Homo sapiens cDNA clone 257115 3′,RC_N63143_atyz37c12.s1 Homo sapiens cDNA clone 285238 3′,RC_R33146_atyh81f02.s1 Homo sapiens cDNA clone 136155 3′ similar to containsAlu repetitive element;,RC_R46206_atyj53d08.s1 Homo sapiens cDNA clone 152463 3′,RC_R49731_s_atyg71e10.s1 Homo sapiens cDNA clone 38554 3′,AA043223_atzk55g12.r1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 486790 5′,AB002346_atHuman mRNA for KIAA0348 gene, complete cds,D81608_atHuman fetal brain cDNA 5′-end GEN-177B09,M83670_s_atHuman carbonic anhydrase IV mRNA, complete cdsN28843_atyx59d10.r1 Homo sapiens cDNA clone 266035 5′,RC_AA149044_atzl45d09.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 504881 3′,RC_AA258130_atzs35f03.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 687197 3′,RC_AA281743_rzt06h05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneatIMAGE: 712377 3′,RC_AA406338_atzv10f06.s1 Soares NhHMPu S1 Homo sapiens cDNA clone753251 3′,RC_AA424524_atzv90g02.s1 Soares NhHMPu S1 Homo sapiens cDNA clone767090 3′,RC_AA435840_atzt80b08.s1 Soares testis NHT Homo sapiens cDNA clone728631 3′,RC_AA027823_atzk05c04.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 469638 3′,RC_AA084138_atzn17a03.s1 Stratagene neuroepithelium NT2RAMI 937234 Homosapiens cDNA clone 547660 3′,RC_AA135406_atzo28e08.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 588230 3′,RC_AA148923_atzl27g11.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 503204 3′,RC_H98653_atyx12h06.s1 Homo sapiens cDNA clone 261563 3′,RC_N30077_atyw81g11.s1 Homo sapiens cDNA clone 258692 3′,RC_R40166_atyf70a09.s1 Homo sapiens cDNA clone 27448 3′,RC_T90374_atyd43e03.s1 Homo sapiens cDNA clone 111004 3′similar toSP: POL2_MOUSE P11369 RETROVIRUS-RELATED POL POLYPROTEIN;,RC_Z38182_atH. sapiens partial cDNA sequence; clone c-02a08,


[0122] In another embodiment genes from the second gene group are selected individually from genes comprising sequences as identified below by EST.
35RC_F03192_atH. sapiens partial cDNA sequence; clone c-1pb12.RC_W81552_atzd87g10.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 347682 3′.RC_F02470_atH. sapiens partial cDNA sequence; clone c-10c01.RC_W44927_atzc20b06.s1 Scares senescent fibroblasts NbHSF Homo sapienscDNA clone 322835 3′ similar to PIR: S44218 S44218 testin —mouse [1];.RC_R45292_atyg46b01.s1 Homo sapiens cDNA clone 35626 3′.RC_H62159_atyr47b09.s1 Homo sapiens cDNA clone 208409 3′ similar to containsAlu repetitive element; contains MER15 repetitive element;.RC_R17059_atyf45a10.s2 Homo sapiens cDNA clone 129786 3′.RC_H15259_atym30c10.s1 Homo sapiens cDNA clone 49795 3′.W26376_at29a6 Human retina cDNA randomly primed sublibrary Homosapiens cDNA.Y09616_atH. sapiens mRNA for putative carboxylesteraseAA425593_atzw48f02.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 773307 5′.RC_AA279980_atzt08e05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 712544 3′.RC_H14089_atym62c07.s1 Homo sapiens cDNA clone 163500 3′.RC_R46079_f_atyg49c02.s1 Homo sapiens cDNA clone 36133 3′.RC_W15360_atzc17d10.s1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 322579 3′ similar to PIR: S39983 S39983 eps8 protein —mouse;.X52773_atHuman mRNA for retinoic acid receptor-like proteinRC_AA053886_sze75b05.s1 Soares fetal heart NbHH19W Homo sapiens cDNAatclone 364785 3′ similar to TR: G451330 G451330 STEROL REGULATORYELEMENT BINDING PROTEIN-2.;.RC_AA143493_atzo31a10.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 588474 3′.RC_Z98492_atHomo sapiens mRNA; expressed sequence tag; cloneDKFZphsnu1_1b13, 3′ read.F15201_atH. sapiens partial cDNA sequence.RC_R61883_atyh10f08.s1 Homo sapiens cDNA clone 42872 3′.W26505_at30e12 Human retina cDNA randomly primed sublibrary Homosapiens cDNA.RC_AA085676_atzn53e03.s1 Stratagene muscle 937209 Homo sapiens cDNAclone 561916 3′.AA018804_atze55c07.r1 Soares retina N2b4HR Homo sapiens cDNA clone362892 5′ similar to SW: RB14_RAT P35287 RAS-RELATEDPROTEIN RAB-14. [1];.U22963_atHuman class I histocompatibility antigen-like protein mRNA.complete cds.RC_R09230_atyf26d08.s1 Homo sapiens cDNA clone 127983 3′.RC_R67918_atyi25g01.s1 Homo sapiens cDNA clone 140304 3′.AA402119_atzu55d04.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 741895 5′ similar to TR: G397579 G397579 LL5 MRNA.;.AA082171_atzn42g07.r1 Stratagene endothelial cell 937223 Homo sapienscDNA clone 550140 5′.R79750_atyi89d09.r1 Homo sapiens cDNA clone 146417 5′.RC_AA431773_atzw80d04.s1 Soares testis NHT Homo sapiens cDNA clone782503 3′.RC_AA280670_atzs97a07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 711540 3′.AA303711_atEST16378 Aorta endothelial cells, TNF alpha-treated Homo sapienscDNA 5′ end.AA400361_atzu64g03.r1 Soares testis NHT Homo sapiens cDNA clone742804 5′.AF007111_atHomo sapiens MDM2-like p53-binding protein (MDMX) mRNA.complete cds.AA504384_ataa59c02.r1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 825218 5′ similar to contains element MIR repetitiveelement;.N88108_atK1565F Fetal heart, Lambda ZAP Express Homo sapiens cDNAclone K1565 5′ similar to EST(YD54C09.R1).RC_AA447769_ataa20e01.s1 Soares NhHMPu S1 Homo sapiens cDNA clone813816 3′.


[0123] In yet another preferred embodiment genes from the second gene group are selected individually from genes comprising sequences as identified below by EST.
36AA402119_atzu55d04.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 741895 5′ similar to TR: G397579 G397579 LL5 MRNA,;,RC_AA102581_atzn42d02.s1 Stratagene endothelial cell 937223 Homo sapienscDNA clone 550083 3′,RC_H14089_atym62c07.s1 Homo sapiens cDNA clone 163500 3′,RC_R46079_f_atyg49c02.s1 Homo sapiens cDNA clone 36133 3′,RC_R67918_atyi25g01.s1 Homo sapiens cDNA clone 140304 3′,RC_W15360_atzc17d10.s1 Soares parathyroid tumor NbHPA Homo sapiens cDNA clone 322579 3′ similar to PIR: S39983 S39983 eps8 protein —mouse;,AA082171_atzn42g07.r1 Stratagene endothelial cell 937223 Homo sapienscDNA clone 550140 5′,AA425593_atzw48f02.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 773307 5′,F15201_atH. sapiens partial cDNA sequence,H15219_atym30f02.r1 Homo sapiens cDNA clone 49693 5′,R60368_atyh04b02.r1 Homo sapiens cDNA clone 42052 5′,R86859_atym86a02.r1 Homo sapiens cDNA clone 165770 5′,RC_AA045342_atzk59g01.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 487152 3′,RC_AA171985_atzo98g05.s1 Stratagene ovarian cancer (#937219) Homo sapienscDNA clone 594968 3′,T63174_s_atyc04e08.r1 Homo sapiens cDNA clone 79718 5′ similar to containsAlu repetitive element;,U90268_atHuman Krit1 mRNA, complete cds,X14787_atHuman mRNA for thrombospondinRC_AA196991_szq10a10.s1 Stratagene muscle 937209 Homo sapiens cDNAatclone 629274 3′ similar to TR: G1049074 G1049074 VASOPRESSIN-ACTIVATED CALCIUM-MOBILIZING PROTEIN,;,RC_F02470_atH. sapiens partial cDNA sequence; clone c-10c01,RC_F08899_atH. sapiens partial cDNA sequence; clone c-2uc10,RC_H15259_atym30c10.s1 Homo sapiens cDNA clone 49795 3′,RC_H52133_atyo44d04.s1 Homo sapiens cDNA clone 180775 3′,RC_R17059_atyf45a10.s2 Homo sapiens cDNA clone 129786 3′,RC_R45292_atyg46b01.s1 Homo sapiens cDNA clone 35626 3′,


[0124] The genes from the second gene group discussed above are preferably genes being expressed in all stages of the biological condition, such as all stages of a bladder tumor, to be used for determining the biological condition.


[0125] Particularly, the genes from the second gene group are selected individually from genes comprising sequences as identified below by EST, and which are associated with muscle invasive tumors.
37RC_R00083_atye73c08.s1 Homo sapiens cDNA clone 123374 3′.RC_R71391_atyj80e01.s1 Homo sapiens cDNA clone 155064 3′.RC_T23991_atseq2147 Homo sapiens cDNA clone NHB3MK-9 3′.RC_T79196_atyd70f06.s1 Homo sapiens cDNA clone 113603 3′ similar to containsAlu repetitive element;.RC_AA130596zo26a09.s1 Stratagene colon (#937204) Homo sapiens cDNA cloneat587992 3′.RC_AA459310zx89d06.s1 Soares ovary tumor NbHOT Homo sapiens cDNA cloner_at810923 3′.RC_AA490965aa48f12.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneatIMAGE: 824207 3′.U88047_atHuman DNA binding protein homolog (DRX) mRNA, partial cdsX56807_atHuman DSC2 mRNA for desmocollins type 2a and 2bAA011479_atzi01b10.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNAclone 429499 5′.AA296821_atEST112387 Aorta endothelial cells Homo sapiens cDNA 5′ end.


[0126] Further, the genes from the second gene group are selected individually from genes comprising sequences as identified below by EST, and which are associated with solid tumors only.
38RC_AA026418_atze92h01.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 366481 3′.RC_D59847_atHuman fetal brain cDNA 3′-end GEN-070G07.RC_T24099_atseq2287 Homo sapiens cDNA clone Cot250Ft-b4HB3MA-8 3′.RC_R59292_atyh16a10.s1 Homo sapiens cDNA clone 37689 3′.RC_W60582_atzd25e10.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 341706 3′ similar to gb: M38188 OVARIAN GRANULOSACELL 13.0 KD PROTEIN HGR74 (HUMAN);.M63262_atHuman 5-lipoxygenase activating protein (FLAP) geneRC_R38678_atyc89d05.s1 Homo sapiens cDNA clone 23443 3′.W60268_atzd29g01.r1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 342096 5′.AA465016_atzx80d02.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 810051 5′ similar to TR: G1020091 G1020091 NEUROPSIN.;contains element LTR3 repetitive element;.RC_T79842_atyd83f04.s1 Homo sapiens cDNA clone 114847 3′.RC_AA206225_atzq56g08.s1 Stratagene neuroepithelium (#937231) Homo sapienscDNA clone 645662 3′.RC_AA449914_atzx37g02.s1 Soares total fetus Nb2HF8 9w Homo sapienscDNA clone 788690 3′.RC_F10211_atH. sapiens partial cDNA sequence; clone c-3bh08.RC_AA480109_r_atzv41f05.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 756225 3′ similar to TR: G498729 G498729 ZINC FINGERPROTEIN;.RC_AA053102_s_atzl72a06.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 5101303 3′.RC_AA434113_atzw24b11.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 770205 3′ similar to contains element TAR1 repetitiveelement;.RC_AA441791_atzw62c02.s1 Soares total fetus Nb2HF8 9w Homo sapienscDNA clone 774626 3′.RC_N67583_atyz42c02.s1 Homo sapiens cDNA clone 285698 3′.RC_T96077_atye47b12.s1 Homo sapiens cDNA clone 120863 3′.AB002316_atHuman mRNA for KIAA0318 gene, partial cds.RC_W96222_atze10g07.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 358620 3′.M16591_s_atHuman hemopoietic cell protein-tyrosine kinase (HCK) gene,complete cds, clone lambda-a2/1aRC_N59808_atyz76b12.s1 Homo sapiens cDNA clone 288959 3′.RC_F10040_atH. sapiens partial cDNA sequence; clone c-39g09.RC_AA461549_atzx62b09.s1 Soares total fetus Nb2HF8 9w Homo sapienscDNA clone 796025 3′.RC_W68683_atzd35d04.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 342631 3′.RC_AA084640_atzn20d05.s1 Stratagene neuroepithelium NT2RAMI 937234Homo sapiens cDNA clone 547977 3′.C01169_atHUMGS0007858, Human Gene Signature, 3′-directed cDNAsequence.RC_AA491465_atab04a05.s1 Stratagene fetal retina 937202 Homo sapienscDNA clone 839792 3′.RC_W67564_s_atzd41c07.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 343212 3′.J03019_s_atHuman beta-1-adrenergic receptor mRNA, complete cds.RC_H80622_atyu77b06.s1 Homo sapiens cDNA clone 239795 3′.RC_N34686_atyy15h06.s1 Homo sapiens cDNA clone 271355 3′.RC_R56066_s_atyg91d08.s1 Homo sapiens cDNA clone 40992 3′.RC_T34611_atEST71577 Homo sapiens cDNA 3′ end similar to None.RC_AA031373_s_atzk15e12.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 470638 3′.X52056_atHuman mRNA for spi-1 proto-oncogeneN77564_atyz89g12.r1 Homo sapiens cDNA clone 290278 5′.C01765_atHUMGS0003713, Human Gene Signature, 3′-directed cDNAsequence.RC_AA496936_atae32d03.s1 Gessler Wilms tumor Homo sapiens cDNA clone897509 3′.RC_AA027103_atzk04e03.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 469564 3′.RC_R44131_atyg32c11.s1 Homo sapiens cDNA clone 34089 3′.RC_N67227_atyz48f04.s1 Homo sapiens cDNA clone 286303 3′.RC_T96677_atye52f03.s1 Homo sapiens cDNA clone 121373 3′.RC_AA134965_i_atzo23g05.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 587768 3′.RC_T86600_atyd87d10.s1 Homo sapiens cDNA clone 115219 3′.RC_AA054087_atzf51f03.s1 Soares retina N2b4HR Homo sapiens cDNA clone380477 3′.AA444374_atzv76b10.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA5′.RC_H72357_atys04f01.s1 Homo sapiens cDNA clone 213817 3′ similar togb: J04970 CARBOXYPEPTIDASE M PRECURSOR (HUMAN);contains Alu repetitive element;.RC_AA017045_atze37d11.s1 Soares retina N2b4HR Homo sapiens cDNA clone361173 3′.AA010324_atzi09c03.r1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 430276 5′.RC_AA234743_atzs38b09.s1 Soares NhHMPu S1 Homo sapiens cDNA clone687449 3′.RC_AA055892_atzf20d06.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 377483 3′.RC_AA446650_atzw89g02.s1 Soares total fetus Nb2HF8 9w Homo sapienscDNA clone 784178 3′.H91747_s_atys80e03.r1 Homo sapiens cDNA clone 221116 5′.AA401510_s_atzu63c08.r1 Soares testis NHT Homo sapiens cDNA clone742670 5′.RC_W61239_atzd31d10.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 342259 3′.


[0127] In another embodiment the genes from the second gene group are selected individually from genes comprising sequences as identified below by EST, and which are associated with mixed tumors comprising both solid and papilloma elements of invasive type.
39AA203639_atzx58c10.r1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 446706 5′ similar to contains Alu repetitive element;.M11844_atHuman prealbumin gene, complete cds.RC_AA206042_atzq77f02.s1 Stratagene hNT neuron (#937233) Homo sapienscDNA clone 647643 3′ similar to contains element MSR1 repetitiveelement;.RC_N51097_atyz03e04.s1 Homo sapiens cDNA clone 281982 3′.RC_H05527_atyl70f08.s1 Soares infant brain 1NIB Homo sapiens cDNA clone43327 3′.AA115572_s_atzl05d11.r1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 491445 5′ similar to TR: G895845 G895845 PUTATIVEP64 CLCP PROTEIN.;.RC_H12863_atyj14b12.s1 Homo sapiens cDNA clone 148703 3′.AA489287_atab36e04.r1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 842910 5′.RC_T96383_atye49h07.s1 Homo sapiens cDNA clone 121117 3′.RC_H56453_atyq98g12.s1 Homo sapiens cDNA clone 203878 3′.RC_AA152194_atzl03h01.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 491281 3′.RC_Z38520_atH. sapiens partial cDNA sequence; clone c-0ed05.RC_R38944_atyd06g09.s1 Homo sapiens cDNA clone 25061 3′ similar tocontains Alu repetitive element;.RC_AA133926_atzo16e11.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 587084 3′.RC_N69908_f_atza68f06.s1 Homo sapiens cDNA clone 297731 3′ similar togb: X59244 ZINC FINGER PROTEIN 43 (HUMAN);.RC_AA151945_atzo02c02.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 566498 3′ similar to contains Alu repetitive element;.S83308_atSOX5 = Sry-related HMG box gene {alternatively spliced} [human,testis, mRNA, 1473 nt]RC_AA406570_atzv11b06.s1 Soares NhHMPu S1 Homo sapiens cDNA clone753299 3′.RC_AA058314_atzl67g04.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 509718 3′ similar to contains Alu repetitive element;contains element PTR5 repetitive element;.RC_R98735_atyr31g12.s1 Homo sapiens cDNA clone 206950 3′.


[0128] More particularly the genes from the second gene group are selected individually from genes comprising sequences as identified below by EST, and which are associated with T1 tumors (mucosa invasive tumor)
40D80002_atHuman mRNA for KIAA0180 gene, partial cdsD82418_atsimilar to none.N28843_atyx59d10.r1 Homo sapiens cDNA clone 266035 5′.RC_F02541H. sapiens partial cDNA sequence; clone c-12c11.atRC_N30806yw65f02.s1 Homo sapiens cDNA clone 257115 3′.atRC_R33146yh81f02.s1 Homo sapiens cDNA clone 136155 3′ similar to containsatAlu repetitive element;.RC_R40166yf70a09.s1 Homo sapiens cDNA clone 27448 3′.atRC_R65998yi23g09.s1 Homo sapiens cDNA clone 140128 3′.atRC_AA027823zk05c04.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAatclone 469638 3′.RC_AA084138zn17a03.s1 Stratagene neuroepithelium NT2RAMI 937234 Homoatsapiens cDNA clone 547660 3′.RC_AA223902zr13a10.s1 Stratagene hNT neuron (#937233) Homo sapiens cDNAatclone 648666 3′.RC_AA424524zv90g02.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 767090at3′.RC_AA505136aa65d11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneatIMAGE: 825813 3′.AA043223_atzk55g12.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 486790 5′.


[0129] Even more particularly the genes from the second gene group are selected individually from genes comprising sequences as identified below by EST, and which are associated with superficial Ta tumors.
41RC_F03192_atH. sapiens partial cDNA sequence; clone c-1pb12.RC_W81552_atzd87g10.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 347682 3′.RC_F02470_atH. sapiens partial cDNA sequence; clone c-10c01.RC_W44927_atzc20b06.s1 Soares senescent fibroblasts NbHSF Homo sapienscDNA clone 322835 3′ similar to PIR: S44218 S44218 testin -mouse [1];.RC_R45292_atyg46b01.s1 Homo sapiens cDNA clone 35626 3′.RC_H62159_atyr47b09.s1 Homo sapiens cDNA clone 208409 3′ similar to containsAlu repetitive element; contains MER15 repetitive element;.RC_R17059_atyf45a10.s2 Homo sapiens cDNA clone 129786 3′.RC_H15259_atym30c10.s1 Homo sapiens cDNA clone 49795 3′.W26376_at29a6 Human retina cDNA randomly primed sublibrary Homosapiens cDNA.Y09616_atH. sapiens mRNA for putative carboxylesteraseAA425593_atzw48f02.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 773307 5′.RC_AA279980_atzt08e05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 712544 3′.RC_H14089_atym62c07.s1 Homo sapiens cDNA clone 163500 3′.RC_R46079_f_atyg49c02.s1 Homo sapiens cDNA clone 36133 3′.RC_W15360_atzc17d10.s1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 322579 3′ similar to PIR: S39983 S39983 eps8 protein -mouse;.X52773_atHuman mRNA for retinoic acid receptor-like proteinRC_AA053886_sze75b05.s1 Soares fetal heart NbHH19W Homo sapiens cDNAatclone 364785 3′ similar to TR: G451330 G451330 STEROL REGULATORYELEMENT BINDING PROTEIN-2.;.RC_AA143493_atzo31a10.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 588474 3′.RC_Z98492_atHomo sapiens mRNA; expressed sequence tag; cloneDKFZphsnu1_1b13, 3′ read.F15201_atH. sapiens partial cDNA sequence.RC_R61883_atyh10f08.s1 Homo sapiens cDNA clone 42872 3′.W26505_at30e12 Human retina cDNA randomly primed sublibrary Homosapiens cDNA.RC_AA085676_atzn53e03.s1 Stratagene muscle 937209 Homo sapiens cDNAclone 561916 3′.AA018804_atze55c07.r1 Soares retina N2b4HR Homo sapiens cDNA clone362892 5′ similar to SW: RB14_RAT P35287 RAS-RELATEDPROTEIN RAB-14. [1];.U22963_atHuman class I histocompatibility antigen-like protein mRNA,complete cds.RC_R09230_atyf26d08.s1 Homo sapiens cDNA clone 127983 3′.RC_R67918_atyi25g01.s1 Homo sapiens cDNA clone 140304 3′.AA402119_atzu55d04.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 741895 5′ similar to TR: G397579 G397579 LL5 MRNA.;.AA082171_atzn42g07.r1 Stratagene endothelial cell 937223 Homo sapienscDNA clone 550140 5′.R79750_atyi89d09.r1 Homo sapiens cDNA clone 146417 5′.RC_AA431773_atzw80d04.s1 Soares testis NHT Homo sapiens cDNA clone782503 3′.RC_AA280670_atzs97a07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 711540 3′.AA303711_atEST16378 Aorta endothelial cells, TNF alpha-treated Homo sapienscDNA 5′ end.AA400361_atzu64g03.r1 Soares testis NHT Homo sapiens cDNA clone742804 5′.AF007111_atHomo sapiens MDM2-like p53-binding protein (MDMX) mRNA,complete cds.AA504384_ataa59c02.r1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 825218 5′ similar to contains element MIR repetitiveelement;.N88108_atK1565F Fetal heart, Lambda ZAP Express Homo sapiens cDNAclone K1565 5′ similar to EST(YD54C09.R1).RC_AA447769_ataa20e01.s1 Soares NhHMPu S1 Homo sapiens cDNA clone813816 3′.


[0130] More particularly the genes from the second gene group are selected individually from genes comprising sequences as identified below by EST, and which are associated with T1 tumors (mucosa invasive tumor).
42D80002_atHuman mRNA for KIAA0180 gene, partial cdsD82418_atsimilar to none.N28843_atyx59d10.r1 Homo sapiens cDNA clone 266035 5′.RC_F02541H. sapiens partial cDNA sequence; clone c-12c11.atRC_N30806yw65f02.s1 Homo sapiens cDNA clone 257115 3′.atRC_R33146yh81f02.s1 Homo sapiens cDNA clone 136155 3′ similar to containsatAlu repetitive element;.RC_R40166yf70a09.s1 Homo sapiens cDNA clone 27448 3′.atRC_R65998yi23g09.s1 Homo sapiens cDNA clone 140128 3′.atRC_AA027823zk05c04.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAatclone 469638 3′.RC_AA084138zn17a03.s1 Stratagene neuroepithelium NT2RAMI 937234 Homoatsapiens cDNA clone 547660 3′.RC_AA223902zr13a10.s1 Stratagene hNT neuron (#937233) Homo sapiens cDNAatclone 648666 3′.RC_AA424524zv90g02.s1 Soares NhHMPu S1 Homo sapiens cDNA clone 767090at3′.RC_AA505136aa65d11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneatIMAGE: 825813 3′.AA043223_atzk55g12.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 486790 5′.


[0131] Number of Genes


[0132] As discussed above, it is possible to use a single gene approach determining the expression of one of the genes only, in order to determine the biological condition of the tissue. It is however preferred that expression from at least one gene from the first group, such as at least two, for example at least three, such as at least four, such as at least five, such as more than six genes are determined as well as expression from at least one gene from the second group, such as at least two, for example at least three, such as at least four, such as at least five, such as more than six genes are determined to obtain a more statistically significant result, that is more independent of the expression level of the individual gene.


[0133] In one embodiment expression from more genes from both groups are determined, such as determination of expression from at least two genes from either of the gene groups, such as determination of expression from at least three genes from either of the gene groups, such as determination of expression from at least four genes from either of the gene groups, such as determination of expression from at least five genes from either of the gene groups, such as determination of expression from at least six genes from either of the gene groups, such as determination of expression from at least seven genes from either of the gene groups.


[0134] A pattern of characteristic expression of one gene can be useful in characterizing a cell type source or a stage of disease. However, more genes may be usefully analyzed. Useful patterns include expression of at least one, two, three, five, ten, fifteen, twenty, twenty-five, fifty, seventy-five, one hundred or several hundred informative genes.


[0135] Expression Level


[0136] Using the results provided in the accompanying figures, a gene is indicated as being expressed if an intensity value of greater than or equal to 20 or scored as P=present by the software is shown. Conversely, an intensity value of less than 20 or scored as A=absent indicates that the gene is not expressed above background levels. Comparison of an expression pattern to another may score a change from expressed to non-expressed, or the reverse. Alternatively, changes in intensity of expression may be scored, either increases or decreases. Any significant change can be used. Typical changes which are more than 2-fold are suitable. Changes which are greater than 5-fold are highly suitable.


[0137] The present invention in particular relates to methods using genes wherein the ratio of the expression level in normal tissue to biological condition tissue for suppressor genes or vice versa of the expression level in biological condition tissue to normal tissue for condition genes is as high as possible, such as at least a two-fold change in expression, such as at least a three-fold change, for example at least a four fold change, such as at least a five fold change, for example at least a six fold change, such as at least a ten fold change, for example at least a fifteen fold change, such as at least a twenty fold change.


[0138] Stages and Grades


[0139] Stage of a bladder tumor indicates how deep the tumor has penetrated. Superficial tumors are termed Ta, T1, T2, T3 and T4 are used to describe increasing degrees of penetration into the muscle. The grade of a bladder tumor is expressed on a scale of I-IV (1-4) according to Bergkvist, A.; Ijungquist, A.; Moberger, B. “Classification of bladder tumours basedf on the cellular pattern. Preliminary report of a clinical-pathological study of 300 cases with a minimum follow-up of eight years”, Acta Chir Scand., 1965, 130(4):371-8). The grade reflects the cytological appearance of the cells. Grade I cells are almost normal. Grade II cells are slightly deviant. Grade III cells are clearly abnormal. And Grade IV cells are highly abnormal. A special form of bladder malignancy is carcinoma-in-situ or dyplasia-in-situ in which the altered cells are located in-situ.


[0140] It is important to classify the stage of a cancer disease, as superficial tumors may require a less intensive treatment than invasive tumors. According to the invention the expression level of genes may be used to identify genes whose expression can be used to identify a certain stage of the disease. These “Classifiers” are divided into those which can be used to identify Ta, T2, T3, and T4 stages. In one aspect of the invention measuring the transcript level of one or more of these genes may lead to a classifier that can add supplementary information to the information obtained from the pathological T2 classification. For example gene expression levels that signify a T2 will be unfavourable to detect in a Ta tumor, as they may signal that the Ta tumor has the potential to become a T2 tumor. The opposite is probably also true, that an expression level that signify Ta will be favorable to have in a T2 tumor. In that way independent information may be obtained from T2-T4 pathological classification and a classification based on gene expression levels is made.


[0141] The method of determining the stage of a tumor may be combined with determination of the biological condition or may be an independent method as such. The difference in expression level of a gene from one stage to the expression level of the gene in another group is preferably at least two-fold, such as at least three-fold.


[0142] Thus, the invention relates to a method of determining the stage of a bladder tumor, wherein the stage is selected from bladder cancer stages Ta, T1; T2, T3 and T4 comprising assaying at least the expression of Ta stage gene from a Ta stage gene group, at least one expression of T1 stage gene from a T1 stage gene group, at least the expression of T2 stage gene from a T2 stage gene group, at least the expression of T3 stage gene from a T3 stage gene group, at least the expression of T4 stage gene from a T4 stage gene group wherein at least one gene from each gene group is expressed in a significantly different amount in that stage than in one of the other stages.


[0143] Preferably, the genes selected may be a gene from each gene group being expressed in a significantly higher amount in that stage than in one of the other stages, such as:


[0144] a Ta stage gene selected individually from any gene comprising a sequence as identified below as EST
43RC_F03192_atH. sapiens partial cDNA sequence; clone c-1pb12.RC_W81552_atzd87g10.s1 Soares fetal heart NbHH19W Homo sapienscDNA clone 347682 3′.RC_F02470_atH. sapiens partial cDNA sequence; clone c-10c01.RC_W44927_atzc20b06.s1 Soares senescent fibroblasts NbHSF Homo sapienscDNA clone 322835 3′ similar to PIR: S44218 S44218testin - mouse [1];.RC_R45292_atyg46b01.s1 Homo sapiens cDNA clone 35626 3′.RC_H62159_atyr47b09.s1 Homo sapiens cDNA clone 208409 3′ similar tocontains Alu repetitive element; contains MER15 repetitiveelement;.RC_R17059_atyf45a10.s2 Homo sapiens cDNA clone 129786 3′.RC_H15259_atym30c10.s1 Homo sapiens cDNA clone 49795 3′.W26376_at29a6 Human retina cDNA randomly primed sublibrary Homosapiens cDNA.Y09616_atH. sapiens mRNA for putative carboxylesteraseAA425593_atzw48f02.r1 Soares total fetus Nb2HF8 9w Homo sapienscDNA clone 773307 5′.RC_AA279980_atzt08e05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 712544 3′.RC_H14089_atym62c07.s1 Homo sapiens cDNA clone 163500 3′.RC_R46079_f_atyg49c02.s1 Homo sapiens cDNA clone 36133 3′.RC_W15360_atzc17d10.s1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 322579 3′ similar to PIR: S39983 S39983 eps8protein - mouse;.X52773_atHuman mRNA for retinoic acid receptor-like proteinRC_AA053886_s_atze75b05.s1 Soares fetal heart NbHH19W Homo sapienscDNA clone 364785 3′ similar to TR: G451330 G451330 STEROLREGULATORY ELEMENT BINDING PROTEIN-2.;.RC_AA143493_atzo31a10.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 588474 3′.RC_Z98492_atHomo sapiens mRNA; expressed sequence tag; cloneDKFZphsnu1_1b13 3′ read.F15201_atH. sapiens partial cDNA sequence.RC_R61883_atyh10f08.s1 Homo sapiens cDNA clone 42872 3′.W26505_at30e12 Human retina cDNA randomly primed sublibrary Homosapiens cDNA.RC_AA085676_atzn53e03.s1 Stratagene muscle 937209 Homo sapiens cDNAclone 561916 3′.AA018804_atze55c07.r1 Soares retina N2b4HR Homo sapiens cDNA clone362892 5′ similar to SW: RB14_RAT P35287 RAS-RELATEDPROTEIN RAB-14. [1];.U22963_atHuman class I histocompatibility antigen-like protein mRNA,complete cds.RC_R09230_atyf26d08.s1 Homo sapiens cDNA clone 127983 3′.RC_R67918_atyi25g01.s1 Homo sapiens cDNA clone 140304 3′.AA402119_atzu55d04.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 741895 5′ similar to TR: G397579 G397579 LL5 MRNA.;.AA082171_atzn42g07.r1 Stratagene endothelial cell 937223 Homo sapienscDNA clone 550140 5′.R79750_atyi89d09.r1 Homo sapiens cDNA clone 146417 5′.RC_AA431773_atzw80d04.s1 Soares testis NHT Homo sapiens cDNA clone782503 3′.RC_AA280670_atzs97a07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 711540 3′.AA303711_atEST16378 Aorta endothelial cells, TNF alpha-treated Homosapiens cDNA 5′ end.AA400361_atzu64g03.r1 Soares testis NHT Homo sapiens cDNA clone742804 5′.AF007111_atHomo sapiens MDM2-like p53-binding protein (MDMX)mRNA, complete cds.AA504384_ataa59c02.r1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 825218 5′ similar to contains element MIR repetitiveelement;.N88108_atK1565F Fetal heart, Lambda ZAP Express Homo sapienscDNA clone K1565 5′ similar to EST(YD54C09.R1).RC_AA447769_ataa20e01.s1 Soares NhHMPu S1 Homo sapiens cDNA clone813816 3′.


[0145] or a sequence as identified below
44UniGene numberHomologous toAA402119_atZu55d04.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 741895 5′ similar to TR: G397579 G397579 LL5 MRNA.;,RC_AA102581_atZn42d02.s1 Stratagene endothelial cell 937223 Homo sapienscDNA clone 550083 3′,RC_H14089_atYm62c07.s1 Homo sapiens cDNA clone 163500 3′,RC_R46079_f_atYg49c02.s1 Homo sapiens cDNA clone 36133 3′,RC_R67918_atYi25g01.s1 Homo sapiens cDNA clone 140304 3′,RC_W15360_atZc17d10.s1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 322579 3′ similar to PIR: S39983 S39983 eps8 protein -mouse;,AA082171_atZn42g07.r1 Stratagene endothelial cell 937223 Homo sapienscDNA clone 550140 5′,AA425593_atZw48f02.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 773307 5′,F15201_atH. sapiens partial cDNA sequence,H15219_atYm30f02.r1 Homo sapiens cDNA clone 49693 5′,R60368_atYh04b02.r1 Homo sapiens cDNA clone 42052 5′,R86859_atYm86a02.r1 Homo sapiens cDNA clone 165770 5′,RC_AA045342_atZk59g01.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 487152 3′,RC_AA171985_atZo98g05.s1 Stratagene ovarian cancer (#937219) Homo sapienscDNA clone 594968 3′,T63174_s_atYc04e08.r1 Homo sapiens cDNA clone 79718 5′ similar to containsAlu repetitive element;,U90268_atHuman Krit1 mRNA, complete cds,X14787_atHuman mRNA for thrombospondinRC_AA196991_sZq10a10.s1 Stratagene muscle 937209 Homo sapiens cDNAatclone 629274 3′ similar to TR: G1049074 G1049074 VASOPRESSIN-ACTIVATED CALCIUM-MOBILIZING PROTEIN.;,RC_F02470_atH. sapiens partial cDNA sequence; clone c-10c01,RC_F08899_atH. sapiens partial cDNA sequence; clone c-2uc10,RC_H15259_atYm30c10.s1 Homo sapiens cDNA clone 49795 3′,RC_H52133_atYo44d04.s1 Homo sapiens cDNA clone 180775 3′,RC_R17059_atYf45a10.s2 Homo sapiens cDNA clone 129786 3′,RC_R45292_atYg46b01.s1 Homo sapiens cDNA clone 35626 3′,


[0146] More preferably, a T1 stage gene is selected individually from any gene comprising a sequence as identified below
45D80002_atHuman mRNA for KIAA0180 gene, partial cdsD82418_atsimilar to none.N28843_atyx59d10.r1 Homo sapiens cDNA clone 266035 5′.RC_F02541_atH. sapiens partial cDNA sequence; clone c-12c11.RC_N30806_atyw65f02.s1 Homo sapiens cDNA clone 257115 3′.RC_R33146_atyh81f02.s1 Homo sapiens cDNA clone 136155 3′ similar tocontains Alu repetitive element;.RC_R40166_atyf70a09.s1 Homo sapiens cDNA clone 27448 3′.RC_R65998_atyi23g09.s1 Homo sapiens cDNA clone 140128 3′.RC_AA027823_atzk05c04.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 469638 3′.RC_AA084138_atzn17a03.s1 Stratagene neuroepithelium NT2RAMI 937234 Homosapiens cDNA clone 547660 3′.RC_AA223902_atzr13a10.s1 Stratagene hNT neuron (#937233) Homo sapienscDNA clone 648666 3′.RC_AA424524_atzv90g02.s1 Soares NhHMPu S1 Homo sapiens cDNA clone767090 3′.RC_AA505136_ataa65d11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 825813 3′.AA043223_atzk55g12.r1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 486790 5′.


[0147] or a sequence as identified below
46UniGene numberHomologous toC01360_atHUMGS0008341, Human Gene Signature, 3′-directed cDNA sequence,D80002_atHuman mRNA for KIAA0180 gene, partial cdsRC_AA149586_atZl39e03.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 504316 3′,RC_H68772_atYr83f01.s1 Homo sapiens cDNA clone 211897 3′,RC_N30806_atYw65f02.s1 Homo sapiens cDNA clone 257115 3′,RC_N63143_atYz37c12.s1 Homo sapiens cDNA clone 285238 3′,RC_R33146_atYh81f02.s1 Homo sapiens cDNA clone 136155 3′ similar to containsAlu repetitive element;,RC_R46206_atYj53d08.s1 Homo sapiens cDNA clone 152463 3′,RC_R49731_s_atYg71e10.s1 Homo sapiens cDNA clone 38554 3′,AA043223_atZk55g12.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 486790 5′,AB002346_atHuman mRNA for KIAA0348 gene, complete cds,D81608_atHuman fetal brain cDNA 5′-end GEN-177B09,M83670_s_atHuman carbonic anhydrase IV mRNA, complete cdsN28843_atYx59d10.r1 Homo sapiens cDNA clone 266035 5′,RC_AA149044_atZl45d09.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 504881 3′,RC_AA258130_atZs35f03.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 687197 3′,RC_AA281743_rZt06h05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneatIMAGE: 712377 3′,RC_AA406338_atZv10f06.s1 Soares NhHMPu S1 Homo sapiens cDNA clone753251 3′,RC_AA424524_atZv90g02.s1 Soares NhHMPu S1 Homo sapiens cDNA clone767090 3′,RC_AA435840_atZt80b08.s1 Soares testis NHT Homo sapiens cDNA clone 7286313′,RC_AA027823_atZk05c04.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 469638 3′,RC_AA084138_atZn17a03.s1 Stratagene neuroepithelium NT2RAMI 937234 Homosapiens cDNA clone 547660 3′,RC_AA135406_atZo28e08.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 588230 3′,RC_AA148923_atZl27g11.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 503204 3′,RC_H98653_atYx12h06.s1 Homo sapiens cDNA clone 261563 3′,RC_N30077_atYw81g11.s1 Homo sapiens cDNA clone 258692 3′,RC_R40166_atYf70a09.s1 Homo sapiens cDNA clone 27448 3′,RC_T90374_atYd43e03.s1 Homo sapiens cDNA clone 111004 3′ similar toSP: POL2_MOUSE P11369 RETROVIRUS-RELATED POL POLYPROTEIN;,RC_Z38182_atH. sapiens partial cDNA sequence; clone c-02a08,


[0148] In yet another preferred embodiment a T2-T4 stage gene is selected individually from any gene comprising a sequence as identified below
47RC_R00083_atye73c08.s1 Homo sapiens cDNA clone 123374 3′.RC_R71391_atyj80e01.s1 Homo sapiens cDNA clone 155064 3′.RC_T23991_atseq2147 Homo sapiens cDNA clone NHB3MK-9 3′.RC_T79196_atyd70f06.s1 Homo sapiens cDNA clone 113603 3′ similar tocontains Alu repetitive element;.RC_AA130596_atzo26a09.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 587992 3′.RC_AA459310_rzx89d06.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 810923 3′.RC_AA490965_ataa48f12.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 824207 3′.U88047_atHuman DNA binding protein homolog (DRX) mRNA, partial cdsX56807_atHuman DSC2 mRNA for desmocollins type 2a and 2bAA011479_atzi01b10.r1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 429499 5′.AA296821_atEST112387 Aorta endothelial cells Homo sapiens cDNA 5′ end.


[0149] or a sequence as identified below
48RC_AA054726_atZk68e06.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 488002 3′,RC_AA206042_atZq77f02.s1 Stratagene hNT neuron (#937233) Homo sapienscDNA clone 647643 3′ similar to contains element MSR1 repetitiveelement;,RC_R98735_atYr31g12.s1 Homo sapiens cDNA clone 206950 3′,AA115572_s_atZl05d11.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 491445 5′ similar to TR: G895845 G895845 PUTATIVEP64 CLCP PROTEIN,;,AA430979_atPMY0789 KG1a Lambda Zap Express cDNA Library Homo sapienscDNA 5′,AA489287_atab36e04.r1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 842910 5′,D82226_s_atsimilar to TAT-binding protein-2,H49499_s_atyq20g10.r1 Soares fetal liver spleen 1NFLS Homo sapienscDNA clone 274386 5′,M11844_atHuman prealbumin gene, complete cds,RC_AA026388_atze92c03.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 366436 3′,RC_AA044601_atzk55d05.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 486729 3′,RC_AA182030_atzp57a03.s1 Stratagene endothelial cell 937223 Homo sapienscDNA clone 624268 3′,RC_AA233451_atzr30b02.s1 Stratagene NT2 neuronal precursor 937230 Homosapiens cDNA clone 664875 3′,RC_AA236493_atzr75c10.s1 Soares NhHMPu S1 Homo sapiens cDNA clone669234 3′,RC_AA401098_fzu50g01.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 741456 3′ similar to contains Alu repetitive element;contains element THR repetitive element;,RC_AA441818_atzw62f01.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 774649 3′,RC_AA478109_atzt89d04.s1 Soares testis NHT Homo sapiens cDNA clone729511 3′,RC_AA481430_atzv06g11.s1 Soares NhHMPu S1 Homo sapiens cDNA clone752900 3′,RC_AA488878_ataa55f02.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 824859 3′,RC_AA599032_atae41h03.s1 Gessler Wilms tumor Homo sapiens cDNA clone898421 3′,S73288_atsmall proline-rich protein SPRK [human, odontogenic keratocysts,mRNA Partial, 317 nt],U87459_atHuman autoimmunogenic cancer/testis antigen NY-ESO-1mRNA, complete cdsU88047_atHuman DNA binding protein homolog (DRX) mRNA, partial cdsRC_AA063574_atze25f03.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 360029 3′ similar to gb: X52104 P68 PROTEIN (HUMAN);,RC_AA132524_atzo20c04.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 587430 3′ similar to contains Alu repetitive element;,RC_F09317_atH. sapiens partial cDNA sequence; clone c-2zh11,RC_H12863_atyj14b12.s1 Homo sapiens cDNA clone 148703 3′,RC_N33927_s_atyv25e09.s1 Homo sapiens cDNA clone 243784 3′,RC_R08189_atyf18f03.s1 Homo sapiens cDNA clone 127229 3′,RC_R39191_s_atyc89c12.s1 Homo sapiens cDNA clone 23345 3′,RC_T82323_atAS322 Homo sapiens cDNA clone AS322 3′,RC_T90746_atyd41f10.s1 Homo sapiens cDNA clone 110827 3′,RC_Z39338_atH. sapiens partial cDNA sequence; clone c-17f11,


[0150] or preferably any gene comprising a sequence as identified below
49AA011479_atzi01b10.r1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 429499 5′,AA314779_atEST186601 Colon carcinoma (HCC) cell line II Homo sapienscDNA 5′ end,RC_AA084640_atzn20d05.s1 Stratagene neuroepithelium NT2RAMI 937234 Homosapiens cDNA clone 547977 3′,RC_AA121534_atzk89d11.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 490005 3′ similar to gb: X79535 TUBULIN BETA-2CHAIN (HUMAN);,RC_AA131047_szo16f05.s1 Stratagene colon (#937204) Homo sapiens cDNAatclone 587073 3′,RC_AA461549_atzx62b09.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 796025 3′,RC_AA491465_atab04a05.s1 Stratagene fetal retina 937202 Homo sapiens cDNAclone 839792 3′,RC_AA496936_atae32d03.s1 Gessler Wilms tumor Homo sapiens cDNA clone897509 3′,RC_AA598689_atae49a08.s1 Stratagene lung carcinoma 937218 Homo sapienscDNA clone 950198 3′,W26392_at30g3 Human retina cDNA randomly primed sublibrary Homosapiens cDNA,RC_AA004887_atzh90g01.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 428592 3′,RC_AA135153_atzo24g02.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 587858 3′,RC_AA197311_szq50e09.s1 Stratagene neuroepithelium (#937231) Homo sapiensatcDNA clone 645064 3′ similar to gb: M24283 INTERCELLULARADHESION MOLECULE-1 PRECURSOR (HUMAN);,RC_H80622_atyu77b06.s1 Homo sapiens cDNA clone 239795 3′,RC_N64436_atza33a09.s1 Homo sapiens cDNA clone 294328 3′,RC_N67583_atyz42c02.s1 Homo sapiens cDNA clone 285698 3′,RC_R38678_atyc89d05.s1 Homo sapiens cDNA clone 23443 3′,RC_R56066_s_atyg91d08.s1 Homo sapiens cDNA clone 40992 3′,RC_R59292_atyh16a10.s1 Homo sapiens cDNA clone 37689 3′,RC_T24099_atseq2287 Homo sapiens cDNA clone Cot250Ft-b4HB3MA-8 3′,AA150364_atzl07b03.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 491597 5′,AA174185_atPTH207 HTCDL1 Homo sapiens cDNA 5′/3′,AA452353_i_atzx15d05.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 786537 5′,AB002316_atHuman mRNA for KIAA0318 gene, partial cds,H86858_atys72d05.r1 Homo sapiens cDNA clone 220329 5′,M93119_s_atHuman zinc-finger DNA-binding motifs (IA-1) mRNA, completecdsR72037_atyj86c09.r1 Homo sapiens cDNA clone 155632 5′,RC_AA004274_atzh97f02.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 429243 3′ similar to contains element MER22 repetitiveelement;,RC_AA004415_atzh89b04.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 428431 3′,RC_AA007160_at13cDNA30A-3,seq Soares infant brain 1NIB Homo sapienscDNA clone HY18-3 3′,RC_AA053660_atzl74e07.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 510372 3′ similar to contains Alu repetitive element;,RC_AA252603_atzs14a11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 685148 3′,RC_AA411944_atzu03h01.s1 Soares testis NHT Homo sapiens cDNA clone730801 3′,RC_AA412700_atzu12g03.s1 Soares testis NHT Homo sapiens cDNA clone731668 3′,RC_AA430032_atzw65f05.s1 Soares testis NHT Homo sapiens cDNA clone781089 3′,RC_AA430368_atzw20f06.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 769859 3′,RC_AA434113_atzw24b11.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 770205 3′ similar to contains element TAR1 repetitive element;,RC_AA441791_atzw62c02.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 774626 3′,RC_AA449419_atzx05b03.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 785549 3′,RC_AA449914_atzx37g02.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 788690 3′,RC_D59847_atHuman fetal brain cDNA 3′-end GEN-070G07,T95813_f_atye45f10.r1 Homo sapiens cDNA clone 120715 5′ similar togb: V00493_rna1 HEMOGLOBIN ALPHA CHAIN (HUMAN);,W80846_atzd83f05.r1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 347265 5′ similar to SW: SYB2_XENLA P47193 SYNAP-TOBREVIN 2;,RC_AA031360_szk16f07.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAatclone 470725 3′,RC_AA063624_atze87h05.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 366009 3′ similar to TR: G300372 G300372 CELLGROWTH REGULATING NUCLEOLAR PROTEIN,;,RC_AA076238_atzm19e04.s1 Stratagene pancreas (#937208) Homo sapienscDNA clone 526110 3′ similar to contains Alu repetitive element;,RC_AA076350_atzm91a02.s1 Stratagene ovarian cancer (#937219) Homo sapienscDNA clone 545258 3′,RC_AA101983_atzk87c02.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 489794 3′,RC_AA151245_atzl40f12.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 504431 3′,RC_AA164252_fzq46f06.s1 Stratagene hNT neuron (#937233) Homo sapiensatcDNA clone 632771 3′,RC_AA167006_atzo86b08.s1 Stratagene ovarian cancer (#937219) Homo sapienscDNA clone 593751 3′,RC_AA206225_atzq56g08.s1 Stratagene neuroepithelium (#937231) Homo sapienscDNA clone 645662 3′,RC_D62834_atHuman aorta cDNA 3′-end GEN-330D04,RC_D80981_atHuman fetal brain cDNA 3′-end GEN-121E12,RC_H16772_atym34g02.s1 Homo sapiens cDNA clone 50227 3′,RC_N62522_atyz74f08.s1 Homo sapiens cDNA clone 288807 3′,RC_N68222_atyz56e12.s1 Homo sapiens cDNA clone 287086 3′,RC_T10316_s_atseq1014 Homo sapiens cDNA clone b4HB3MA-COT8-HAP-Ft266 3′,RC_W37382_atzc12c07.s1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 322092 3′,RC_W60582_atzd25e10.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 341706 3′ similar to gb: M38188 OVARIAN GRANULOSACELL 13,0 KD PROTEIN HGR74 (HUMAN);,RC_W84768_atzh53d03.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 415781 3′ similar to contains L1,b1 L1 repetitiveelement;,


[0151] or a sequence as identified below expressed in solid tumors
50RC_AA026418_atze92h01.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 366481 3′ .RC_D59847_atHuman fetal brain cDNA 3′-end GEN-070G07.RC_T24099_atseq2287 Homo sapiens cDNA clone Cot250Ft-b4HB3MA-8 3′.RC_R59292_atyh16a10.s1 Homo sapiens cDNA clone 37689 3′.RC_W60582_atzd25e10.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 341706 3′ similar to gb: M38188 OVARIAN GRANULOSACELL 13.0 KD PROTEIN HGR74 (HUMAN);.M63262_atHuman 5-lipoxygenase activating protein (FLAP) geneRC_R38678_atyc89d05.s1 Homo sapiens cDNA clone 23443 3′.W60268_atzd29g01.r1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 342096 5′.AA465016_atzx80d02.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 810051 5′ similar to TR: G1020091 G1020091 NEUROPSIN.;contains element LTR3 repetitive element;.RC_T79842_atyd83f04.s1 Homo sapiens cDNA clone 114847 3′.RC_AA206225_atzq56g08.s1 Stratagene neuroepithelium (#937231) Homo sapienscDNA clone 645662 3′.RC_AA449914_atzx37g02.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 788690 3′.RC_F10211_atH. sapiens partial cDNA sequence; clone c-3bh08.RC_AA480109_rzv41f05.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 756225 3′ similar to TR: G498729 G498729 ZINC FINGERPROTEIN;.RC_AA053102_szl72a06.s1 Stratagene colon (#937204) Homo sapiens cDNAatclone 510130 3′.RC_AA434113_atzw24b11.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 770205 3′ similar to contains element TAR1 repetitive element;.RC_AA441791_atzw62c02.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 774626 3′.RC_N67583_atyz42c02.s1 Homo sapiens cDNA clone 285698 3′.RC_T96077_atye47b12.s1 Homo sapiens cDNA clone 120863 3′.AB002316_atHuman mRNA for KIAA0318 gene, partial cds.RC_W96222_atze10g07.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 358620 3′.M16591_s_atHuman hemopoietic cell protein-tyrosine kinase (HCK) gene.complete cds, clone lambda-a2/1aRC_N59808_atyz76b12.s1 Homo sapiens cDNA clone 288959 3′.RC_F10040_atH. sapiens partial cDNA sequence; clone c-39g09.RC_AA461549_atzx62b09.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 796025 3′.RC_W68683_atzd35d04.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 342631 3′.RC_AA084640_atzn20d05.s1 Stratagene neuroepithelium NT2RAMl 937234 Homosapiens cDNA clone 547977 3′.C01169_atHUMGS0007858, Human Gene Signature, 3′-directed cDNAsequence.RC_AA491465_atab04a05.s1 Stratagene fetal retina 937202 Homo sapiens cDNAclone 839792 3′.RC_W67564_s_atzd41c07.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 343212 3′.J03019_s_atHuman beta-1-adrenergic receptor mRNA, complete cds.RC_H80622_atyu77b06.s1 Homo sapiens cDNA clone 239795 3′.RC_N34686_atyy15h06.s1 Homo sapiens cDNA clone 271355 3′.RC_R56066_s_atyg91d08.s1 Homo sapiens cDNA clone 40992 3′.RC_T34611_atEST71577 Homo sapiens cDNA 3′ end similar to None.RC_AA031373_szk15e12.s1 Soares pregnant uterus NbHPU Homo sapiensatcDNA clone 470638 3′.X52056_atHuman mRNA for spi-1 proto-oncogeneN77564_atyz89g12.r1 Homo sapiens cDNA clone 290278 5′.C01765_atHUMGS0003713, Human Gene Signature, 3′-directed cDNAsequence.RC_AA496936_atae32d03.s1 Gessler Wilms tumor Homo sapiens cDNA clone897509 3′.RC_AA027103_atzk04e03.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 469564 3′.RC_R44131_atyg32c11.s1 Homo sapiens cDNA clone 34089 3′.RC_N67227_atyz48f04.s1 Homo sapiens cDNA clone 286303 3′.RC_T96677_atye52f03.s1 Homo sapiens cDNA clone 121373 3′.RC_AA134965_izo23g05.s1 Stratagene colon (#937204) Homo sapiens cDNAatclone 587768 3′.RC_T86600_atyd87d10.s1 Homo sapiens cDNA clone 115219 3′.RC_AA054087_atzf51f03.s1 Soares retina N2bHR Homo sapiens cDNA clone380477 3′.AA444374_atzv76b10.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNA5′.RC_H72357_atys04f01.s1 Homo sapiens cDNA clone 213817 3′ similar togb: J04970 CARBOXYPEPTIDASE M PRECURSOR (HUMAN);contains Alu repetitive element;.RC_AA017045_atze37d11.s1 Soares retina N2b4HR Homo sapiens cDNA clone361173 3′.AA010324_atzi09c03.r1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 430276 5′.RC_AA234743_atzs38b09.s1 Soares NhHMPu S1 Homo sapiens cDNA clone687449 3′.RC_AA055892_atzf20d06.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 377483 3′.RC_AA446650_atzw89g02.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 784178 3′.H91747_s_atys80e03.r1 Homo sapiens cDNA clone 221116 5′.AA401510_s_atzu63c08.r1 Soares testis NHT Homo sapiens cDNA clone742670 5′.RC_W61239_atzd31d10.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 342259 3′.


[0152] or a sequence as identified below expressed in mixed tumors
51AA203639_atzx58c10.r1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 446706 5′ similar to contains Alu repetitive element;.M11844_atHuman prealbumin gene, complete cds.RC_AA206042_atzq77f02.s1 Stratagene hNT neuron (#937233) Homo sapienscDNA clone 647643 3′ similar to contains element MSR1 repetitiveelement;.RC_N51097_atyz03e04.s1 Homo sapiens cDNA clone 281982 3′.RC_H05527_atyl70f08.s1 Soares infant brain 1NIB Homo sapiens cDNA clone43327 3′.AA115572_s_atzl05d11.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 491445 5′ similar to TR: G895845 G895845 PUTATIVEP64 CLCP PROTEIN.;.RC_H12863_atyj14b12.s1 Homo sapiens cDNA clone 148703 3′.AA489287_atab36e04.r1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 842910 5′.RC_T96383_atye49h07.s1 Homo sapiens cDNA clone 121117 3′.RC_H56453_atyq98g12.s1 Homo sapiens cDNA clone 203878 3′.RC_AA152194_atzl03h01.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 491281 3′.RC_Z38520_atH. sapiens partial cDNA sequence; clone c-0ed05.RC_R38944_atyd06g09.s1 Homo sapiens cDNA clone 25061 3′ similar to containsAlu repetitive element;.RC_AA133926_atzo16e11.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 587084 3′.RC_N69908_f_atza68f06.s1 Homo sapiens cDNA clone 297731 3′ similar togb: X59244 ZINC FINGER PROTEIN 43 (HUMAN);.RC_AA151945_atzo02c02.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 566498 3′ similar to contains Alu repetitive element;.S83308_atSOX5 = Sry-related HMG box gene {alternatively spliced} [human,testis, mRNA, 1473 nt]RC_AA406570_atzv11b06.s1 Soares NhHMPu S1 Homo sapiens cDNA clone753299 3′.RC_AA058314_atzl67g04.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 509718 3′ similar to contains Alu repetitive element;contains element PTR5 repetitive element;.RC_R98735_atyr31g12.s1 Homo sapiens cDNA clone 206950 3′.


[0153] The genes selected may be a gene from each gene group being expressed in a significantly lower amount in that stage than in one of the other stages.


[0154] Expression Patterns


[0155] The objects of the invention are achieved by providing one or more of the embodiments described below. In one embodiment a method is provided for determining an expression pattern of a cell sample preferably independent of the proportion of submucosal, muscle and connective tissue cells present. Expression is determined of one or more genes in a sample comprising cells, said genes being selected from the same genes as discussed above and shown in the tables.


[0156] It is an object of the present invention that characteristic patterns of expression of genes can be used to characterize different types of tissue. Thus, for example gene expression patterns can be used to characterize stages and grades of bladder tumors. Similarly, gene expression patterns can be used to distinguish cells having a bladder origin from other cells. Moreover, gene expression of cells which routinely contaminate bladder tumor biopsies has been identified, and such gene expression can be removed or subtracted from patterns obtained from bladder biopsies. Further, the gene expression patterns of single-cell solutions of bladder tumor cells have been found to be substantially without interfering expression of contaminating muscle, submucosal, and connective tissue cells than biopsy samples.


[0157] The one or more genes exclude genes which are expressed in the submucosal, muscle, and connective tissue. A pattern of expression is formed for the sample which is independent of the proportion of submucosal, muscle, and connective tissue cells in the sample.


[0158] In another aspect of the invention a method of determining an expression pattern of a cell sample is provided. Expression is determined of one or more genes in a sample comprising cells. A first pattern of expression is thereby formed for the sample. Genes which are expressed in submucosal, muscle, and connective tissue cells are removed from the first pattern of expression, forming a second pattern of expression which is independent of the proportion of submucosal, muscle, and connective tissue cells in the sample.


[0159] Another embodiment of the invention provides a method for determining an expression pattern of a bladder mucosa or bladder cancer cell. Expression is determined of one or more genes in a sample comprising bladder mucosa or bladder cancer cells; the expression determined forms a first pattern of expression. A second pattern of expression which was formed using the one or more genes and a sample comprising predominantly submucosal, muscle, and connective tissue cells, is subtracted from the first pattern of expression, forming a third pattern of expression. The third pattern of expression reflects expression of the bladder mucosa or bladder cancer cells independent of the proportion of submucosal, muscle, and connective tissue cells present in the sample.


[0160] Diagnosing


[0161] In another embodiment of the invention a method is provided for detecting an invasive tumor in a patient. A marker is detected in a sample of a body fluid. The body fluid is selected from the group consisting of blood, plasma, serum, faeces, mucus, sputum, cerebrospinal fluid and/or urine. The marker is an mRNA or protein expression product of a gene which is more prevalent in submucosal, muscle, and connective tissue than in the body fluid. An increased amount of the marker in the body fluid indicates a tumor which has become invasive in the patient.


[0162] In another aspect of the invention a method is provided for diagnosing a bladder cancer. A first pattern of expression is determined of one or more genes in a sample from bladder tissue suspected of being neoplastic. The first pattern of expression is compared to a second and third reference pattern of expression. The second pattern is of the one or more genes in normal bladder mucosa and the third pattern is of the one or more genes in bladder cancer. A first pattern of expression which is found to be more similar to the third pattern than the second indicates neopiasia of the bladder tissue sample.


[0163] According to yet another aspect of the invention a method is provided for predicting the outcome, or prescribing a treatment of a bladder tumor. A first pattern of expression is determined of one or more genes in a bladder tumor sample. The first pattern is compared to one or more reference patterns of expression determined for bladder tumors at a grade between I and IV. The reference pattern which shares maximum similarity with the first pattern is identified. The outcome or treatment appropriate for the grade of tumor of the reference pattern with the maximum similarity is assigned to the bladder tumor sample.


[0164] In another embodiment of the invention a method is provided for determining the grade of a bladder tumor. A first pattern of expression is determined of one or more genes in a bladder tumor sample. The first pattern is compared to one or more reference patterns of expression determined for bladder tumors at a grade between I and IV. The grade of the reference pattern with the maximum similarity is assigned to the bladder tumor sample.


[0165] Yet another embodiment of the invention provides a method to determine the stage of a bladder tumor as described above. A first pattern of expression is determined of one or more genes in a bladder tumor sample. The first pattern is compared to one or more reference patterns of expression determined for bladder tumors at different stages. The reference pattern which shares maximum similarity with the first pattern is identified. The stage of the reference pattern with the maximum similarity is assigned to the bladder tumor sample.


[0166] In still another embodiment of the invention a method is provided for identifying a tissue sample as being from bladder. A first pattern of expression is determined for one or more genes in a tissue sample. The first pattern is compared to a second pattern of expression determined, obtained for normal mucosa cells. Similarities between the first and the second patterns suggest that the tissue sample is mucosa in its origin. This method being particularly useful when diagnosing metastasis possibly distant from its origin.


[0167] Another aspect of the invention is a method to aid in diagnosing, predicting the outcome, or prescribing treatment of bladder cancer. A first pattern of expression is determined for one or more genes in a first bladder tissue sample. And a second pattern of expression is determined for the one or more genes in a second bladder tissue sample. The first bladder tissue sample is a normal bladder mucosa sample or an earlier stage or lover grade of bladder tumor than the second bladder tissue sample. The first pattern of expression is compared to the second pattern of expression to identify a first set of genes which are increased in the second bladder tissue sample relative to the first bladder tissue sample, and a second set of genes which are decreased in the second bladder tissue sample relative to the first bladder tissue sample. Those genes which are expressed in submucosal, muscle or connective tissue are removed from the first set of genes. Those genes which are not expressed in submucosal, muscle, or connective tissue are removed from the second set of genes.


[0168] Independence of Submucosal, Muscle and Conn Ctive Tissue


[0169] Since a biopsy of the tissue often contains more tissue material such as connective tissue than the tissue to be examined, when the tissue to be examined is epithelial or mucosa, the invention also relates to methods, wherein the expression pattern of the tissue is independent of the amount of connective tissue in the sample.


[0170] Biopsies contain epithelial cells that most often are the targets for the studies, and in addition many other cells that contaminate the epithelial cell fraction to a varying extent. The contaminants include histiocytes, endothelial cells, leukocytes, nerve cells, muscle cells etc. Micro dissection is the method of choice for DNA examination, but in the case of expression studies this procedure is difficult due to RNA degradation during the procedure. The epithelium may be gently removed and the expression in the remaining submucosa and underlying connective tissue (the bladder wall) monitored. Genes expressed at high or low levels in the bladder wall should be interrogated when performing expression monitoring of the mucosa and tumors. A similar approach could be used for studies of epithelia in other organs.


[0171] In one embodiment of the invention normal mucosa lining the bladder lumen from bladders for cancer is scraped off. Then biopsies is taken from the denuded submucosa and connective tissue, reaching approximately 5 mm into the bladder wall, and immediately disintegrated in guanidinium isothiocyanate. Total RNA may be extracted, pooled, and poly(A)+ mRNA may be prepared from the pool followed by conversion to double-stranded cDNA and in vitro transcription into cDNA containing biotin-labeled CTP and UTP.


[0172] Genes that are expressed and genes that are not expressed in bladder wall can both interfere with the interpretation of the expression in a biopsy, and should be considered when interpreting expression intensities in tumor biopsies, as the bladder wall component of a biopsy varies in amount from biopsy to biopsy.


[0173] When having determined the pattern of genes expressed in bladder wall components said pattern may be subtracted from a pattern obtained from the sample resulting in a third pattern related to the mucosa (epithelial) cells.


[0174] In another aspect of the invention a method is provided for determining an expression pattern of a bladder tissue sample independent of the proportion of submucosal, muscle and connective tissue cells present. A single-cell suspension of disaggregated bladder tumor cells is isolated from a bladder tissue sample comprising bladder tumor cells is isolated from a bladder tissue sample comprising bladder cells, submucosal cells, muscle cells, and connective tissue cells. A pattern of expression is thus formed for the sample which is independent of the proportion of submucosal, muscle, and connective tissue cells in the bladder tissue sample.


[0175] Yet another method relates to the elimination of mRNA from bladder wall components before determining the pattern, e.g. by filtration and/or affinity chromatography to remove mRNA related to the bladder wall.


[0176] Detection


[0177] Working with human tumor material requires biopsies, and working with RNA requires freshly frozen or immediately processed biopsies, or chemical pretreatment of the biopsy. Apart from the cancer tissue, biopsies do inevitably contain many different cell types, such as cells present in the blood, connective and muscle tissue, endothelium etc. In the case of DNA studies, microdissection or laser capture are methods of choice, however the time-dependent degradation of RNA makes it difficult to perform manipulation of the tissue for more than a few minutes. Furthermore, studies of expressed sequences may be difficult on the few cells obtained via microdissection or laser capture, as these cells may have an expression pattern that deviates from the predominant pattern in a tumor due to large intratumoral heterogeneity.


[0178] In the present context high density expression arrays may be used to evaluate the impact of bladder wall components in bladder tumor biopsies, and tested preparation of single cell solutions as a means of eliminating the contaminants. The results of these evaluations permit for the design of methods of evaluating bladder samples without the interfering background noise caused by ubiquitous contaminating submucosal, muscle, and connective tissue cells. The evaluating assays of the invention may be of any type.


[0179] While high density expression arrays can be used, other techniques are also contemplated. These include other techniques for assaying for specific mRNA species, including RT-PCR and Northern Blotting, as well as techniques for assaying for particular protein products, such as ELISA, Western blotting, and enzyme assays. Gene expression patterns according to the present invention are determined by measuring any gene product of a particular gene, including mRNA and protein. A pattern may be for one or more genes.


[0180] RNA or protein can be isolated and assayed from a test sample using any techniques known in the art. They can for example be isolated from a fresh or frozen biopsy, from formalin-fixed tissue, from body fluids, such as blood, plasma, serum, urine, or sputum.


[0181] Detection of Expression


[0182] Expression of genes may in general be detected by either detecting mRNA from the cells and/or detecting expression products, such as peptides and proteins.


[0183] mRNA Detection


[0184] The detection of mRNA of the invention may be a tool for determining the developmental stage of a cell type which may be definable by its pattern of expression of messenger RNA. For example, in particular stages of cells, high levels of ribosomal RNA are found whereas relatively low levels of other types of messenger RNAs may be found. Where a pattern is shown to be characteristic of a stage, said stage may be defined by that particular pattern of messenger RNA expression. The mRNA population is a good determinant of a developmental stage, and maybe correlated with other structural features of the cell. In this manner, cells at specific developmental stages will be characterized by the intracellular environment, as well as the extracellular environment. The present invention also allows the combination of definitions based in part upon antigens and in part upon mRNA expression. In one embodiment, the two may be combined in a single incubation step. A particular incubation condition may be found which is compatible with both hybridization recognition and non-hybridization recognition molecules. Thus, e.g. an incubation condition may be selected which allows both specificity of antibody binding and specificity of nucleic acid hybridization. This allows simultaneous performance of both types of interactions on a single matrix. Again, where developmental mRNA patterns are correlated with structural features, or with probes which are able to hybridize to intracellular mRNA populations, a cell sorter may be used to sort specifically those cells having desired mRNA population patterns.


[0185] It is within the general scope of the present invention to provide methods for the detection of mRNA. Such methods often involve sample extraction, PCR amplification, nucleic acid fragmentation and labeling, extension reactions, and transcription reactions.


[0186] Sample Preparation


[0187] The nucleic acid (either genomic DNA or mRNA) may be isolated from the sample according to any of a number of methods well known to those of skill in the art. One of skill will appreciate that where alterations in the copy number of a gene are to be detected genomic DNA is preferably isolated. Conversely; where expression levels of a gene or genes are to be detected, preferably RNA (mRNA) is isolated.


[0188] Methods of isolating total mRNA are well known to those of skill in the art. In one embodiment, the total nucleic acid is isolated from a given sample using, for example, an acid guanidinium-phenol-chloroform extraction method and polyA.sup. and mRNA is isolated by oligo dT column chromatography or by using (dT)n magnetic beads (see, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd.ed.), Vols. 1-3, Cold Spring Harbor Laboratory, (1989), or Current Protocols in Molecular Biology, F. Ausubel et al., ed. Greene Publishing and Wiley-Interscience, New York (1987)).


[0189] The sample may be from tissue and/or body fluids, as defined elsewhere herein. Before analyzing the sample, e.g., on an oligonucleotide array, it will often be desirable to perform one or more sample preparation operations upon the sample. Typically, these sample preparation operations will include such manipulations as extraction of intracellular material, e.g., nucleic acids from whole cell samples, viruses, amplification of nucleic acids, fragmentation, transcription, labeling and/or extension reactions. One or more of these various operations may be readily incorporated into the device of the present invention.


[0190] DNA Extraction


[0191] DNA extraction may be relevant under circumstances where possible mutations in the genes are to be determined in addition to the determination of expression of the genes.


[0192] For those embodiments where whole cells, or other tissue samples are being analyzed, it will typically be necessary to extract the nucleic acids from the cells or viruses, prior to continuing with the various sample preparation operations. Accordingly, following sample collection, nucleic acids may be liberated from the collected cells, viral coat etc. into a crude extract followed by additional treatments to prepare the sample for subsequent operations, such as denaturation of contaminating (DNA binding) proteins, purification, filtration and desalting.


[0193] Liberation of nucleic acids from the sample cells, and denaturation of DNA binding proteins may generally be performed by physical or chemical methods. For example, chemical methods generally employ lysing agents to disrupt the cells and extract the nucleic acids from the cells, followed by treatment of the extract with chaotropic salts such as guanidinium isothiocyanate or urea to denature any contaminating and potentially interfering proteins.


[0194] Alternatively, physical methods may be used to extract the nucleic acids and denature DNA binding proteins, such as physical protrusions within microchannels or sharp edged particles piercing cell membranes and extract their contents. Combinations of such structures with piezoelectric elements for agitation can provide suitable shear forces for lysis.


[0195] More traditional methods of cell extraction may also be used, e.g., employing a channel with restricted cross-sectional dimension which causes cell lysis when the sample is passed through the channel with sufficient flow pressure. Alternatively, cell extraction and denaturing of contaminating proteins may be carried out by applying an alternating electrical current to the sample. More specifically, the sample of cells is flowed through a microtubular array while an alternating electric current is applied across the fluid flow. Subjecting cells to ultrasonic agitation, or forcing cells through microgeometry apertures, thereby subjecting the cells to high shear stress resulting in rupture are also possible extraction methods.


[0196] Filtration


[0197] Following extraction, it will often be desirable to separate the nucleic acids from other elements of the crude extract, e.g. denatured proteins, cell membrane particles and salts. Removal of particulate matter is generally, accomplished by filtration or flocculation. Further, where chemical denaturing methods are used, it may be desirable to desalt the sample prior to proceeding to the next step. Desalting of the sample and isolation of the nucleic acid may generally be carried out in a single step, e.g. by binding the nucleic acids to a solid phase and washing away the contaminating salts, or performing gel filtration chromatography on the sample passing salts through dialysis membranes. Suitable solid supports for nucleic acid binding include e.g. diatomaceous earth or silica (i.e., glass wool). Suitable gel exclusion media also well known in the art may be readily incorporated into the devices of the present invention and is commercially available from, e.g., Pharmacia and Sigma Chemical.


[0198] Alternatively, desalting methods may generally take advantage of the high electrophoretic mobility and negativity of DNA compared to other elements. Electrophoretic methods may also be utilized in the purification of nucleic acids from other cell contaminants and debris. Upon application of an appropriate electric field, the nucleic acids present in, the sample will migrate toward the positive electrode and become trapped on the capture membrane. Sample impurities remaining free of the membrane are then washed away by applying an appropriate fluid flow. Upon reversal of the voltage, the nucleic acids are released from the membrane in a substantially purer form. Further, coarse filters may also be overlaid on the barriers to avoid any fouling of the barriers by particulate matter, proteins or nucleic acids, thereby permitting repeated use.


[0199] Separation of Contaminants by Chromatography


[0200] In a similar aspect, the high electrophoretic mobility of nucleic acids with their negative charges, may be utilized to separate nucleic acids from contaminants by utilizing a short column of a gel or other appropriate matrices or gels which will slow or retard the flow of other contaminants while allowing the faster nucleic acids to pass.


[0201] This invention provides nucleic acid affinity matrices that bear a large number of different nucleic acid affinity ligands allowing the simultaneous selection and removal of a large number of preselected nucleic acids from the sample. Methods of producing such affinity matrices are also provided. In general the methods involve the steps of a) providing a nucleic acid amplification template array comprising a surface to which are attached at least 50 oligonucleotides having different nucleic acid sequences, and wherein each different oligonucleotide is localized in a predetermined region of said surface, the density of said oligonucleotides is greater than about 60 different oligonucleotides per 1 cm.sup.2, and all of said different oligonucleotides have an identical terminal 3′ nucleic acid sequence and an identical terminal 5′ nucleic acid sequence b) amplifying said multiplicity of oligonucleotides to provide a pool of amplified nucleic acids; and c) attaching the pool of nucleic acids to a solid support.


[0202] For example, nucleic acid affinity chromatography is based on the tendency of complementary, single-stranded nucleic acids to form a double-stranded or duplex structure through complementary base pairing. A nucleic acid (either DNA or RNA) can easily be attached to a solid substrate (matrix) where it acts as an immobilized ligand that interacts with and forms duplexes with complementary nucleic acids present in a solution contacted to the immobilized ligand. Unbound components can be washed away from the bound complex to either provide a solution lacking the target molecules bound to the affinity column, or to provide the isolated target molecules themselves. The nucleic acids captured in a hybrid duplex can be separated and released from the affinity matrix by denaturation either through heat, adjustment of salt concentration, or the use of a destabilizing agent such as formamide, TWEEN.TM.-20 denaturing agent, or sodium dodecyl sulfate (SDS).


[0203] Affinity columns (matrices) are typically used either to isolate a single nucleic acid typically by providing a single species of affinity ligand. Alternatively, affinity columns bearing a single affinity ligand (e.g. oligo dt columns) have been used to isolate a multiplicity of nucleic acids where the nucleic acids all share a common sequence (e.g. a polyA).


[0204] Affinity Matrices


[0205] The type of affinity matrix used depends on the purpose of the analysis. For example, where it is desired to analyze mRNA expression levels of particular genes in a complex nucleic acid sample (e.g., total mRNA) it is often desirable to eliminate nucleic acids produced by genes that are constitutively overexpressed and thereby tend to mask gene products expressed at characteristically lower levels. Thus, in one embodiment, the affinity matrix can be used to remove a number of preselected gene products (e.g., actin, GAPDH, etc.). This is accomplished by providing an affinity matrix bearing nucleic acid affinity ligands complementary to the gene products (e.g., mRNAs or nucleic acids derived therefrom) or to subsequences thereof. Hybridization of the nucleic acid sample to the affinity matrix will result in duplex formation between the affinity ligands and their target nucleic acids. Upon elution of the sample from the affinity matrix, the matrix will retain the duplexes nucleic acids leaving a sample depleted of the overexpressed target nucleic acids.


[0206] The affinity matrix can also be used to identify unknown mRNAs or cDNAs in a sample. Where the affinity matrix contains nucleic acids complementary to every known gene (e.g., in a cDNA library, DNA reverse transcribed from an mRNA, mRNA used directly or amplified, or polymerized from a DNA template) in a sample, capture of the known nucleic acids by the affinity matrix leaves a sample enriched for those nucleic acid sequences that are unknown. In effect, the affinity matrix is used to perform a subtractive hybridization to isolate unknown nucleic acid sequences. The remaining “unknown” sequences can then be purified and sequenced according to standard methods.


[0207] The affinity matrix can also be used to capture (isolate) and thereby purify unknown nucleic acid sequences. For example, an affinity matrix can be prepared that contains nucleic acid. (affinity ligands) that are complementary to sequences not previously identified, or not previously known to be expressed in a particular nucleic acid sample. The sample is then hybridized to the affinity matrix and those sequences that are retained on the affinity matrix are “unknown” nucleic acids. The retained nucleic acids can be eluted from the matrix (e.g. at increased temperature, increased destabilizing agent concentration, or decreased salt) and the nucleic acids can then be sequenced according to standard methods.


[0208] Similarly, the affinity matrix can be used to efficiently capture (isolate) a number of known nucleic acid sequences. Again, the matrix is prepared bearing nucleic acids complementary to those nucleic acids it is desired to isolate. The sample is contacted to the matrix under conditions where the complementary nucleic acid sequences hybridize to the affinity ligands in the matrix. The non-hybridized material is washed off the matrix leaving the desired sequences bound. The hybrid duplexes are then denatured providing a pool of the isolated nucleic acids. The different nucleic acids in the pool can be subsequently separated according to standard methods (e.g. gel electrophoresis).


[0209] As indicated above the affinity matrices can be used to selectively remove nucleic acids from virtually any sample containing nucleic acids (e.g. in a cDNA library, DNA reverse transcribed from an mRNA, mRNA used directly or amplified, or polymerized from a DNA template, and so forth). The nucleic acids adhering to the column can be removed by washing with a low salt concentration buffer, a buffer containing a destabilizing agent such as formamide, or by elevating the column temperature.


[0210] In one particularly preferred embodiment, the affinity matrix can be used in a method to enrich a sample for unknown RNA sequences (e.g. expressed sequence tags (ESTs)). The method involves first providing an affinity matrix bearing a library of oligonucleotide probes specific to known RNA (e.g., EST) sequences. Then, RNA from undifferentiated and/or unactivated cells and RNA from differentiated or activated or pathological, (e.g., transformed) or otherwise having a different metabolic state are separately hybridized against the affinity matrices to provide two pools of RNAs lacking the known RNA sequences.


[0211] In a preferred embodiment, the affinity matrix is packed into a columnar casing. The sample is then applied to the affinity matrix (e.g. injected onto a column or applied to a column by a pump such as a sampling pump driven by an autosampler). The affinity matrix (e.g. affinity column) bearing the sample is subjected to conditions under which the nucleic acid probes comprising the affinity matrix hybridize specifically with complementary target nucleic acids. Such conditions are accomplished by maintaining appropriate pH, salt and temperature conditions to facilitate hybridization as discussed above.


[0212] For a number of applications, it may be desirable to extract and separate messenger RNA from cells, cellular debris, and other contaminants. As such, the device of the present invention may, in some cases, include a mRNA purification chamber or channel. In general, such purification takes advantage of the poly-A tails on mRNA. In particular and as noted above, poly-T oligonucleotides may be immobilized within a chamber or channel of the device to serve as affinity ligands for mRNA. Poly-T oligonucleotides may be immobilized upon a solid support incorporated within the chamber or channel, or alternatively, may be immobilized upon the surface(s) of the chamber or channel itself. Immobilization of oligonucleotides on the surface of the chambers or channels may be carried out by methods described herein including, e.g., oxidation and silanation of the surface followed by standard DMT synthesis of the oligonucleotides.


[0213] In operation, the lysed sample is introduced to a high salt solution to increase the ionic strength for hybridization, whereupon the mRNA will hybridize to the immobilized poly-T. The mRNA bound to the immobilized poly-T oligonucleotides is then washed free in a low ionic strength buffer. The poly-T oligonucleotides may be immobiliized upon poroussurfaces, e.g., porous silicon, zeolites silica xerogels, scintered particles, or other solid supports.


[0214] Hybridization


[0215] Following sample preparation, the sample can be subjected to one or more different analysis operations. A variety of analysis operations may generally be performed, including size based analysis using, e.g., microcapillary electrophoresis, and/or sequence based analysis using, e.g., hybridization to an oligonucleotide array.


[0216] In the latter case, the nucleic acid sample may be probed using an array of oligonucleotide probes. Oligonucleotide arrays generally include a substrate having a large number of positionally distinct oligonucleotide probes attached to the substrate. These arrays may be produced using mechanical or light directed synthesis methods which incorporate a combination of photolithographic methods and solid phase oligonucleotide synthesis methods.


[0217] Light Directed Synthesis of Oligonucleotide Arrays


[0218] The basic strategy for light directed synthesis of oligonucleotide arrays is as follows. The surface of a solid support, modified with photosensitive protecting groups is illuminated through a photolithographic mask, yielding reactive hydroxyl groups in the illuminated regions. A selected nucleotide, typically in the form of a 3′-O-phosphoramidite-activated deoxynucleoside (protected at the 5′ hydroxyl with a photosensitive protecting group), is then presented to the surface and coupling occurs at the sites that were exposed to light. Following capping and oxidation, the substrate is rinsed and the surface is illuminated through a second mask to expose additional hydroxyl groups for coupling. A second selected nucleotide (e.g., 5′-protected, 3′-O-phosphoramidite-activated deoxynucleoside) is presented to the surface. The selective deprotection and coupling cycles are repeated until the desired set of products is obtained. Since photolithography is used the process can be readily miniaturized to generate high density arrays of oligonucleotide probes. Furthermore, the sequence of the oligonucleotides at each site is known. See Pease et al. Mechanical synthesis methods are similar to the light directed methods except involving mechanical direction of fluids for deprotection and addition in the synthesis steps.


[0219] For some embodiments, oligonucleotide arrays may be prepared having all possible probes of a given length. The hybridization pattern of the target sequence on the array may be used to reconstruct the target DNA sequence. Hybridization analysis of large numbers of probes can be used to sequence long stretches of DNA or provide an oligonucleotide array which is specific and complementary to a particular nucleic acid sequence. For example, in particularly preferred aspects, the oligonucleotide array will contain oligonucleotide probes which are complementary to specific target sequences, and individual or multiple mutations of these. Such arrays are particularly useful in the diagnosis of specific disorders which are characterized by the presence of a particular nucleic acid sequence.


[0220] Following sample collection and nucleic acid extraction, the nucleic acid portion of the sample is typically subjected to one or more preparative reactions. These preparative reactions include in vitro transcription, labeling, fragmentation, amplification and other reactions. Nucleic acid amplification increases the number of copies of the target nucleic acid sequence of interest. A variety of amplification methods are suitable for use in the methods and device of the present invention, including for example, the polymerase chain reaction method or (PCR), the ligase chain reaction (LCR), self sustained sequence replication (3SR), and nucleic acid based sequence amplification (NASBA).


[0221] The latter two amplification methods involve isothermal reactions based on isothermal transcription, which produce both single stranded RNA (ssRNA) and double stranded DNA (dsDNA) as the amplification products in a ratio of approximately 30 or 100 to 1, respectively. As a result, where these latter methods are employed, sequence analysis may be carried out using either type of substrate, i.e. complementary to either DNA or RNA.


[0222] Frequently, it is desirable to amplify the nucleic acid sample prior to hybridization. One of skill in the art will appreciate that whatever amplification method is used, if a quantitative result is desired, care must be taken to use a method that maintains or controls for the relative frequencies of the amplified nucleic acids.


[0223] PCR


[0224] Methods of “quantitative” amplification are well known to those of skill in the art. For example, quantitative PCR involves simultaneously co-amplifying a known quantity of a control sequence using the same primers. This provides an internal standard that may be used to calibrate the PCR reaction. The high density array may then include probes specific to the internal standard for quantification of the amplified nucleic acid.


[0225] Thus, in one embodiment, this invention provides-for a method of optimizing a probe set for detection of a particular gene. Generally, this method involves providing a high density array containing a multiplicity of probes of one or more particular length(s) that are complementary to subsequences of the mRNA transcribed by the target gene. In one embodiment the high density array may contain every probe of a particular length that is complementary to a particular mRNA. The probes of the high density array are then hybridized with their target nucleic acid alone and then hybridized with a high complexity, high concentration nucleic acid sample that does not contain the targets complementary to the probes. Thus, for example, where the target nucleic acid is an RNA, the probes are first hybridized with their target nucleic acid alone and then hybridized with RNA made from a cDNA library (e.g., reverse transcribed polyA.sup.+mRNA) where the sense of the hybridized RNA is opposite that of the target nucleic acid (to insure that the high complexity sample does not contain targets for the probes). Those probes that show a strong hybridization signal with their target and little or no cross-hybridization with the high complexity sample are preferred probes for use in the high density arrays of this invention.


[0226] PCR amplification generally involves the use of one strand of the target nucleic acid sequence as a template for producing a large number of complements to that sequence. Generally, two primer sequences complementary to different ends of a segment of the complementary strands of the target sequence hybridize with their respective strands of the target sequence, and in the presence of polymerase enzymes and nucleoside triphosphates, the primers are extended along the target sequence. The extensions are melted from the target sequence and the process is repeated, this time with the additional copies of the target sequence synthesized in the preceding steps. PCR amplification typically involves repeated cycles of denaturation, hybridization and extension reactions to produce sufficient amounts of the target nucleic acid. The first step of each cycle of the PCR involves the separation of the nucleic acid duplex formed by the primer extension. Once the strands are separated, the next step in PCR involves hybridizing the separated strands with primers that flank the target sequence. The primers are then extended to form complementary copies of the target strands. For successful PCR amplification, the primers are designed so that the position at which each primer hybridizes along a duplex sequence is such that an extension product synthesized from one primer, when separated from the template (complement), serves as a template for the extension of the other primer. The cycle of denaturation, hybridization, and extension is repeated as many times as necessary to obtain the desired amount of amplified nucleic acid.


[0227] In PCR methods, strand separation is normally achieved by heating the reaction to a sufficiently high temperature for a sufficient time to cause the denaturation of the duplex but not to cause an irreversible denaturation of the polymerase. Typical heat denaturation involves temperatures ranging from about 80.degree. C. to 105.degree. C. for times ranging from seconds to minutes. Strand separation, however, can be accomplished by any suitable denaturing method including physical, chemical, or enzymatic means. Strand separation may be induced by a helicase, for example, or an enzyme capable of exhibiting helicase activity.


[0228] In addition to PCR and IVT reactions, the methods and devices of the present invention are also applicable to a number of other reaction types, e.g., reverse transcription, nick translation, and the like.


[0229] Labelling Before Hybridization


[0230] The nucleic acids in a sample will generally be labeled to facilitate detection in subsequent steps. Labeling may be carried out during the amplification, in vitro transcription or nick translation processes. In particular, amplification, in vitro transcription or nick translation may incorporate a label into the amplified or transcribed sequence, either through the use of labeled primers or the incorporation of labeled dNTPs into the amplified sequence.


[0231] Hybridization between the sample nucleic acid and the oligonucleotide probes upon the array is then detected, using, e.g., epifluorescence confocal microscopy. Typically, sample is mixed during hybridization to enhance hybridization of nucleic acids in the sample to nucleoc acid probes on the array.


[0232] Labelling After Hybridization


[0233] In some cases, hybridized oligonucleotides may be labeled following hybridization. For example, where biotin labeled dNTPs are used in, e.g. amplification or transcription, streptavidin linked-reporter groups may be used to label hybridized complexes. Such operations are readily integratable into the systems of the present invention. Alternatively, the nucleic acids in the sample may be labeled following amplification. Post amplification labeling typically involves the covalent, attachment of a particular detectable group upon the amplified sequences. Suitable labels or detectable groups include a variety of fluorescent or radioactive labeling groups well known in the art. These labels may also be coupled to the sequences using methods that are well known in the art.


[0234] Methods for detection depend upon the label selected. A fluorescent label is preferred because of its extreme sensitivity and simplicity. Standard labeling procedures are used to determine the positions where interactions between a sequence and a reagent take place. For example, if a target sequence is labeled and exposed to a matrix of different probes, only those locations where probes do interact with the target will exhibit any signal. Alternatively, other methods may be used to scan the matrix to determine where interaction takes place. Of course, the spectrum of interactions may be determined in a temporal manner by repeated scans of interactions which occur at each of a multiplicity of conditions. However, instead of testing each individual interaction separately, a multiplicity of sequence interactions may be simultaneously determined on a matrix.


[0235] Means of detecting labeled target (sample) nucleic acids hybridized to the probes of the high density array are known to those of skill in the art. Thus, for example, where a colorimetric label is used, simple visualization of the label is sufficient. Where a radioactive labeled probe is used, detection of the radiation (e.g with photographic film or a solid state detector) is sufficient.


[0236] In a preferred embodiment, however, the target nucleic acids are labeled with a fluorescent label and the localization of the label on the probe array is accomplished with fluorescent microscopy. The hybridized array is excited with a light source at the excitation wavelength of the particular fluorescent label and the resulting fluorescence at the emission wavelength is detected. In a particularly preferred embodiment, the excitation light source is a laser appropriate for the excitation of the fluorescent label.


[0237] The target polynucleotide may be labeled by any of a number of convenient detectable markers. A fluorescent label is preferred because it provides a very strong signal with low background. It is also optically detectable at high resolution and sensitivity through a quick scanning procedure. Other potential labeling moieties include, radioisotopes, chemiluminescent compounds, labeled, binding proteins, heavy metal atoms, spectroscopic markers, magnetic labels, and linked enzymes. Another method for labeling may bypass any label of the target sequence. The target may be exposed to the probes, and a double strand hybrid is formed at those positions only. Addition of a double strand specific reagent will detect where hybridization takes place. An intercalative dye such as ethidium bromide may be used as long as the probes themselves do not fold back on themselves to a significant extent forming hairpin loops. However, the length of the hairpin loops in short oligonucleotide probes would typically be insufficient to form a stable duplex.


[0238] Suitable chromogens will include molecules and compounds which absorb light in a distinctive range of wavelengths so that a color may be observed, or emit light when irradiated with radiation of a particular wave length or wave length range, e.g., fluorescers. Biliproteins, e.g., phycoerythrin, may also serve as labels.


[0239] A wide variety of suitable dyes are available, being primarily chosen to provide an intense color with minimal absorption by their surroundings. Illustrative dye types include quinoline dyes, triarylmethane dyes, acridine dyes, alizarine dyes, phthaleins, insect dyes, azo dyes, anthraquinoid dyes, cyanine dyes, phenazathionium dyes, and phenazoxonium dyes.


[0240] A wide variety of fluorescers may be employed either by themselves or in conjunction with quencher molecules. Fluorescers of interest fall into a variety of categories having certain primary functionalities. These primary functionalities include 1- and 2-aminonaphthalene, p,p′-diaminostilbenes, pyrenes, quaternary phenanthridine salts, 9-aminoacridines, p,p′-diaminobenzophenone imines, anthracenes, oxacarbocyanine, merocyanine, 3-aminoequilenin, perylene, bis-benzoxazole, bis-p-oxazolyl benzene, 1,2-benzophenazin, retinol, bis-3-aminopyridinium salts, hellebrigenin, tetracycline, sterophenol, benzimidzaolylphenylamine, 2-oxo-3-chromen, indole, xanthen, 7-hydroxycoumarin, phenoxazine, salicylate, strophanthidin, porphyrins, triarylmethanes and flavin. Individual fluorescent compounds which have functionalities for linking or which can be modified to incorporate such functionalities include, e.g., dansyl chloride; fluoresceins such as 3,6-dihydroxy-9-phenylxanthhydrol; rhodamineisothiocyanate; N-phenyl 1-amino-8-sulfonatonaphthalene; N-phenyl 2-amino-6-sulfonatonaphthalene; 0.4-acetamido-4-isothiocyanato-stilbene-2,2′-disulfonic acid; pyrene-3-sulfonic acid; 2-toluidinonaphthalene-6-sulfonate; N-phenyl, N-methyl 2-aminoaphthalene-6-sulfonate; ethidium bromide; stebrine; auromine-0,2-(9′-anthroyl)palmitate; dansyl phosphatidylethanolamine; N,N′-dioctadecyl oxacarbocyanine; N,N′-dihexyl oxacarbocyanine; merocyanine, 4-(3′-pyrenyl)butyrate; d-3-aminodesoxy-equilenin; 1,2-(9′-anthroyl)stearate; 2-methylanthracene; 9-vinylanthracene; 2,2′-(vinylene-p-phenylene)bisbenzoxazole; p-bis)2-(4-methyl-5-phenyl-oxazolyl) benzene; 6-dimethylamino-1,2-benzophenazin; retinol; bis(3′-aminopyridinium) 1,10-decandiyl diiodide; sulfonaphthylhydrazone of hellibrienin; chlorotetracycline; N-(7-dimethylamino-4-methyl-2-oxo-3-chromenyl)maleimide; N-)p-(2-benzimidazolyl)-phenyl!maleimide; N-(4-fluoranthyl)maleimide; bis(homovanillic acid); resazarin; 4-chloro-7-nitro-2,1,3-benzooxadiazole; merocyanine 540; resorufin; rose bengal; and 2,4-diphenyl-3(2H)-furanone.


[0241] Desirably, fluorescers should absorb light above about 300 nm, preferably about 350 nm, and more preferably above about 400 nm, usually emitting at wavelengths greater than about 10 nm higher than the wavelength of the light absorbed. It should be noted that the absorption and emission characteristics of the bound dye may differ from the unbound dye; Therefore, when referring to the various wavelength ranges and characteristics of the dyes, it is intended to indicate the dyes as employed and not the dye which is unconjugated and characterized in an arbitrary solvent.


[0242] Fluorescers are generally preferred because by irradiating a fluorescer with light, one can obtain a plurality of emissions. Thus, a single label can provide for a plurality of measurable events.


[0243] Detectable signal may also be provided by chemiluminescent and bioluminescent sources. Chemiluminescent sources include a compound which becomes electronically excited by a chemical reaction and may then emit light which serves as the detectible signal or donates energy to a fluorescent acceptor. A diverse number of families of compounds have been found to provide chemiluminescence under a variety of conditions. One family of compounds is 2,3-dihydro-1,-4-phthalazinedione. The most popular compound is luminol, which is the 5-amino compound. Other members of the family include the 5-amino-6,7,8-trimethoxy- and the dimethylamino<calbenz analog. These compounds can be made to luminesce with alkaline hydrogen peroxide or calcium hypochlorite and base. Another family of compounds is the 2,4,5-triphenylimidazoles, with lophine as the common name for the parent product. Chemiluminescent analogs include para-dimethylamino and—methoxy substituents. Chemiluminescence may also be obtained with oxalates, usually oxalyl active esters, e.g., p-nitrophenyl and a peroxide, e.g., hydrogen peroxide, under basic conditions. Alternatively, luciferins may be used in conjunction with luciferase or lucigenins to provide bioluminescence.


[0244] Spin labels are provided by reporter molecules with an unpaired electron spin which can be detected by electron spin resonance (ESR) spectroscopy. Exemplary spin labels include organic free radicals, transitional metal complexes, particularly vanadium, copper, iron, and manganese, and the like. Exemplary spin labels include nitroxide free radicals.


[0245] Fragmentation


[0246] In addition, amplified sequences may be subjected to other post amplification treatments. For example, in some cases, it may be desirable to fragment the sequence prior to hybridization with an oligonucleotide array, in order to provide segments which are more readily accessible to the probes, which avoid looping and/or hybridization to multiple probes. Fragmentation of the nucleic acids may generally be carried out by physical, chemical or enzymatic methods that are known in the art.


[0247] Sample Analysis


[0248] Following the various sample preparation operations, the sample will generally be subjected to one or more analysis operations. Particularly preferred analysis operations include, e.g. sequence based analyses using an oligonucleotide array and/or size based analyses using, e.g. microcapillary array electrophoresis.


[0249] Capillary Electrophoresis


[0250] In some embodiments it may be desirable to provide an additional, or alternative means for analyzing the nucleic acids from the sample


[0251] Microcapillary array electrophoresis generally involves the use of a thin capillary or channel which may, or may not be filled with a particular separation medium. Electrophoresis of a sample through the capillary provides a size based separation profile for the sample. Microcapillary array electrophoresis generally provides a rapid method for size based sequencing, PCR product analysis and restriction fragment sizing. The high surface to volume ratio of these capillaries allows for the application of higher electric fields across the capillary without substantial thermal variation across the capillary, consequently allowing for more rapid separations. Furthermore, when combined with confocal imaging methods these methods provide sensitivity in the range of attomoles, which is comparable to the sensitivity of radioactive sequencing methods.


[0252] In many capillary electrophoresis methods, the capillaries e.g. fused silica capillaries or channels etched, machined or molded into planar substrates, are filled with an appropriate separation/sieving matrix. Typically, a variety of sieving matrices are known in the art may be used in the microcapillary arrays. Examples of such matrices include, e.g. hydroxyethyl cellulose, polyacrylamide and agarose. Gel matrices may be introduced and polymerized within the capillary channel. However, in some cases this may result in entrapment of bubbles within the channels which can interfere with sample separations. Accordingly, it is often desirable to place a preformed separation matrix within the capillary channel(s), prior to mating the planar elements of the capillary portion. Fixing the two parts, e.g. through sonic welding, permanently fixes the matrix within the channel. Polymerization outside of the channels helps to ensure that no bubbles are formed. Further, the pressure of the welding process helps to ensure a void-free system.


[0253] In addition to its use in nucleic acid “fingerprinting” and other sized based analyses the capillary arrays may also be used in sequencing applications. In particular, gel based sequencing techniques may be readily adapted for capillary array electrophoresis.


[0254] Expression Products


[0255] In addition to detection of mRNA or as the sole detection method expression products from the genes discussed above may be detected as indications of the biological condition of the tissue. Expression products may be detected in either the tissue sample as such, or in a body fluid sample, such as blood, serum, plasma, faeces, mucus, sputum, cerebrospinal fluid, and/or urine of the individual.


[0256] The expression products, peptides and proteins, may be detected by any suitable technique known to the person skilled in the art.


[0257] In a preferred embodiment the expression products are detected by means of specific antibodies directed to the various expression products, such as immunofluorescent and/or immunohistochemical staining of the tissue.


[0258] Immunohistochemical localization of expressed proteins may be carried out by immunostaining of tissue sections from the single tumors to determine which cells expressed the protein encoded by the transcript in question. The transcript levels may be used to select a group of proteins supposed to show variation from sample to sample making a rough correlation between the level of protein detected and the intensity of the transcript on the microarray possible.


[0259] For example sections may be cut from paraffin-embedded tissue blocks, mounted, and deparaffinized by incubation at 80 C° for 10 min. followed by immersion in heated oil at 60° C. for 10 min. (Estisol 312, Estichem A/Si Denmark) and rehydration. Antigen retrieval is achieved in TEG (TrisEDTA-Glycerol) buffer using microwaves at 900 W. The tissue sections may be cooled in the buffer for 15 min before a brief rinse in tap water. Endogenous peroxidase activity is blocked by incubating the sections with 1% H2O2 for 20 min. followed by three rinses in tap water, 1 min each. The sections may then be soaked in PBS buffer for 2 min. The next steps can be modified from the descriptions given by Oncogene Science Inc., in the Mouse Immunohistochemistry Detection System, XHCO1 (UniTect, Uniondale, N.Y., USA). Briefly, the tissue sections are incubated overnight at 4° C. with primary antibody (against beta-2 microglobulin (Dako), cytokeratin 8, cystatin-C (both from Europa, US), junB, CD59, E-cadherin, apo-E, cathepsin E, vimentin, IGFII (all from Santa Cruz), followed by three rinses in PBS buffer for 5 min each. Afterwards, the sections are incubated with biotinylated secondary antibody for 30 min, rinsed three times with PBS buffer and subsequently incubated with ABC (avidin-biotinlylated horseradish peroxidase complex) for 30 min. followed by three rinses in PBS buffer.


[0260] Staining may be performed by incubation with AEC (3-amino-ethylcarbazole) for 10 min. The tissue sections are counter stained with Mayers hematoxylin, washed in tap water for 5 min. and mounted with glycerol-gelatin. Positive and negative controls may be included in each staining round with all antibodies.


[0261] In yet another embodiment the expression products may be detected by means of conventional enzyme assays, such as ELISA methods.


[0262] Furthermore, the expression products may be detected by means of peptide/protein chips capable of specifically binding the peptides and/or proteins assessed. Thereby an expression pattern may be obtained.


[0263] Assay


[0264] Thus, in a further aspect the invention relates to an assay for determining an expression pattern of a bladder cell, comprising at least a first marker and/or a second marker, wherein the first marker is capable of detecting a gene from a first gene group as defined above, and/or the second marker is capable of detecting a gene from a second gene group as defined above, correlating the first expression level and/or the second expression level to a standard level of the assessed genes to determine the presence or absence of a biological condition in the animal tissue. The marker(s) are preferably specifically detecting a gene as identified herein.


[0265] In another embodiment the assay comprises at least two markers for each gene group.


[0266] As discussed above the marker may be any nucleotide probe, such as a DNA, RNA, PNA, or LNA probe capable of hybridising to mRNA indicative of the expression level. The hybridisation conditions are preferably as described below for probes. In another embodiment the marker is an antibody capable of specifically binding the expression product in question.


[0267] Detection


[0268] Patterns can be compared manually by a person or by a computer or other machine. An algorithm can be used to detect similarities and differences. The algorithm may score and compare, for example, the genes which are expressed and the genes which are not expressed. Alternatively, the algorithm may look for changes in intensity of expression of a particular gene and score changes in intensity between two samples. Similarities may be determined on the basis of genes which are expressed in both samples and genes which are not expressed in both samples or on the basis of genes whose intensity of expression are numerically similar.


[0269] Generally, the detection operation will be performed using a reader device external to the diagnostic device. However, it may be desirable in some cases to incorporate the data gathering operation into the diagnostic device itself.


[0270] The detection apparatus may be a fluorescence detector, or a spectroscopic detector, or another detector.


[0271] Although hybridization is one type of specific interaction which is clearly useful for use in this mapping embodiment antibody reagents may also be very useful.


[0272] Data Gathering and Analysis


[0273] Gathering data from the various analysis operations, e.g. oligonucleotide and/or microcapillary arrays will typically be carried out using methods known in the art. For example, the arrays may be scanned using lasers to excite fluorescently labeled targets that have hybridized to regions of probe arrays mentioned above, which can then be imaged using charged coupled devices (“CCDs”) for a wide field scanning of the array. Alternatively, another particularly useful method for gathering data from the arrays is through the use of laser confocal microscopy which combines the ease and speed of a readily automated process with high resolution detection.


[0274] Following the data gathering operation, the data will typically be reported to a data analysis operation. To facilitate the sample analysis operation, the data obtained by the reader from the device will typically be analyzed using a digital computer. Typically, the computer will be appropriately programmed for receipt and storage of the data from the device, as well as for analysis and reporting of the data gathered, i.e., interpreting fluorescence data to determine the sequence of hybridizing probes, normalization of background and single base mismatch hybridizations, ordering of sequence data in SBH applications, and the like.


[0275] It is an object of the present invention to provide a biological sample which may be classified or characterized by analyzing the pattern of specific interactions mentioned above. This may be applicable to a cell or tissue type, to the messenger RNA population expressed by a cell to the genetic content of a cell, or to virtually any sample which can be classified and/or identified by its combination of specific molecular properties.


[0276] Pharmaceutical Composition


[0277] The invention also relates to a pharmaceutical composition for treating a biological condition, such as bladder tumors.


[0278] In one embodiment the pharmaceutical composition comprises one or more of the peptides being expression products as defined above. In a preferred embodiment, the peptides are bound to carriers. The peptides may suitably be coupled to a polymer carrier, for example a protein carrier, such as BSA. Such formulations are well-known to the person skilled in the art.


[0279] The peptides may be suppressor peptides normally lost or decreased in tumor tissue administered in order to stabilise tumors towards a less malignant stage. In another embodiment the peptides are onco-peptides capable of eliciting an immune response towards the tumor cells.


[0280] In another embodiment the pharmaceutical composition comprises genetic material, either genetic material for substitution therapy, or for suppressing therapy as discussed below.


[0281] In a third embodiment the pharmaceutical composition comprises at least one anti-body produced as described above.


[0282] In the present context the term pharmaceutical composition is used synonymously with the, term medicament. The medicament of the invention comprises an effective amount of one or more of the compounds as defined above, or a composition as defined above in combination with pharmaceutically acceptable additives. Such medicament may suitably be formulated for oral, percutaneous, intramuscular, intravenous, intracranial, intrathecal, intracerebroventricular, intranasal or pulmonal administration. For most indications a localised or substantially localised application is preferred.


[0283] Strategies in formulation development of medicaments and compositions based on the compounds of the present invention generally correspond to formulation strategies for any other protein-based drug product. Potential problems and the guidance required to overcome these problems are dealt with in several textbooks, e.g. “Therapeutic Peptides and Protein Formulation. Processing and Delivery Systems”, Ed. A. K. Banga, Technomic Publishing AG, Basel, 1995.


[0284] Injectables are usually prepared either: as liquid solutions or suspensions, solid forms suitable for solution in, or suspension in, liquid prior to injection. The preparation may also be emulsified. The active ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like, and combinations thereof. In addition, if desired, the preparation may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or which enhance the effectiveness or transportation of the preparation.


[0285] Formulations of the compounds of the invention can be prepared by techniques known to the person skilled in the art. The formulations may contain pharmaceutically acceptable carriers and excipients including microspheres, liposomes, microcapsules and nanoparticles.


[0286] The preparation may suitably be administered by injection, optionally at the site, where the active ingredient is to exert its effect. Additional formulations which are suitable for other modes of administration include suppositories, and in some cases, oral formulations. For suppositories, traditional binders and carriers include polyalkylene glycols or triglycerides. Such suppositories may be formed from mixtures containing the active ingredient(s) in the range of from 0.5% to 10%, preferably 1-0.2%. Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium, saccharine, cellulose, magnesium carbonate, and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formutations or powders and generally contain 10-95% of the active ingredient(s), preferably 25-70%.


[0287] The preparations are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective. The quantity to be administered depends on the subject to be treated, including, e.g. the weight and age of the subject, the disease to be treated and the stage of disease. Suitable dosage ranges are of the order of several hundred μg active ingredient per administration with a preferred range of from about 0.1 μg to 1000 μg, such as in the range of from about 1 μg to 300 μg, and especially in the range of from about 10 μg to 50 μg. Administration may be performed once or may be followed by subsequent administrations. The dosage will also depend on the route of administration and will vary with the age and weight of the subject to be treated. A preferred dosis would be in the interval 30 mg to 70 mg per 70 kg body weight.


[0288] Some of the compounds of the present invention are sufficiently active, but for some of the others, the effect will be enhanced if the preparation further comprises pharmaceutically acceptable additives and/or carriers. Such additives and carriers will be known in the art. In some cases, it will be advantageous to include a compound, which promote delivery of the active substance to its target.


[0289] In many instances, it will be necessary to administrate the formulation multiple times. Administration may be a continuous infusion, such as intraventricular infusion or administration in more doses such as more times a day, daily, more times a week, weekly, etc.


[0290] Vaccines


[0291] In a further embodiment the present invention relates to a vaccine for the prophylaxis or treatment of a biological condition comprising at least one expression product from at least one gene said gene being expressed as defined above.


[0292] The term vaccines is used with its normal meaning, i.e preparations of immunogenic material for administration to induce in the recipient an immunity to infection or intoxication by a given infecting agent. Vaccines may be administered by intravenous injection or through oral, nasal and/or mucosal administration. Vaccines may be either simple vaccines prepared from one species of expression products, such as proteins or peptides, or a variety of expression products, or they may be mixed vaccines containing two or more simple vaccines. They are prepared in such a manner as not to destroy the immunogenic material, although the methods of preparation vary, depending on the vaccine.


[0293] The enhanced immune response achieved according to the invention can be attributable to e.g. an enhanced increase in the level of immunoglobulins or in the level of T-cells including cytotoxic T-cells will result in immunisation of at least 50% of individuals exposed to said immunogenic composition or vaccine, such as at least 55%, for example at least 60%, such as at least 65%, for example at least 70%, for example at least 75%, such as at least 80%, for example at least 85%, such as at least 90%, for example at least 92%, such as at least 94%, for example at least 96%, such as at least 97%, for example at least 98%, such as at least 98.5%, for example at least 99%, for example at least 99.5% of the individuals exposed to said immunogenic composition or vaccine are immunised.


[0294] Compositions according to the invention may also comprise any carrier and/or adjuvant known in the art including functional equivalents thereof. Functionally equivalent carriers are capable of presenting the same immunogenic determinant in essentially the same steric conformation when used under similar conditions. Functionally equivalent adjuvants are capable of providing similar increases in the efficacy of the composition when used under similar conditions.


[0295] Therapy


[0296] The invention further relates to a method of treating individuals suffering from the biological condition in question, in particular for treating a bladder tumor.


[0297] In one embodiment the invention relates to a method of substitution therapy, ie. administration of genetic material generally expressed in normal cells, but lost or decreased in biological condition cells (tumor suppressors). Thus, the invention relates to a method for reducing cell tumorigenicity or malignancy of a cell, said method comprising


[0298] obtaining at least one gene selected from genes being expressed in an amount two-fold higher in normal cells than the amount expressed in said tumor cell (tumor suppressors),


[0299] introducing said at least one gene into the tumor cell in a manner allowing expression of said gene(s).


[0300] The at least one gene is preferably selected individually from genes comprising a sequence as identified below
52RC_AA158234_atzo76b01.s1 Stratagene pancreas (#937208) Homo sapienscDNA clone 592777 3′.RC_H42123_atyo61a11.s1 Homo sapiens cDNA clone 182396 3′.RC_Z39200_atH. sapiens partial cDNA sequence; clone c-13f02.RC_N21687_atyx63h03.s1 Soares melanocyte 2NbHM Homo sapiens cDNAclone 266453 3′.Y13645_atHomo sapiens mRNA for uroplakin II.RC_N98461_atzb86b03.s1 Soares senescent fibroblasts NbHSF Homo sapienscDNA clone 310445 3′.RC_W92449_atzd99d10.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 357619 3′.RC_Z39191_atH. sapiens partial cDNA sequence; clone c-13c12.RC_AA125808_atzl29e12.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 503374 3′.RC_T40767_atya11a06.s1 Homo sapiens cDNA clone 61138 3′.RC_T51972_atyb29c05.s1 Homo sapiens cDNA clone 72584 3′.RC_AA286862_atzs58b06.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 701651 3′.RC_N29764_atyw91b09.s1 Homo sapiens cDNA clone 259577 3′.AA428172_f_atzw32b06.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 770963 5′.RC_H02265_atyj35d05.s1 Homo sapiens cDNA clone 150729 3′.RC_W44745_atzb98a11.s1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 320828 3′.RC_R91819_atyp99c05.s1 Homo sapiens cDNA clone 195560 3′ similar tocontains MER1 repetitive element;.AA464468_atzx84d05.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 810441 5′.RC_AA188647_atzp78e01.s1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 626328 3′ similar to TR: G998813 G998813 TIF1. [1];.RC_AA405832_atzu57g11.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 742148 3′ similar to TR: G780241 G780241 AU-BINDINGPROTEIN/ENOYL-COA HYDRATASE.;.RC_W37778_f_atzc13b12.s1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 322175 3′ similar to contains LTR2.t3 LTR2 repetitiveelement;.AF010126_atHomo sapiens breast cancer-specific protein 1 (BCSG1) mRNA,complete cds.N36432_atyx83a05.r1 Homo sapiens cDNA clone 268304 5′.RC_AA236533_szr74c04.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneat669126 3′ similar to gb: S69002 ECOTROPIC VIRUS INTEGRATION1 SITE PROTEIN (HUMAN);.RC_AA293163_atzt55e05.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 726272 3′.RC_AA196790_atzq60b06.s1 Stratagene neuroepithelium (#937231) Homo sapienscDNA clone 645971 3′.RC_AA253220_atzr53g12.s1 Soares NhHMPu S1 Homo sapiens cDNA clone667174 3′.RC_AA100437_atzn59e02.s1 Stratagene muscle 937209 Homo sapiens cDNAclone 562490 3′.RC_AA293300_szt28d03.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 714437 3′.RC_Z39652_atH. sapiens partial cDNA sequence; clone c-1fg03.M63509_s_atHuman glutathione transferase M2 (GSTM2) mRNA, completecdsRC_Z39842_atH. sapiens partial cDNA sequence; clone c-1ke11.RC_N23319_atyx78e10.s1 Homo sapiens cDNA clone 267882 3′.RC_AA278817_atzs78d11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 703605 3′.L20773_atHomo sapiens mRNA in the region near the btk gene involved ina-gamma-globulinemiaRC_R69276_atyi44h05.s1 Soares placenta Nb2HP Homo sapiens cDNA clone142137 3′.RC_F02641_atH. sapiens partial cDNA sequence; clone c-15d02.RC_AA424791_atzw03a04.s1 Soares NhHMPu S1 Homo sapiens cDNA clone768174 3′ similar to contains Alu repetitive element;.RC_R39869_atyf63b06.s1 Homo sapiens cDNA clone 26725 3′.RC_AA482224_fab15c03.s1 Stratagene lung (#937210) Homo sapiens cDNAatclone 840868 3′.RC_AA025277_atze76f02.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 364923 3′ similar to contains Alu repetitive element;contains element LTR4 repetitive element;.AA482319_f_atab15c03.r1 Stratagene lung (#937210) Homo sapiens cDNAclone 840868 5′.RC_AA001045_atze47b04.s1 Soares retina N2b4HR Homo sapiens cDNA clone362095 3′.RC_AA130645_szo10f03.s1 Stratagene neuroepithelium NT2RAMI 937234 Homoatsapiens cDNA clone 567293 3′ similar to SW: NI2M_BOVINQ02369 NADH-UBIQUINONE OXIDOREDUCTASE B22SUBUNIT;.RC_AA291659_atzt37c02.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 724514 3′.AA046768_atzk72d02.r1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 488355 5′.H07011_atyl81e01.r1 Homo sapiens cDNA clone 44466 5′.RC_AA293533_izt54g04.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 726198 3′ similar to gb: J05158 CARBOXYPEPTIDASE N83 KD CHAIN (HUMAN);.RC_AA100649_atzn63g10.s1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 562914 3′ similar to SW: LCFA_ECOLI P29212LONG-CHAIN-FATTY-ACID—COA LIGASE;.RC_AA017146_atze41a07.s1 Soares retina N2b4HR Homo sapiens cDNA clone361524 3′ similar to contains element PTR7 repetitive element;.RC_AA180054_atzp40g07.s1 Stratagene muscle 937209 Homo sapiens cDNAclone 611964 3′.AA263032_s_atPMY0335 KG1a Lambda Zap Express cDNA Library Homo sapienscDNA 5′.W69310_atzd46f07.r1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 343717 5′.RC_AA219653_atzr05e02.s1 Stratagene NT2 neuronal precursor 937230 Homosapiens cDNA clone 650618 3′.RC_AA457235_ataa91c07.s1 Stratagene fetal retina 937202 Homo sapiens cDNAclone 838668 3′.RC_AA455967_ataa16h10.s1 Soares NhHMPu S1 Homo sapiens cDNA clone813475 3′.N27670_atyx51a09.r1 Homo sapiens cDNA clone 265240 5′.RC_N80152_atza65e02.s1 Homo sapiens cDNA clone 297434 3′.RC_R64660_atyi22a10.s1 Homo sapiens cDNA clone 139962 3′.RC_AA147218_szo64g03.s1 Stratagene pancreas (#937208) Homo sapiensatcDNA clone 591700 3′.C01139_atHUMGS0007818, Human Gene Signature, 3′-directed cDNAsequence.AA285284_atPMY0691 KG1a Lambda Zap Express cDNA Library Homo sapienscDNA 5′.RC_AA451685_atzx44c03.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 789316 3′.AA203222_atzx56e01.r1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 446520 5′ similar to contains element MER17 repetitiveelement;.RC_AA394071_atzt52g01.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 726000 3′ similar to SW: ADG_MOUSE P22892 GAMMAADAPTIN;.RC_AA479096_atzv17e07.s1 Soares NhHMPu S1 Homo sapiens cDNA clone753924 3′.RC_AA156532_atzo34b05.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 588753 3′.RC_Z40233_atH. sapiens partial cDNA sequence; clone c-1wg05.RC_T03927_atseq2490 Homo sapiens cDNA clone 3HFLSK20-87 3′.AA314457_atEST186294 Colon carcinoma (HCC) cell line II Homo sapienscDNA 5′ end.RC_N50550_atyy89f05.s1 Homo sapiens cDNA clone 280737 3′.RC_AA191524_atzp88f04.s1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 627295 3′.RC_N29740_atyw90b12.s1 Homo sapiens cDNA clone 259487 3′.RC_N48715_atyy75h02.s1 Homo sapiens cDNA clone 279411 3′.RC_AA463637_atzx98h04.s1 Soares NhHMPu S1 Homo sapiens cDNA clone811831 3′.RC_AA404487_atzw38a06.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 772306 3′.RC_H16666_atym26a10.s1 Homo sapiens cDNA clone 49155 3′.RC_AA406197_atzv24d11.s1 Soares NhHMPu S1 Homo sapiens cDNA clone754581 3′.RC_H09594_atyl97b11.s1 Homo sapiens cDNA clone 46276 3′.RC_AA161085_atzo62h09.s1 Stratagene pancreas (#937208) Homo sapienscDNA clone 591521 3′ similar to SW: PPAP_RAT P20646 PROSTATICACID PHOSPHATASE PRECURSOR;.RC_AA452131_atzx15d06.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 786539 3′.RC_AA293533_fzt54g04.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 726198 3′ similar to gb: J05158 CARBOXYPEPTIDASE N83 KD CHAIN (HUMAN);.RC_AA398197_atzt59a08.s1 Soares testis NHT Homo sapiens cDNA clone726614 3′.AA464051_s_atzx86d04.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 810631 5′.RC_T51990_atyb29e01.s1 Homo sapiens cDNA clone 72600 3′.RC_AA236356_atzr54a11.s1 Soares NhHMPu S1 Homo sapiens cDNA clone667196 3′.W92678_atzd92a04.r1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 356910 5′ similar to contains element LTR3 repetitive element;.RC_N63332_atyz33d11.s1 Homo sapiens cDNA clone 284853 3′ similar tocontains Alu repetitive element;.C16281_s_atHuman aorta cDNA 5′-end GEN-259H09.RC_AA477252_atzu29h10.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 739459 3′.H88035_s_atyw20e07.r1 Homo sapiens cDNA clone 252804 5′.AB002387_atHuman mRNA for KIAA0389 gene, complete cds.RC_R45698_atyg45h12.s1 Homo sapiens cDNA clone 35838 3′.RC_AA236542_atzr75g11.s1 Soares NhHMPu S1 Homo sapiens cDNA clone669284 3′.AA376875_atEST89388 Small intestine I Homo sapiens cDNA 5′ end similarto monoamine oxidase A.RC_R43365_atyg15g06.s1 Homo sapiens cDNA clone 32365 3′.RC_H06746_atyl83h08.s1 Homo sapiens cDNA clone 44847 3′.RC_AA233837_atzr47f06.s1 Soares NhHMPu S1 Homo sapiens cDNA clone666563 3′.RC_AA057620_atzf15h06.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 377051 3′.RC_AA450118_atzx42e09.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 789160 3′.RC_AA598872_atae37b10.s1 Gessler Wilms tumor Homo sapiens cDNA clone897979 3′.RC_AA147646_szl52g06.s1 Soares pregnant uterus NbHPU Homo sapiensatcDNA clone 505594 3′.RC_W04698_atzb94b05.s1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 320433 3′.RC_N54365_atyv39c06.s1 Homo sapiens cDNA clone 245098 3′.RC_AA256208_atzr80a08.s1 Soares NhHMPu S1 Homo sapiens cDNA clone681974 3′.AA046593_atzk62g01.r1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 487440 5′.RC_AA002088_atzh85g03.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 428116 3′.RC_AA256273_atzr81c12.s1 Soares NhHMPu S1 Homo sapiens cDNA clone682102 3′.AA491114_ataa46e04.r1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 823998 5′.RC_AA293719_atzt55h03.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 726293 3′.RC_AA086005_atzl84c04.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 511302 3′.RC_AA479885_atzw44a07.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 772884 3′.AA442428_atzv70f08.r1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 759015 5′ similar to SW: YB72_YEAST P38137 HYPOTHETICAL60.5 KD PROTEIN IN PDB1-ABD1 INTERGENICREGION. ;.RC_AA486410_atab36b12.s1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 842879 3′.R15268_atyf89f02.r1 Homo sapiens cDNA clone 29665 5′.RC_AA443658_atzw86a10.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 783834 3′ similar to TR: G438639 G438639 LAMIN B RECEPTOR.[1];.RC_H16790_atym39b01.s1 Homo sapiens cDNA clone 50559 3′.AA465000_s_atzx80b07.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 810037 5′.RC_N38930_atyy43e04.s1 Homo sapiens cDNA clone 274014 3′.AB002321_atHuman mRNA for KIAA0323 gene, partial cds.RC_Z38810_atH. sapiens partial cDNA sequence; clone c-0qb09.AC000115_cds1WUGSC: H_GS188P18.1a gene extracted from Human BACatclone GS188P18RC_AA255464_atzr83b02.s1 Soares NhHMPu S1 Homo sapiens cDNA clone682251 3′.RC_AA255628_atzs31g06.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 686842 3′.RC_H70554_atyr91a03.s1 Homo sapiens cDNA clone 212620 3′.AA309880_atEST180743 Jurkat T-cells V Homo sapiens cDNA 5′ end.RC_R43812_atyg21a08.s1 Homo sapiens cDNA clone 32940 3′.RC_AA425636_atzv47a04.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 756750 3′.RC_N66388_atyz39f01.s1 Homo sapiens cDNA clone 285433 3′.RC_AA279420_atzs85d09.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 704273 3′ similar to TR: G974805 G974805 T08A11.2;.RC_AA033974_atzi05c10.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 429906 3′.AF007216_atHomo sapiens sodium bicarbonate cotransporter (HNBC1)mRNA, complete cds.RC_AA489101_ataa56h11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 824997 3′.D79601_f_atHuman aorta cDNA 5′-end GEN-286G10.RC_N30856_atyw70f05.s1 Homo sapiens cDNA clone 257601 3′.L29218_s_atHomo sapiens clk2 mRNA, complete cdsRC_AA143726_atzo67g06.s1 Stratagene pancreas (#937208) Homo sapienscDNA clone 591994 3′ similar to TR: G530823 G530823 EPIDERMALGROWTH FACTOR RECEPTOR KINASE SUBSTRATE. ;.AA126592_atzl17g05.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 502232 5′.RC_F02397_s_atH. sapiens partial cDNA sequence; clone c-0xh11.RC_AA252765_atzs27d03.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 686405 3′.RC_W46846_atzc36a04.s1 Soares senescent fibroblasts NbHSF Homo sapienscDNA clone 324366 3′.RC_AA135185_atzo27a05.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 588080 3′.RC_R40702_atyf73f10.s1 Homo sapiens cDNA clone 27969 3′.RC_N52565_atyv36d12.s1 Homo sapiens cDNA clone 244823 3′.RC_W32506_s_atzc06a02.s1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 321482 3′.RC_AA255539_atzr85c04.s1 Soares NhHMPu S1 Homo sapiens cDNA clone682470 3′.RC_AA449951_atzx38a10.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 788730 3′.AA091278_atcchn2404.seq.F Fetal heart, Lambda ZAP Express Homo sapienscDNA 5′.RC_AA236037_atzs05g08.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 684350 3′.AA091412_s_atII2053.seq.F Fetal heart, Lambda ZAP Express Homo sapienscDNA 5′.AA046865_atzf12b09.r1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 376697 5′.AA324825_atEST27743 Cerebellum II Homo sapiens cDNA 5′ end.RC_AA454840_szx79d09.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 809969 3′.RC_W80354_atzh49a02.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 415370 3′.RC_AA402484_atzt65c03.s1 Soares testis NHT Homo sapiens cDNA clone727204 3′.W26883_at15h10 Human retina cDNA randomly primed sublibrary Homosapiens cDNA.RC_AA262485_atzs17h07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 685501 3′.RC_AA405543_atzw39c01.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 772416 3′.RC_N21380_atyx54c04.s1 Homo sapiens cDNA clone 265542 3′.RC_AA121360_szn77a05.s1 Stratagene NT2 neuronal precursor 937230 Homoatsapiens cDNA clone 564176 3′.L32832_s_atHomo sapiens zinc finger homeodomain protein (ATBF1-A)mRNA, complete cds.D31313_s_atHuman fetal-lung cDNA 5′-end sequence.H18718_atym45b05.r1 Homo sapiens cDNA clone 51043 5′ similar to containsAlu repetitive element;.RC_AA037828_atzf03g09.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 375904 3′.RC_R67996_atyi04c10.s1 Homo sapiens cDNA clone 138258 3′.RC_AA026417_atze92g08.s1 Soares fetal heart NbHHI9W Homo sapiens cDNAclone 366494 3′.RC_F11115_atH. sapiens partial cDNA sequence; clone c-33a10.RC_R08871_atyf21e07.s1 Homo sapiens cDNA clone 127524 3′.RC_AA224324_atzr12e05.s1 Stratagene hNT neuron (#937233) Homo sapienscDNA clone 648608 3′.RC_AA399226_atzt50c01.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 725760 3′.R66920_atyi25f09.r1 Homo sapiens cDNA clone 140297 5′ similar to containsAlu repetitive element;.RC_AA464240_szx81a05.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 810128 3′.AA436536_atzv08g07.r1 Soares NhHMPu S1 Homo sapiens cDNA clone753084 5′.RC_N71875_atyz34f07.s1 Homo sapiens cDNA clone 284965 3′.RC_AA029288_atzk10b03.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 470093 3′ similar to PIR: H45193 H45193 zinc fingerprotein ZNF65;.H27242_atyl63h11.r1 Homo sapiens cDNA clone 162981 5′ similar toSP: GCN5_YEAST Q03330 TRANSCRIPTIONAL ACTIVATOR;.J04813_s_atHuman cytochrome P450 PCN3 gene, complete cdsRC_AA465093_ataa32h08.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 815007 3′.RC_AA282791_atzs91c05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 704840 3′.RC_AA464180_atzx83f04.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 810367 3′ similar to gb: M38188 OVARIAN GRANULOSACELL 13.0 KD PROTEIN HGR74 (HUMAN);.RC_AA149987_atzo03d03.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 566597 3′.RC_AA256680_atzr82h09.s1 Soares NhHMPu S1 Homo sapiens cDNA clone682241 3′.AA147510_s_atzl50c12.r1 Soares pregnant uterus NbHPU Homo sapiens cDNAclone 505366 5′.R78119_atyi80c10.r1 Homo sapiens cDNA clone 145554 5′.RC_Z38407_s_atH. sapiens partial cDNA sequence; clone c-0ac03.RC_AA287107_szs58f12.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneatIMAGE: 701711 3′.RC_AA287042_atzs57e07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 701604 3′.AA489299_atab35g04.r1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 842838 5′.AA504744_ataa63f03.r1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 825629 5′.RC_AA402622_atzu47g07.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 741180 3′.RC_AA436628_atzw55e10.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 773994 3′.RC_AA282138_atzt02a10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 711930 3′.AA045870_atzk75a04.r1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 488622 5′.AA418098_atzv94b04.r1 Soares NhHMPu S1 Homo sapiens cDNA clone767407 5′.RC_AA242799_atzr65f06.s1 Soares NhHMPu S1 Homo sapiens cDNA clone668291 3′ similar to SW: SPO8_YEAST P41833 TRANSCRIPTIONALREGULATOR SPO8. [1];.RC_AA609210_ataf12f04.s1 Soares testis NHT Homo sapiens cDNA clone1031455 3′.RC_AA133469_atzo13e11.s1 Stratagene colon (#937204) Homo sapiens cDNAclone 586796 3′.R22139_atyh25b11.r1 Homo sapiens cDNA clone 130749 5′.AA305116_atEST176117 Colon carcinoma (Caco-2) cell line II Homo sapienscDNA 5′ end.RC_AA027954_atzk05c12.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 469654 3′.AA036900_atzk29e11.r1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 471980 5′.RC_AA026397_atze92d07.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 366445 3′.RC_D59981_s_atHuman fetal brain cDNA 3′-end GEN-079C04.RC_AA284143_atzs47c07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 700620 3′.W16686_atzb08f12.r1 Soares fetal lung NbHL19W Homo sapiens cDNAclone 301487 5′.H89575_s_atyw28c11.r1 Homo sapiens cDNA clone 253556 5′.RC_AA251003_atzs07g11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 684548 3′.RC_AA279408_atzs84h09.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 704225 3′.RC_AA281760_atzt07g10.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 712482 3′ similar to TR: G808826 G808826 HYPOTHETICAL25.7 KD PROTEIN.;.AB002381_atHuman mRNA for KIAA0383 gene, partial cds.AA459542_s_atzx89d08.r1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 810927 5′ similar to TR: G608025 G608025 ANKYRING.;.RC_AA115559_atzl07b12.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 491615 3′.T94506_atye36a05.r1 Homo sapiens cDNA clone 119792 5′.D55869_s_atHuman fetal brain cDNA 5′-end GEN-404F02.L02547_atHomo sapiens (clone pZ50-19) cleavage stimulation factor50 kDa subunit, complete cdsU77942_atHuman syntaxin 7 mRNA, complete cds.AA431505_atzw76e03.r1 Soares testis NHT Homo sapiens cDNA clone782140 5′.RC_AA194045_atzr38c08.s1 Soares NhHMPu S1 Homo sapiens cDNA clone665678 3′.RC_AA025104_atze78f05.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 365121 3′.RC_AA242822_atzr65e09.s1 Soares NhHMPu S1 Homo sapiens cDNA clone668296 3′.RC_AA287388_atzs50f04.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 700927 3′.AA247679_athfe0045.seq.F Human fetal heart, Lambda ZAP Express Homosapiens cDNA 5′.RC_AA489383_atab41e08.s1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 843398 3′.RC_AA621188_atzu81a08.s1 Soares testis NHT Homo sapiens cDNA clone744374 3′.RC_AA486182_atab35a01.s1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 842760 3′.RC_AA393876_szv64h10.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAatclone 758467 3′.RC_AA034189_atzi06h12.s1 Soares fetal liver spleen 1NFLS S1 Homo sapienscDNA clone 430055 3′.RC_AA024866_atze79b09.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 365177 3′.RC_AA450373_atzx05h06.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 785627 3′.N78483_atyz78d07.r1 Homo sapiens cDNA clone 289165 5′.RC_AA281245_atzs94d07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 705133 3′.W52431_atzc45b12.r1 Soares senescent fibroblasts NbHSF Homo sapienscDNA clone 325247 5′ similar to SW: WDNM_RAT P14730WDNM1 PROTEIN. [2] PIR: S07807;.RC_AA446597_atzw84f01.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAclone 783673 3′.RC_AA256996_atzr81h11.s1 Soares NhHMPu S1 Homo sapiens cDNA clone682149 3′.X73501_atH. sapiens gene for cytokeratin 20RC_AA287131_atzt20g02.s1 Soares ovary tumor NbHOT Homo sapiens cDNAclone 713714 3′ similar to TR: E124071 E124071 NAD +−ISOCITRATE DEHYDROGENASE;.


[0301] or from a sequence as identified below
53AB002370_atHuman mRNA for KIAA0372 gene, complete cds.AF000546_atHomo sapiens purinergic receptor P2Y5 mRNA, complete cds.H43922_atyo70c03.r1 Homo sapiens cDNA clone 183268 5′.H44269_atyp17b05.r1 Homo sapiens cDNA clone 187665 5′ similar to containsAlu repetitive element;.H88706_s_atyw23e08.r1 Homo sapiens cDNA clone 253094 5′.L25880_s_atHomo sapiens epoxide hydrolase (EPHX) gene, complete cdsN81162_atyw36d01.r1 Homo sapiens cDNA clone 254305 5′.RC_F10381_s_atH. sapiens partial cDNA sequence; clone c-3ec07.RC_H54558_atEST00018 HE6W Homo sapiens cDNA clone HE6WCR108 3′.RC_H58692_syr20g08.s1 Homo sapiens cDNA clone 205886 3′ similar toatSP: FTDH_RAT P28037 FORMYLTETRAHYDROFOLATE DEHYDROGENASE;.RC_N20047_atyx28d06.s1 Homo sapiens cDNA clone 263051 3′.RC_N38810_atyv28e04.s1 Homo sapiens cDNA clone 244062 3′.RC_R46497_atyg51h01.s1 Homo sapiens cDNA clone 36305 3′.RC_R55001_atyj76a08.s1 Homo sapiens cDNA clone 154646 3′.RC_T29986_s_atEST10130 Homo sapiens cDNA 3′ end similar to None.RC_T30214_atEST12901 Homo sapiens cDNA 3′ end similar to None.RC_T40438_atya01c07.s2 Homo sapiens cDNA clone 60204 3′.RC_W51910_atzc37f06.s1 Soares senescent fibroblasts NbHSF Homo sapienscDNA clone 324515 3′.RC_W73949_atzd71f09.s1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 346121 3′.RC_W86375_szh55a02.s1 Soares fetal liver spleen 1NFLS S1 Homo sapiensatcDNA clone 415946 3′.RC_Z38289_atH. sapiens partial cDNA sequence; clone c-05e04.RC_Z38807_s_atH. sapiens partial cDNA sequence; clone c-0qb04.RC_Z39599_atH. sapiens partial cDNA sequence; clone c-1ed10.RC_AA025351ze74h03.s1 Soares fetal heart NbHH19W Homo sapiens cDNAatclone 364757 3′ similar to contains OFR.t1 OFR repetitive element;.RC_AA136474zl01f04.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAatclone 491071 3′.RC_AA136611zk99b02.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAatclone 490923 3′.RC_AA233375zr48f07.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneat666661 3′.RC_AA235621zt36c05.s1 Soares ovary tumor NbHOT Homo sapiens cDNA clones_at724424 3′.RC_AA253331zr72g02.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneat668978 3′.RC_AA393793zv64a10.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAatclone 758394 3′.RC_AA419547zv04a05.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneat752624 3′.RC_AA421100zu27d11.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 739221 3′.RC_AA443277zw87f06.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAatclone 783971 3′.RC_AA446570zw84c05.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAatclone 783656 3′.RC_AA447123zw93c01.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAatclone 784512 3′.RC_AA449343zx06g09.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAatclone 785728 3′.RC_AA456016aa03a08.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneat812150 3′.RC_AA479299zv21f04.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneat754303 3′.RC_AA479350zv17d09.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneat753905 3′ similar to contains element TAR1 TAR1 repetitive element;.U85707_atHuman leukemogenic homolog protein (MEIS1) mRNA, completecdsU94831_atHuman multispanning membrane protein mRNA, complete cds./gb = U94831/ntype = RNAW27827_at38c8 Human retina cDNA randomly primed sublibrary Homo sapienscDNA.W81301_atzd85a12.r1 Soares fetal heart NbHH19W Homo sapiens cDNAclone 347422 5′.Y12711_atH. sapiens mRNA for putative progesterone binding proteinAA074407_atzm15c08.r1 Stratagene pancreas (#937208) Homo sapiens cDNAclone 525710 5′.AA091017_atyy1646.seq.F Fetal heart, Lambda ZAP Express Homo sapienscDNA 5′.AA104023_atl7134.seq.F Fetal heart, Lambda ZAP Express Homo sapienscDNA 5′.AA171913_atzo95d05.r1 Stratagene ovarian cancer (#937219) Homo sapienscDNA clone 594633 5′.AA195678_atzr32h05.r1 Soares NhHMPu S1 Homo sapiens cDNA clone665145 5′.AA227678_atzr55e05.r1 Soares NhHMPu S1 Homo sapiens cDNA clone667328 5′.AA247204_atcsg0306.seq.F Human fetal heart, Lambda ZAP Express Homosapiens cDNA 5′.AA479995_atzv18b05.r1 Soares NhHMPu S1 Homo sapiens cDNA clone753969 5′.


[0302] or from a sequence as identified below
54RC_H14633_atyl26e06.s1 Homo sapiens cDNA clone 159394 3′.RC_N62506_atyz74d02.s1 Homo sapiens cDNA clone 288771 3′.RC_N70481_atza74g10.s1 Homo sapiens cDNA clone 298338 3′.RC_N73988_atza57b06.s1 Homo sapiens cDNA clone 296627 3′.RC_T53404_atya88g06.s1 Homo sapiens cDNA clone 68794 3′.RC_Z38149_atH. sapiens partial cDNA sequence; clone c-01a09.RC_Z38849_atH. sapiens partial cDNA sequence; clone c-0rb11.RC_AA037409zc03h03.s1 Soares parathyroid tumor NbHPA Homo sapiensatcDNA clone 321269 3′.RC_AA084318zn18b04.s1 Stratagene neuroepithelium NT2RAMI 937234 Homoatsapiens cDNA clone 547759 3′.RC_AA126419zk94d04.s1 Soares pregnant uterus NbHPU Homo sapiens cDNAatclone 490471 3′.RC_AA128407zm24d04.s1 Stratagene pancreas (#937208) Homo sapiensatcDNA clone 526567 3′.RC_AA173430zp02e08.s1 Stratagene ovarian cancer (#937219) Homo sapiensatcDNA clone 595238 3′.RC_AA398104zt58d03.s1 Soares testis NHT Homo sapiens cDNA clone 726533at3′.RC_AA399414zt50e07.s1 Soares ovary tumor NbHOT Homo sapiens cDNA cloneat725796 3′.RC_AA431479zw72f05.s1 Soares testis NHT Homo sapiens cDNA clone 781761at3′.RC_AA436471zv08e05.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneat753056 3′.RC_AA449455zx05e10.s1 Soares total fetus Nb2HF8 9w Homo sapiens cDNAatclone 785610 3′ similar to contains Alu repetitive element;.RC_AA458899zx88d07.s1 Soares ovary tumor NbHOT Homo sapiens cDNAatclone 810829 3′.RC_AA463630zx98g09.s1 Soares NhHMPu S1 Homo sapiens cDNA clones_at811840 3′.RC_AA489009aa54d11.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneatIMAGE: 824757 3′.W37319_atzc11f08.r1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 322023 5′.


[0303] or from a sequence as identified below
55yx16e10.r1 Homo sapiens cDNA clone 261930 5′.N24990_s_atyf41e08.r1 Homo sapiens cDNA clone 129446 5′ similar toR11267_atSP: A46661 A46661 LEUKOTRIENE B4 OMEGA-HYDROXYLASE, P-450LTB OMEGA = CYTOCHROME P-450SUPERFAMILY MEMBER-;.yq76e12.s1 Homo sapiens cDNA clone 201742 3′ similar toRC_H52937_atgb: J02982 GLYCOPHORIN B PRECURSOR (HUMAN);.yr89e02.s1 Homo sapiens cDNA clone 212474 3′.RC_H69547_atyu73c12.s1 Homo sapiens cDNA clone 239446 3′.RC_H70047_atyx99c11.s1 Homo sapiens cDNA clone 269876 3′.RC_N24879_atyz38a06.s1 Homo sapiens cDNA clone 285298 3′.RC_N66312_atyh26a02.s1 Homo sapiens cDNA clone 130826 3′.RC_R22189_atyg44f05.s1 Homo sapiens cDNA clone 35270 3′.RC_R45582_atyg83e10.s1 Homo sapiens cDNA clone 39835 3′.RC_R53457_atyi49g10.s1 Homo sapiens cDNA clone 142626 3′.RC_R70903_atzl68c01.s1 Stratagene colon (#937204) Homo sapiens cDNARC_AA054321_s_atclone 509760 3′.zk87c05.s1 Soares pregnant uterus NbHPU Homo sapiensRC_AA099820_atcDNA clone 489800 3′.zl17g05.s1 Soares pregnant uterus NbHPU Homo sapiensRC_AA127238_atcDNA clone 502232 3′.zo64h02.s1 Stratagene pancreas (#937208) Homo sapiensRC_AA147224_atcDNA clone 591699 3′.zq12e02.s1 Stratagene muscle 937209 Homo sapiens cDNARC_AA192765_atclone 629498 3′.zr33d07.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA195718_at665197 3′.zr28b08.s1 Stratagene NT2 neuronal precursor 937230 HomoRC_AA232114_s_atsapiens cDNA clone 664695 3′ similar to gb: L05779 SOLUBLEEPOXIDE HYDROLASE (HUMAN);.zt07h12.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA281770_atIMAGE: 712487 3′.zw59e03.s1 Soares total fetus Nb2HF8 9w Homo sapiensRC_AA430209_atcDNA clone 774364 3′ similar to TR: G1199667 G1199667PROTEIN KINASE C-BINDING PROTEIN ENIGMA;.zx31f03.s1 Soares total fetus Nb2HF8 9w Homo sapiensRC_AA452410_atcDNA clone 788093 3′.aa39g12.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA485115_atIMAGE: 815686 3′.zk85e12.r1 Soares pregnant uterus NbHPU Homo sapiensAA099391_s_atcDNA clone 489646 5′.zo16a05.r1 Stratagene colon (#937204) Homo sapiens cDNAAA131127_atclone 587024 5′ similar to SW: CATX_BOVIN P05689 CATHEPSIN;.zp02c06.r1 Stratagene ovarian cancer (#937219) Homo sapiensAA173505_atcDNA clone 595210 5′ similar to SW: QRI2_YEASTP43124 HYPOTHETICAL 46.1 KD PROTEIN IN PHO2-POL3INTERGENIC REGION. [1];.zt39b07.r1 Soares ovary tumor NbHOT Homo sapiens cDNAAA291786_s_atclone 724693 5′.zu53f10.r1 Soares ovary tumor NbHOT Homo sapiens cDNAAA402971_s_atclone 741739 5′.


[0304] or from a sequence as identified below
56Human mRNA for IgG Fc binding protein, complete cdsD84239_atyv73b09.s1 Soares fetal liver spleen 1NFLS Homo sapiensRC_N54841_atcDNA clone 248345 3′.ya88f04.s1 Home sapiens cDNA clone 68767 3′.RC_T53389_s_atye30d12.s1 Homo sapiens cDNA clone 119255 3′.RC_T98227_atzr97c07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA215379_atIMAGE: 683628 3′.zr81e12.s1 Soares NhHMPu S1 Home sapiens cDNA cloneRC_AA256485_at682126 3′.zt19f03.s1 Soares ovary tumor NbHOT Home sapiens cDNARC_AA290679_atclone 713597 3′ similar to TR: E92665 E92665 AP56;.zw46c01.s1 Soares total fetus Nb2HF8 9w Home sapiensRC_AA425309_atcDNA clone 773088 3′.zw71d04.s1 Soares testis NHT Homo sapiens cDNA cloneRC_AA429655_at781639 3′.aa90h11.s1 Stratagene fetal retina 937202 Homo sapiensRC_AA456981_atcDNA clone 838629 3′ similar to contains Alu repetitive element;.zx70c04.s1 Soares total fetus Nb2HF8 9w Homo sapiensRC_AA461174_atcDNA clone 796806 3′.zd27g09.r1 Soares fetal heart NbHH19W Homo sapiensW61377_atcDNA clone 341920 5′.


[0305] In one embodiment at least one gene is introduced into the tumor cell. In another embodiment at least two genes are introduced into the tumor cell.


[0306] In one aspect of the invention small molecules that either inhibit increased gene expression or their effects or substitute decreased gene expression or their effects, are introduced to the cellular environment or the cells. Application of small molecules to tumor cells may be performed by e.g. local application or intravenous injection or by oral ingestion. Small molecules have the ability to restore function of reduced gene expression in tumor or cancer tissue.


[0307] In another aspect the invention relates to a therapy whereby genes (increase and/or decrease) generally are correlated to disease are inhibited by one or more of the following methods:


[0308] A method for reducing cell tumorigenicity or malignancy of a cell, said method comprising


[0309] obtaining at least one nucleotide probe capable of hybridising with at least one gene of a tumor cell, said at least one gene being selected from genes being expressed in an amount at least one-fold lower in normal cells than the amount expressed in said tumor cell, and


[0310] introducing said at least one nucleotide probe into the tumor cell in a manner allowing the probe to hybridise to the at least one gene, thereby inhibiting expression of said at least one gene. This method is preferably based on anti-sense technology, whereby the hybridisation of said probe to the gene leads to a downregulation of said gene.


[0311] The down-regulation may of course also be based on a probe capable of hybridising to regulatory components of the genes in question, such as promoters.


[0312] The probes are preferably selected from probes capable of hybridising to a nucleotide sequence comprising a sequence as identified below
57Homo sapiens mRNA for CC chemokine, complete cds.AB000221_atHuman fetal brain cDNA 3′-end GEN-097D06.RC_D60296_atHuman fetal brain cDNA 3′-end GEN-132E11.RC_D60813_atyg71a11.s1 Homo sapiens cDNA clone 38542 3′.RC_R49708_s_atH. sapiens partial cDNA sequence; clone c-02a08.RC_Z38182_ataa38e07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA456821_atIMAGE: 815556 3′;ae53d05.s1 Stratagene lung carcinoma 937218 Homo sapiensRC_AA608545_atcDNA clone 950601 3′.ae58g12.s1 Stratagene lung carcinoma 937218 Homo sapiensRC_AA620553_s_atcDNA clone 951142 3′.cp3087.seq.F Fetal heart, Lambda ZAP Express Homo sapiensAA095119_atcDNA 5′.


[0313] or from
58yn53b04.s1 Homo sapiens cDNA clone 172111 3′.RC_H20269_atH. sapiens partial cDNA sequence; clone c-2ea12.RC_Z40715_atzm79a11.s1 Stratagene neuroepithelium (#937231) Homo sapiensRC_AA116036_atcDNA clone 531836 3′.zn92a08.s1 Stratagene lung carcinoma 937218 Homo sapiensRC_AA133250_atcDNA clone 565622 3′.


[0314] or from a sequence as identified below
59Human threonyl-tRNA synthetase mRNA, complete cdsM63180_atHFBEST-40 Human fetal brain QBoqin2 Homo sapiens cDNA.N89563_s_atHuman fetal brain cDNA 3′-end GEN-045C11.RC_D80198_atH. sapiens partial cDNA sequence; clone c-0kf11.RC_F01986_f_atyn51g07.s1 Homo sapiens cDNA clone 171996 3′.RC_H18997_atzn76c11.s1 Stratagene NT2 neuronal precursor 937230 HomoRC_AA101562_atsapiens cDNA clone 564116 3′ similar to contains Alu repetitive.element;.


[0315] or from a sequence as identified below
60Ye73c08.s1 Homo sapiens cDNA clone 123374 3′.RC_R00083_atyj80e01.s1 Homo sapiens cDNA clone 155064 3′.RC_R71391_atSeq2147 Homo sapiens cDNA clone NHB3MK-9 3′.RC_T23991_atYd70f06.s1 Homo sapiens cDNA clone 113603 3′ similar toRC_T79196_atcontains Alu repetitive element;.Zo26a09.s1 Stratagene colon (#937204) Homo sapiens cDNARC_AA130596_atclone 587992 3′.Zx89d06.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA459310_r_atclone 810923 3′.aa48f12.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA490965_atIMAGE: 824207 3′.Human DNA binding protein homolog (DRX) mRNA, partialU88047_atcdsHuman DSC2 mRNA for desmocollins type 2a and 2bX56807_atzi01b10.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiensAA011479_atcDNA clone 429499 5′.EST112387 Aorta endothelial cells Homo sapiens cDNA 5′AA296821_atend.


[0316] or from a sequence as identified below
61zx58c10.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiensAA203639_atcDNA clone 446706 5′ similar to contains Alu repetitive element;.Human prealbumin gene, complete cds.M11844_atzq77f02.s1 Stratagene hNT neuron (#937233) Homo sapiensRC_AA206042_atcDNA clone 647643 3′ similar to contains element MSR1 repetitiveelement;.yz03e04.s1 Homo sapiens cDNA clone 281982 3′.RC_N51097_atyl70f08.s1 Soares infant brain 1NIB Homo sapiens cDNA cloneRC_H05527_at43327 3′.zl05d11.r1 Soares pregnant uterus NbHPU Homo sapiensAA115572_s_atcDNA clone 491445 5′ similar to TR: G895845 G895845 PUTATIVEP64 CLCP PROTEIN.;.yj14b12.s1 Homo sapiens cDNA clone 148703 3′.RC_H12863_atab36e04.r1 Stratagene HeLa cell s3 937216 Homo sapiensAA489287_atcDNA clone 842910 5′.ye49h07.s1 Homo sapiens cDNA clone 121117 3′.RC_T96383_atyq98g12.s1 Homo sapiens cDNA clone 203878 3′.RC_H56453_atzl03h01.s1 Soares pregnant uterus-NbHPU Homo sapiensRC_AA152194_atcDNA clone 491281 3′.H. sapiens partial cDNA sequence; clone c-0ed05.RC_Z38520_atyd06g09.s1 Homo sapiens cDNA clone 25061 3′ similar toRC_R38944_atcontains Alu repetitive element;.zo16e11.s1 Stratagene colon (#937204) Homo sapiens cDNARC_AA133926_atclone 587084 3′.za68f06.s1 Homo sapiens cDNA clone 297731 3′ similar toRC_N69908_f_atgb: X59244 ZINC FINGER PROTEIN 43 (HUMAN);.zo02c02.s1 Stratagene colon (#937204) Homo sapiens cDNARC_AA151945_atclone 566498 3′ similar to contains Alu repetitive element;.SOX5 = Sry-related HMG box gene {alternatively spliced} [human,S83308_attestis, mRNA, 1473 nt]zv11b06.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA406570_at753299 3′.zl67g04.s1 Stratagene colon (#937204) Homo sapiens cDNARC_AA058314_atclone 509718 3′ similar to contains Alu repetitive element;contains element PTR5 repetitive element;.yr31g12.s1 Homo sapiens cDNA clone 206950 3′.RC_R98735_at


[0317] or from a sequence as identified below
62Human mRNA for KIAA0180 gene, partial cdsD80002_atSimilar to none.D82418_atYx59d10.r1 Homo sapiens cDNA clone 266035 5′.N28843_atH. sapiens partial cDNA sequence; clone c-12c11.RC_F02541_atYw65f02.s1 Homo sapiens cDNA clone 257115 3′.RC_N30806_atYh81f02.s1 Homo sapiens cDNA clone 136155 3′RC_R33146_atsimilar to contains Alu repetitive element;.Yf70a09.s1 Homo sapiens cDNA clone 27448 3′.RC_R40166_atYi23g09.s1 Homo sapiens cDNA clone 140128 3′.RC_R65998_atZk05c04.s1 Soares pregnant uterus NbHPRC_AA027823_atHomo sapiens cDNA clone 469638 3′.Zn17a03.s1 Stratagene neuroepithelium NT2RAMIRC_AA084138_at937234 Homo sapiens cDNA clone 547660 3′.Zr13a10.s1 Stratagene hNT neuron (#937233) HomoRC_AA223902_atsapiens cDNA clone 648666 3′.Zv90g02.s1 Soares NhHMPu S1 Homo sapiensRC_AA424524_atcDNA clone 767090 3′.Aa65d11.s1 NCI_CGAP_GCB1RC_AA505136_atHomo sapiens cDNA clone IMAGE: 825813 3′.Zk55g12.r1 Soares pregnant uterus NbHPUAA043223_atHomo sapiens cDNA clone 486790 5′.


[0318] or from a sequence as identified below
63H. sapiens partial cDNA sequence; clone c-1pb12.RC_F03192_atZd87g10.s1 Soares fetal heart NbHH19W Homo sapiensRC_W81552_atcDNA clone 347682 3′.H. sapiens partial cDNA sequence; clone c-10c01.RC_F02470_atzc20b06.s1 Soares senescent fibroblasts NbHSF Homo sapiensRC_W44927_atcDNA clone 322835 3′ similar to PIR: S44218 S44218testin - mouse [1];.yg46b01.s1 Homo sapiens cDNA clone 35626 3′.RC_R45292_atyr47b09.s1 Homo sapiens cDNA clone 208409 3′ similar toRC_H62159_atcontains Alu repetitive element; contains MER15 repetitiveelement;.yf45a10.s2 Homo sapiens cDNA clone 129786 3′.RC_R17059_atym30c10.s1 Homo sapiens cDNA clone 49795 3′.RC_H15259_at29a6 Human retina cDNA randomly primed sublibrary HomoW26376_atsapiens cDNA.H. sapiens mRNA for putative carboxylesteraseY09616_atzw48f02.r1 Soares total fetus Nb2HF8 9w Homo sapiensAA425593_atcDNA clone 773307 5′.zt08e05.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA279980_atIMAGE: 712544 3′.ym62c07.s1 Homo sapiens cDNA clone 163500 3′.RC_H14089_atyg49c02.s1 Homo sapiens cDNA clone 36133 3′.RC_R46079_f_atzc17d10.s1 Soares parathyroid tumor NbHPA Homo sapiensRC_W15360_atcDNA clone 322579 3′ similar to PIR: S39983 S39983 eps8protein - mouse;.Human mRNA for retinoic acid receptor-like proteinX52773_atze75b05.s1 Soares fetal heart NbHH19W Homo sapiensRC_AA053886_s_atcDNA clone 364785 3′ similar to TR: G451330 G451330STEROL REGULATORY ELEMENT BINDING PROTEIN-2.;.zo31a10.s1 Stratagene colon (#937204) Homo sapiens cDNARC_AA143493_atclone 588474 3′.Homo sapiens mRNA; expressed sequence tag; cloneRC_Z98492_atDKFZphsnu1_1b13, 3′ read.H. sapiens partial cDNA sequence.F15201_atyh10f08.s1 Homo sapiens cDNA clone 42872 3′.RC_R61883_at30e12 Human retina cDNA randomly primed sublibrary HomoW26505_atsapiens cDNA.zn53e03.s1 Stratagene muscle 937209 Homo sapiens cDNARC_AA085676_atclone 561916 3′.ze55c07.r1 Soares retina N2b4HR Homo sapiens cDNA cloneAA018804_at362892 5′ similar to SW: RB14_RAT P35287 RAS-RELATED PROTEIN RAB-14. [1];.Human class I histocompatibility antigen-like protein mRNA,U22963_atcomplete cds.yf26d08.s1 Homo sapiens cDNA clone 127983 3′.RC_R09230_atyi25g01.s1 Homo sapiens cDNA clone 140304 3′.RC_R67918_atzu55d04.r1 Soares ovary tumor NbHOT Homo sapiens cDNAAA402119_atclone 741895 5′ similar to TR: G397579 G397579 LL5 MRNA.zn42g07.r1 Stratagene endothelial cell 937223 Homo sapiensAA082171_atcDNA clone 550140 5′.yi89d09.r1 Homo sapiens cDNA clone 146417 5′.R79750_atzw80d04.s1 Soares testis NHT Homo sapiens cDNA cloneRC_AA431773_at782503 3′.zs97a07.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneRC_AA280670_atIMAGE: 711540 3′.EST16378 Aorta endothelial cells, TNF alpha-treated HomoAA303711_atsapiens cDNA 5′ end.zu64g03.r1 Soares testis NHT Homo sapiens cDNA cloneAA400361_at742804 5′.Homo sapiens MDM2-like p53-binding protein (MDMX)AF007111_atmRNA, complete cds.aa59c02.r1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneAA504384_atIMAGE: 825218 5′ similar to contains element MIR repetitiveelementK1565F Fetal heart, Lambda ZAP Express Homo sapiensN88108_atcDNA clone K1565 5′ similar to EST(YD54C09.R1).aa20e01.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA447769_at813816 3′.


[0319] or from a sequence as identified below
64Ze92h01.s1 Soares fetal heart NbHH19W Homo sapiensRC_AA026418_atcDNA clone 366481 3′.Human fetal brain cDNA 3′-end GEN-070G07.RC_D59847_atSeq2287 Homo sapiens cDNA clone Cot250Ft-b4HB3MA-8RC_T24099_at3′.Yh16a10.s1 Homo sapiens cDNA clone 37689 3′.RC_R59292_atZd25e10.s1 Soares fetal heart NbHH19W Homo sapiensRC_W60582_atcDNA clone 341706 3′ similar to gb: M38188 OVARIANGRANULOSA CELL 13.0 KD PROTEIN HGR74 (HUMAN);.Human 5-lipoxygenase activating protein (FLAP) geneM63262_atYc89d05.s1 Homo sapiens cDNA clone 23443 3′.RC_R38678_atZd29g01.r1 Soares fetal heart NbHH19W Homo sapiensW60268_atcDNA clone 342096 5′.Zx80d02.r1 Soares ovary tumor NbHOT Homo sapiens cDNAAA465016_atclone 810051 5′ similar to TR: G1020091 G1020091 NEUROPSIN.;contains element LTR3 repetitive element;.Yd83f04.s1 Homo sapiens cDNA clone 114847 3′.RC_T79842_atZq56g08.s1 Stratagene neuroepithelium (#937231) HomoRC_AA206225_atsapiens cDNA clone 645662 3′.Zx37g02.s1 Soares total fetus Nb2HF8 9w Homo sapiensRC_AA449914_atcDNA clone 788690 3′.H. sapiens partial cDNA sequence; clone c-3bh08.RC_F10211_atzv41f05.s1 Soares ovary tumor NbHOT Homo sapiens cDNARC_AA480109_r_atclone 756225 3′ similar to TR: G498729 G498729 ZINC FINGERPROTEIN;.zl72a06.s1 Stratagene colon (#937204) Homo sapiens cDNARC_AA053102_s_atclone 510130 3′.zw24b11.s1 Soares ovary tumor NbHOT Homo sapiensRC_AA434113_atcDNA clone 770205 3′ similar to contains element TAR1 repetitiveelement;.zw62c02.s1 Soares total fetus Nb2HF8 9w Homo sapiensRC_AA441791_atcDNA clone 774626 3′.yz42c02.s1 Homo sapiens cDNA clone 285698 3′.RC_N67583_atye47b12.s1 Homo sapiens cDNA clone 120863 3′.RC_T96077_atHuman mRNA for KIAA0318 gene, partial cds.AB002316_atze10g07.s1 Soares fetal heart NbHH19W Homo sapiensRC_W96222_atcDNA clone 358620 3′.Human hemopoietic cell protein-tyrosine kinase (HCK) gene,M16591_s_atcomplete cds, clone lambda-a2/1ayz76b12.s1 Homo sapiens cDNA clone 288959 3′.RC_N59808_atH. sapiens partial cDNA sequence; clone c-39g09.RC_F10040_atzx62b09.s1 Soares total fetus Nb2HF8 9w Homo sapiensRC_AA461549_atcDNA clone 796025 3′.zd35d04.s1 Soares fetal heart NbHH19W Homo sapiensRC_W68683_atcDNA clone 342631 3′.zn20d05.s1 Stratagene neuroepithelium NT2RAMI 937234RC_AA084640_atHomo sapiens cDNA clone 547977 3′.HUMGS0007858, Human Gene Signature, 3′-directed cDNAC01169_atsequence.ab04a05.s1 Stratagene fetal retina 937202 Homo sapiensRC_AA491465_atcDNA clone 839792 3′.zd41c07.s1 Soares fetal heart NbHH19W Homo sapiensRC_W67564_s_atcDNA clone 343212 3′.Human beta-1-adrenergic receptor mRNA, complete cds.J03019_s_atyu77b06.s1 Homo sapiens cDNA clone 239795 3′.RC_H80622_atyy15h06.s1 Homo sapiens cDNA clone 271355 3′.RC_N34686_atyg91d08.s1 Homo sapiens cDNA clone 40992 3′.RC_R56066_s_atEST71577 Homo sapiens cDNA 3′ end similar to None.RC_T34611_atzk15e12.s1 Soares pregnant uterus NbHPU Homo sapiensRC_AA031373_s_atcDNA clone 470638 3′.Human mRNA for spi-1 proto-oncogeneX52056_atyz89g12.r1 Homo sapiens cDNA clone 290278 5′.N77564_atHUMGS0003713, Human Gene Signature, 3′-directed cDNAC01765_atsequence.ae32d03.s1 Gessler Wilms tumor Homo sapiens cDNA cloneRC_AA496936_at897509 3′.zk04e03.s1 Soares pregnant uterus NbHPU Homo sapiensRC_AA027103_atcDNA clone 469564 3′.yg32c11.s1 Homo sapiens cDNA clone 34089 3′.RC_R44131_atyz48f04.s1 Homo sapiens cDNA clone 286303 3′.RC_N67227_atye52f03.s1 Homo sapiens cDNA clone 121373 3′.RC_T96677_atzo23g05.s1 Stratagene colon (#937204) Homo sapiens cDNARC_AA134965_i_atclone 587768 3′.yd87d10.s1 Homo sapiens cDNA clone 115219 3′.RC_T86600_atzf51f03.s1 Soares retina N2b4HR Homo sapiens cDNA cloneRC_AA054087_at380477 3′.zv76b10.r1 Soares total fetus Nb2HF8 9w Homo sapiensAA444374_atcDNA 5′.ys04f01.s1 Homo sapiens cDNA clone 213817 3′ similar toRC_H72357_atgb: J04970 CARBOXYPEPTIDASE M PRECURSOR (HUMAN);contains Alu repetitive element;.ze37d11.s1 Soares retina N2b4HR Homo sapiens cDNA cloneRC_AA017045_at361173 3′.zi09c03.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiensAA010324_atcDNA clone 430276 5′.zs38b09.s1 Soares NhHMPu S1 Homo sapiens cDNA cloneRC_AA234743_at687449 3′.zf20d06.s1 Soares fetal heart NbHH19W Homo sapiensRC_AA055892_atcDNA clone 377483 3′.zw89g02.s1 Soares total fetus Nb2HF8 9w Homo sapiensRC_AA446650_atcDNA clone 784178 3′.ys80e03.r1 Homo sapiens cDNA clone 221116 5′.H91747_s_atzu63c08.r1 Soares testis NHT Homo sapiens cDNA cloneAA401510_s_at742670 5′.zd31d10.s1 Soares fetal heart NbHH19W Homo sapiensRC_W61239_atcDNA clone 342259 3′.


[0320] In another embodiment the probes consists of the sequences identified above.


[0321] The hybridization may be tested in vitro at conditions corresponding to in vivo conditions. Typically, hybridization conditions are of low to moderate stringency. These conditions favour specific interactions between completely complementary sequences, but allow some non-specific interaction between less than perfectly matched sequences to occur as well. After hybridization, the nucleic acids can be “washed” under moderate or high conditions of stringency to dissociate duplexes that are bound together by some non-specific interaction (the nucleic acids that form these duplexes are thus not completely complementary).


[0322] As is known in the art, the optimal conditions for washing are determined empirically, often by gradually increasing the stringency. The parameters that can be changed to affect stringency include, primarily, temperature and salt concentration. In general, the lower the salt concentration and the higher the temperature the higher the stringency. Washing can be initiated at a low temperature (for example, room temperature) using a solution containing a salt concentration that is equivalent to or lower than that of the hybridization solution. Subsequent washing can be carried out using progressively warmer solutions having the same salt concentration. As alternatives, the salt concentration can be lowered and the temperature maintained in the washing step, or the salt concentration can be lowered and the temperature increased. Additional parameters can also be altered. For example, use of a destabilizing agent, such as formamide, alters the stringency conditions.


[0323] In reactions where nucleic acids are hybridized, the conditions used to achieve a given level of stringency will vary. There is not one set of conditions, for example, that will allow duplexes to form between all nucleic acids that are 85% identical to one another; hybridization also depends on unique features of each nucleic acid. The length of the sequence, the composition of the sequence (for example, the content of purine-like nucleotides versus the content of pyrimidine-like nucleotides) and the type of nucleic acid (for example, DNA or RNA) affect hybridization. An additional consideration is whether one of the nucleic acids is immobilized (for example on a filter).


[0324] An example of a progression from lower to higher stringency conditions is the following, where the salt content is given as the relative abundance of SSC (a salt solution containing sodium chloride and sodium citrate; 2×SSC is 10-fold more concentrated than 0.2×SSC). Nucleic acids are hybridized at 42° C. in 2×SSC/0.1% SDS (sodium dodecylsulfate; a detergent) and then washed in 0.2×SSC/0.1% SDS at room temperature (for conditions of low stringency); 0.2×SSC/0.1% SDS at 42° C. (for conditions of moderate stringency); and 0.1×SSC at 68° C. (for conditions of high stringency). Washing can be carried out using only one of the conditions given, or each of the conditions can be used (for example, washing for 10-15 minutes each in the order listed above). Any or all of the washes can be repeated. As mentioned above, optimal conditions will vary and can be determined empirically.


[0325] In another aspect a method of reducing tumoregeneicity relates to the use of antibodies against an expression product of a cell from the biological tissue. The antibodies may be produced by any suitable method, such as a method comprising the steps of


[0326] obtaining expression product(s) from at least one gene said gene being expressed as defined above for oncogenes,


[0327] immunising a mammal with said expression product(s) obtaining antibodies against the expression product.


[0328] Use


[0329] The methods described above may be used for producing an assay for diagnosing a biological condition in animal tissue, or for identification of the origin of a piece of tissue. Further, the methods of the invention may be used for prediction of a disease course and treatment response.


[0330] Furthermore, the invention relates to the use of a peptide as defined above for preparation of a pharmaceutical composition for the treatment of a biological condition in animal tissue.


[0331] Furthermore, the invention relates to the use of a gene as defined above for preparation of a pharmaceutical composition for the treatment of a biological condition in animal tissue.


[0332] Also, the invention relates to the use of a probe as defined above for preparation of a pharmaceutical composition for the treatment of a biological condition in animal tissue.


[0333] Gene Delivery Therapy


[0334] The genetic material discussed above for may be any of the described genes or functional parts thereof. The constructs may be introduced as a single DNA molecule encoding all of the genes, or different DNA molecules having one or more genes. The constructs may be introduced simultaneously or consecutively, each with the same or different markers.


[0335] The gene may be linked to the complex as such or protected by any suitable system normally used for transfection such as viral vectors or artificial viral envelope, liposomes or micellas, wherein the system is linked to the complex.


[0336] Numerous techniques for introducing DNA into eukaryotic cells are known to the skilled artisan. Often this is done by means of vectors, and often in the form of nucleic acid encapsidated by a (frequently virus-like) proteinaceous coat. Gene delivery systems may be applied to a wide range of clinical as well as experimental applications.


[0337] Vectors containing useful elements such as selectable and/or amplifiable markers, promoter/enhancer elements for expression in mammalian, particularly human, cells, and which may be used to prepare stocks of construct DNAs and for carrying out transfections are well known in the art. Many are commercially available.


[0338] Various techniques have been developed for modification of target tissue and cells in vivo. A number of virus vectors, discussed below, are known which allow transfection and random integration of the virus into the host. See, for example, Dubensky et al. (1984) Proc. Natl. Acad. Sci. USA 81:7529-7533; Kaneda et al., (1989) Science 243:375-378; Hiebert et al. (1989) Proc. Natl. Acad. Sci. USA 86:3594-3598; Hatzoglu et al., (1990) J. Biol. Chem. 265:17285-17293; Ferry et al. (1991) Proc. Natl. Acad. Sci. USA 88:8377-8381. Routes and modes of administering the vector include injection, e.g intravascularly or intramuscularly, inhalation, or other parenteral administration.


[0339] Advantages of adenovirus vectors for human gene therapy include the fact that recombination is rare, no human malignancies are known to be associated with such viruses, the adenovirus genome is double stranded DNA which can be manipulated to accept foreign genes of up to 7.5 kb in size, and live adenovirus is a safe human vaccine organisms.


[0340] Another vector which can express the DNA molecule of the present invention, and is useful in gene therapy, particularly in humans, is vaccinia virus, which can be rendered non-replicating (U.S. Pat. Nos. 5,225,336; 5,204,243; 5,155,020; 4,769,330).


[0341] Based on the concept of viral mimicry, artificial viral envelopes (AVE) are designed based on the structure and composition of a viral membrane, such as HIV-1 or RSV and used to deliver genes into cells in vitro and in vivo. See, for example, U.S. Pat. No. 5,252,348, Schreier H. et al., J. Mol. Recognit., 1995, 8:59-62; Schreier H et al., J. Biol. Chem., 1994, 269:9090-9098; Schreier, H., Pharm. Acta Helv. 1994, 68:145-159; Chander, R et al. Life Sci., 1992, 50:481-489, which references are hereby incorporated by reference in their entirety. The envelope is preferably produced in a two-step dialysis procedure where the “naked” envelope is formed initially, followed by unidirectional insertion of the viral surface glycoprotein of interest. This process and the physical characteristics of the resulting AVE are described in detail by Chander et al., (supra). Examples of AVE systems are (a) an AVE containing the HIV-1 surface glycoprotein gp160 (Chander et al., supra; Schreier et al., 1995, supra) or glycosyl phosphatidylinositol (GPI)-linked gp120 (Schreier et al., 1994, supra), respectively, and (b) an AVE containing the respiratory syncytial virus (RSV) attachment (G) and fusion (F) glycoproteins (Stecenko, A. A. et al., Pharm. Pharmacol. Left. 1:127-129 (1992)). Thus, vesicles are constructed which mimic the natural membranes of enveloped viruses in their ability to bind to and deliver materials to cells bearing corresponding surface receptors.


[0342] AVEs are used to deliver genes both by intravenous injection and by instillation in the lungs. For example, AVEs are manufactured to mimic RSV, exhibiting the RSV F surface glycoprotein which provides selective entry into epithelial cells. F-AVE are loaded with a plasmid coding for the gene of interest, (or a reporter gene such as CAT not present in mammalian tissue).


[0343] The AVE system described herein in physically and chemically essentially identical to the natural virus yet is entirely “artificial”, as it is constructed from phospholipids, cholesterol, and recombinant viral surface glycoproteins. Hence, there is no carry-over of viral genetic information and no danger of inadvertant viral infection. Construction of the AVEs in two independent steps allows for bulk production of the plain lipid envelopes which, in a separate second step, can then be marked with the desired viral glycoprotein, also allowing for the preparation of protein cocktail formulations if desired.


[0344] Another delivery vehicle for use in the present invention are based on the recent description of attenuated Shigella as a DNA delivery system (Sizemore, D. R. et al., Science 270:299-302 (1995), which reference is incorporated by reference in its entirety). This approach exploits the ability of Shigellae to enter epithelial cells and escape the phagocytic vacuole as a method for delivering the gene construct into the cytoplasm of the target cell. Invasion with as few as one to five bacteria can result in expression of the foreign plasmid DNA delivered by these bacteria.


[0345] A preferred type of mediator of nonviral transfection in vitro and in vivo is cationic (ammonium derivatized) lipids. These positively charged lipids form complexes with negatively charged DNA, resulting in DNA charged neutralization and compaction. The complexes endocytosed upon association with the cell membrane, and the DNA somehow escapes the endosome, gaining access to the cytoplasm. Cationic lipid:DNA complexes appear highly stable under normal conditions. Studies of the cationic lipid DOTAP suggest the complex dissociates when the inner layer of the cell membrane is destabilized and anionic lipids from the inner layer displace DNA from the cationic lipid. Several cationic lipids are available commercially. Two of these, DMRI and DC-cholesterol, have been used in human clinical trials. First generation cationic lipids are less efficient than viral vectors. For delivery to lung, any inflammatory responses accompanying the liposome administration are reduced by changing the delivery mode to aerosol administration which distributes the dose more evenly.


[0346] Drug Screening


[0347] Genes identified as changing in various stages of bladder cancer can be used as markers for drug screening. Thus by treating bladder cancer cells with test compounds or extracts, and monitoring the expression of genes identified as changing in the progression of bladder cancers, one can identify compounds or extracts which change expression of genes to a pattern which is of an earlier stage or even of normal bladder mucosa.


[0348] It is also within the scope of the invention to use small molecules in drug screening.


[0349] The following are non-limiting examples illustrating the present invention.


[0350] Experimentals


[0351] Affymetrix GeneChip Expression Analysis cRNA Preparation


[0352] 10 μg total RNA was used as starting material for the cDNA preparation. The first and second strand cDNA synthesis was performed using the SuperScript Choice System (Life Technologies) according to the manufacturers instructions except using a oligo-dT primer containing a T7 RNA polymerase promoter site. Labeled cRNA was prepared using the BioArray High Yield RNA Transcript Labeling Kit (ENZO). Biotin labeled CTP and UTP (Enzo) were used in the reaction together with unlabeled NTP's. Following the IVT reaction, the unincorporated nucleotides were removed using RNeasy columns (Qiagen).


[0353] Array Hybridization and Scanning


[0354] Fifteen μg of cRNA was fragmented at 94° C. for 35 min in a fragmentation buffer containing 40 mM Tris-acetate pH 8.1, 100 mM KOAc, 30 mM MgOAc. Prior to hybridization, the fragmented cRNA in a 6×SSPE-T hybridization buffer (1 M NaCl, 10 mM Tris pH 7.6, 0.005% Triton), was heated to 95° C. for 5 min and subsequently to 40° C. for 5 min before loading onto the Affymetrix probe array cartridge. The probe array was then incubated for 16 h at 45° C. at constant rotation (60 rpm). The washing and staining procedure was performed in the Affymetrix Fluidics Station. The probe array was exposed to 10 washes in 6×SSPE-T at 25° C. followed by 4 washes in 0.5×SSPE-T at 50° C. The biotinylated cRNA was stained with a streptavidin-phycoerythrin conjugate, final concentration 2 μg/μl (Molecular Probes, Eugene, Oreg.) in 6×SSPE-T for 30 min at 25° C. followed by 10 washes in 6×SSPE-T at 25° C. An antibody amplification step was added using normal goat IgG final concentration 0.1 mg/ml (Sigma) and Anti-streptavidin antibody (goat) biotinylated final concentration 3 μg/ml. (Vector Laboratories). This was followed by a staining step with a streptavidin-phycoerythrin conjugate, final concentration 2 μg/μl (Molecular Probes, Eugene, Oreg.) in 6×SSPE-T for 30 min at 25° C. and 10 washes in 6×SSPE-T at 25° C.


[0355] The probe arrays were scanned at 560 nm using a confocal laser-scanning microscope with an argon ion laser as the excitation source, (Hewlett Packard GeneArray Scanner G2500A). The readings from the quantitative scanning were analysed by the Affymetrix Gene Expression Analysis Software. For comparison from array to array, these were scaled to a global intensity of 150, as previously published (Zhu, H., Cong, J. P., Mamtora, G., Gingeras, T., and Shenk, T. Cellular gene expression altered by human cytomegalovirus: Global monitoring with oligonucleotide arrays. Proc. Natl Acad USA, 95:14470-75,1998).


[0356] A spreadsheat approach using the fold change of gene level and the scoring of presence or absence of genes was used to sort genes in the different categories.


[0357] Western Blotting Analysis


[0358] Ten μl diluted protein marker (ECL protein molecular marker, Amersham) were used. The samples were electrophoresed at 200 V for 50 min in an X-CELL system (Novex). Then the proteins were transferred to a PVDF membrane at 30 V for 1 hour followed by blocking for 1 hour. The membrane was subsequently washed in 3×10 min in PBS buffer pH 7.4+0.1% Tween 20. The membrane was incubated with polyclonal antibodies, against peptides derived from two genes with accession numbers Z40715 and AA116036, overnight at 4° C. The membrane was then washed 3×10 min in PBS buffer pH 7.4+0.1% Tween 20, followed by incubation for 1 hour with a biotinylated streptavidin horseradish peroxidase complex. The detection reagent (ECL+Western blotting detection system, Amersham) was applied for 5 min. Finally, the membrane was wrapped in plastic, sealed, and scanned in a Phosphorimager, STORM 840 (Molecular Dynamics, Amersham Pharmacia, Sweden).


[0359] Quantitative PCR Analysis Using Light Cycler (Roche™).


[0360] Quantitative PCR analysis was performed as described in the manufacturers instructions and as described in (Morrison et al (1998) Biotechniques 24 (6):954-962.). The quantitation was in all cases related to GAPDH. Ten samples was used in the quantitation experiment: Four T2-4 bladder tumor samples, four Ta bladder tumor samples, and two normal bladder samples.


[0361] For verification of expression levels by another method quantitative PCR based on a light cycler was made on three genes using Normal, Ta and T2 biopsy material. RNA was amplified and the data shown in the table below (Table XX) were obtained. It shows that a similar finding as made with the arrays were made using the light cycler. Genes that varied between normal and tumor samples and between tumor samples were reproduced by this independent method, showing the validity of the data. Due to the high number of genes only a few were selected for this reproducibility study, as a proof of principle.
65Quantitative PCR analysisCategory GeneChip:Upregulated inUpregulated inUpregulated intumorInvasive tumorstumorAccession #:AA101562AA417030H20264RNARelativeRelativeRelativesamplesexpressionexpressionexpressionT2-4 #15.324.80T2-4 #212.030.55.8T2-4 #31.063.80.8T2-4 #412.16.84.8Ta #14.814.26.8Ta #26.121.75.4Ta #37.72.20.9Ta #49.89.02.4Normal #1AbsentAbsentAbsentNormal #2AbsentAbsentAbsentAverage T2-47.631.52.9Average Ta7.111.73.9Average NormalAbsentAbsentAbsent


[0362] To correlate between RNA levels and protein levels western blots based on antibodies raised against synthetic peptides selected from the EST sequence was a performed (see FIG. 18). This was done with two EST's and the resulting two antibodies were used for western blotting of solubilized Normal, stage Ta and stage T2 bladder tumors. The experiment showed that similar findings were made using this protein apporoach. The level of proteins was much higher and more consistent in the tumor tissue than in the normal tissue, often being absent from normal tissue. Due to the high number of EST's only two were selected for this antibody based verification of the proteins (see FIG. 18). It should be regarded as a proof of principle.


Claims
  • 1. A method of determining the presence or absence of a biological condition in animal tissue comprising collecting a sample comprising cells from the tissue and/or expression products from the cells, assaying a first expression level of at least one gene from a first gene group, wherein the gene from the first gene group is selected from genes expressed in normal tissue cells in an amount higher than expression in biological condition cells, and/or assaying a second expression level of at least one gene from a second gene group, wherein the second gene group is selected from genes expressed in a normal tissue cells in an amount lower than expression in biological condition cells, correlating the first expression level to a standard expression for normal tissue, and/or the second expression level to a standard expression level for biological condition cells to determine the presence or absence of a biological condition in the animal tissue.
  • 2. The method of claim 1, wherein the animal tissue is selected from body organs.
  • 3. The method of claim 2, wherein the animal tissue is selected from epithelial tissue in body organs.
  • 4. The method of claim 3, wherein the animal tissue is selected from epithelial tissue in the urinary bladder.
  • 5. The method according to claim 4, wherein the animal tissue is mucosa.
  • 6. The method of any of the preceding claims, wherein the biological condition is an adenocarcinoma, a carcinoma, a teratoma, a sarcoma, and/or a lymphoma and/or carcinoma-in-situ, and/or dysplasia-in-situ.
  • 7. The method of any of the preceding claims, wherein the sample is a biopsy of the tissue or of metastasis originating from said tissue.
  • 8. The method according to any of the preceding claim 1-6, wherein the sample is a cell suspension made from the tissue.
  • 9. The method according to any of the preceding claims, wherein the sample comprises substantially only cells from said tissue.
  • 10. The method according to claim 9, wherein the sample comprises substantially only cells from mucosa or tumors derived from said mucosa cells.
  • 11. The method according to any of the claims 3-10, wherein the gene from the first gene group is selected individually from genes comprising a sequence as identified below
  • 12. The method according to claim 11, wherein the gene from the first gene group is selected individually from genes comprising a sequence as identified below
  • 13. The method according to claim 12, wherein the gene from the first gene group is selected individually from genes comprising a sequence as identified below
  • 14. The method according to claim 13, wherein the gene from the first gene group is selected individually from genes comprising a sequence as identified below
  • 15. The method according to any of claims 4-14, wherein the second gene group are selected individually from genes comprising a sequence as identified below
  • 16. The method according to any of claims 4-15, wherein the second gene group are selected individually from genes comprising a sequence as identified below
  • 17. The method according to any of claims 4-14, wherein the second gene group are selected individually from genes comprising a sequence as identified below
  • 18. The method according to any of claims 4-17, wherein the second gene group comprises a sequence as identified below
  • 19. The method according to any of the preceding claims, wherein the expression level of at least one gene from the first gene group is determined.
  • 20. The method according to any of the preceding claims, wherein the expression level of at least two genes from the first gene group are determined.
  • 21. The method according to any of the preceding claims, wherein the expression level of at least three genes from the first gene group are determined.
  • 22. The method according to any of the preceding claims, wherein the expression level of at least four genes from the first gene group are determined.
  • 23. The method according to any of the preceding claims, wherein the expression level of at least five genes from the first gene group are determined.
  • 24. The method according to any of the preceding claims, wherein the expression level of more than six genes from the first gene group are determined.
  • 25. The method according to any of the preceding claims, wherein the expression level of at least one gene from the second gene group is determined.
  • 26. The method according to any of the preceding claims, wherein the expression level of at least two genes from the second gene group are determined.
  • 27. The method according to any of the preceding claims, wherein the expression level of at least three genes from the second gene group are determined.
  • 28. The method according to any of the preceding claims, wherein the expression level of at least four genes from the second gene group are determined.
  • 29. The method according to any of the preceding claims, wherein the expression level of at least five genes from the second gene group are determined.
  • 30. The method according to any of the preceding claims, wherein the expression level of more than six genes from the second gene group are determined.
  • 31. The method according to any of the preceding claims, wherein the difference in expression level of a gene from one group to the expression level of a gene from another group is at least two-fold.
  • 32. The method according to any of the preceding claims, wherein the difference in expression level of a gene from one group to the expression level of a gene from another group is at least three-fold.
  • 33. The method according to any of the preceding claims, wherein the expression level is determined by determining the mRNA of the cells.
  • 34. The method according to any of the claims 1-32, wherein the expression level is determined by determining expression products, such as peptides, in the cells.
  • 35. The method according to claim 34, wherein the expression level is determined by determining expression products, such as peptides, in the body fluids, such as blood, serum, plasma, faeces, mucus, sputum, cerebrospinal fluid, and/or urine.
  • 36. A method of determining the stage of a biological condition in animal tissue, comprising collecting a sample comprising cells from the tissue, assaying the expression of at least, a first stage gene from a first stage gene group and/or at least a second stage gene from a second stage gene group, wherein at least one of said genes is expressed in said first stage of the condition in a higher amount than in said second stage, and the other gene is a expressed in said first stage of the condition in a lower amount than in said second stage of the condition, correlating the expression level of the assessed genes to a standard level of expression determining the stage of the condition.
  • 37. The method according to claim 36, wherein the tissue is selected from the epithelial tissue in bladder.
  • 38. The method according to any of the preceding claims 36-37, wherein the difference in expression levels between a gene from one group to a gene from another group is at least one-fold.
  • 39. The method according to any of the preceding claims 36-38, wherein the difference in expression levels between a gene from one group to a gene from another group is at least two-fold.
  • 40. The method according to claim 36, wherein the stage is selected from bladder cancer stages Ta, T1, T2, T3 and T4.
  • 41. The method according to claim 40, comprising assaying at least the expression of a Ta stage gene from a Ta stage gene group, at least one T1 stage gene from a T1 stage gene group, at least a T2 stage gene from a T2 stage gene group, at least a T3 stage gene from a T3 stage gene group, at least a T4 stage gene group from a T4 stage gene group, wherein at least one gene from each gene group is expressed in a significantly different amount in that stage than in one of the other stages.
  • 42. The method according to claim 41, wherein at least one gene from each gene group is expressed in a significantly higher amount in that stage than in one of the other stages.
  • 43. The method according to claim 42, wherein a Ta stage gene is selected individually from any gene comprising a sequence as identified below
  • 44. The method according to claim 42, wherein a T1 stage gene is selected individually from any gene comprising a sequence as identified below
  • 45. The method according to claim 42, wherein a T2 stage gene is selected individually from any gene comprising a sequence as identified below wherein the notation refers to Accession No. in the database UniGene (Build 18). 82RC_AA054726_atzk68e06.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 488002 3′.RC_AA206042_atzq77f02.s1 Stratagene hNT neuron (#937233) Homosapiens cDNA clone 647643 3′ similar to contains elementMSR1 repetitive element;.RC_R98735_atyr31g12.s1 Homo sapiens cDNA clone 206950 3′.AA115572_s_atzl05d11.r1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 491445 5′ similar to TR: G895845G895845 PUTATIVE P64 CLCP PROTEIN,;.AA430979_atPMY0789 KG1a Lambda Zap Express cDNA LibraryHomo sapiens cDNA 5′.AA489287_atab36e04.r1 Stratagene HeLa cell s3 937216 Homo sapienscDNA clone 842910 5′.D82226_s_atsimilar to TAT-binding protein-2.H49499_s_atyq20g10.r1 Soares fetal liver spleen 1NFLS Homo sapienscDNA clone 274386 5′.M11844_atHuman prealbumin gene, complete cds.RC_AA026388_atze92c03.s1 Soares fetal heart NbHH19W Homo sapienscDNA clone 366436 3′.RC_AA044601_atzk55d05.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 486729 3′.RC_AA182030_atzp57a03.s1 Stratagene endothelial cell 937223 Homosapiens cDNA clone 624268 3′.RC_AA233451_atzr30b02.s1 Stratagene NT2 neuronal precursor 937230Homo sapiens cDNA clone 664875 3′.RC_AA236493_atzr75c10.s1 Soares NhHMPu S1 Homo sapiens cDNAclone 669234 3′.RC_AA401098_f_atzu50g01.s1 Soares ovary tumor NbHOT Homo sapienscDNA clone 741456 3′ similar to contains Alu repetitiveelement; contains element THR repetitive element;.RC_AA441818_atzw62f01.s1 Soares total fetus Nb2HF8 9w Homo sapienscDNA clone 774649 3′.RC_AA478109_atzt89d04.s1 Soares testis NHT Homo sapiens cDNA clone729511 3′.RC_AA481430_atzv06g11.s1 Soares NhHMPu S1 Homo sapiens cDNAclone 752900 3′.RC_AA488878_ataa55f02.s1 NCI_CGAP_GCB1 Homo sapiens cDNA cloneIMAGE: 824859 3′.RC_AA599032_atae41h03.s1 Gessler Wilms tumor Homo sapiens cDNAclone 898421 3′.S73288_atsmall proline-rich protein SPRK [human, odontogenickeratocysts, mRNA Partial, 317 nt].U87459_atHuman autoimmunogenic cancer/testis antigen NY-ESO-1 mRNA, complete cdsU88047_atHuman DNA binding protein homolog (DRX) mRNA, partialcdsRC_AA063574_atze25f03.s1 Soares fetal heart NbHH19W Homo sapienscDNA clone 360029 3′ similar to gb: X52104 P68 PROTEIN(HUMAN);.RC_AA132524_atzo20c04.s1 Stratagene colon (#937204) Homo sapienscDNA clone 587430 3′ similar to contains Alu repetitive element;.RC_F09317_atH. sapiens partial cDNA sequence; clone c-2zh11.RC_H12863_atyj14b12.s1 Homo sapiens cDNA clone 148703 3′.RC_N33927_s_atyv25e09.s1 Homo sapiens cDNA clone 243784 3′.RC_R08189_atyf18f03.s1 Homo sapiens cDNA clone 127229 3′.RC_R39191_s_atyc89c12.s1 Homo sapiens cDNA clone 23345 3′.RC_T82323_atAS322 Homo sapiens cDNA clone AS322 3′.RC_T90746_atyd41f10.s1 Homo sapiens cDNA clone 110827 3′.RC_Z39338_atH. sapiens partial cDNA sequence; clone c-17f11.or a sequence as identified below 83AA011479_atzi01b10.r1 Soares fetal liver spleen 1NFLS S1 Homosapiens cDNA clone 429499 5′.AA314779_atEST186601 Colon carcinoma (HCC) cell line II Homosapiens cDNA 5′ end.RC_AA084640_atzn20d05.s1 Stratagene neuroepithelium NT2RAMI937234 Homo sapiens cDNA clone 547977 3′.RC_AA121534_atzk89d11.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 490005 3′ similar to gb: X79535 TUBULINBETA-2 CHAIN (HUMAN);.RC_AA131047_s_atzo16f05.s1 Stratagene colon (#937204) Homo sapienscDNA clone 587073 3′.RC_AA461549_atzx62b09.s1 Soares total fetus Nb2HF8 9w Homo sapienscDNA clone 796025 3′.RC_AA491465_atab04a05.s1 Stratagene fetal retina 937202 Homo sapienscDNA clone 839792 3′.RC_AA496936_atae32d03.s1 Gessler Wilms tumor Homo sapiens cDNAclone 897509 3′.RC_AA598689_atae49a08.s1 Stratagene lung carcinoma 937218 Homosapiens cDNA clone 950198 3′.W26392_at30g3 Human retina cDNA randomly primed sublibraryHomo sapiens cDNA.RC_AA004887_atzh90g01.s1 Soares fetal liver spleen 1NFLS S1 Homosapiens cDNA clone 428592 3′.RC_AA135153_atzo24g02.s1 Stratagene colon (#937204) Homo sapienscDNA clone 587858 3′.RC_AA197311_s_atzq50e09.s1 Stratagene neuroepithelium (#937231) Homosapiens cDNA clone 645064 3′ similar to gb: M24283INTERCELLULAR ADHESION MOLECULE-1 PRECURSOR(HUMAN);.RC_H80622_atyu77b06.s1 Homo sapiens cDNA clone 239795 3′.RC_N64436_atza33a09.s1 Homo sapiens cDNA clone 294328 3′.RC_N67583_atyz42c02.s1 Homo sapiens cDNA clone 285698 3′.RC_R38678_atyc89d05.s1 Homo sapiens cDNA clone 23443 3′.RC_R56066_s_atyg91d08.s1 Homo sapiens cDNA clone 40992 3′.RC_R59292_atyh16a10.s1 Homo sapiens cDNA clone 37689 3′.RC_T24099_atseq2287 Homo sapiens cDNA clone Cot250Ft-b4HB3MA-8 3′.AA150364_atzl07b03.r1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 491597 5′.AA174185_atPTH207 HTCDL1 Homo sapiens cDNA 5′/3′.AA452353_i_atzx15d05.r1 Soares total fetus Nb2HF8 9w Homo sapienscDNA clone 786537 5′.AB002316_atHuman mRNA for KIAA0318 gene, partial cds.H86858_atys72d05.r1 Homo sapiens cDNA clone 220329 5′.M93119_s_atHuman zinc-finger DNA-binding motifs (IA-1) mRNA.complete cdsR72037_atyj86c09.r1 Homo sapiens cDNA clone 155632 5′.RC_AA004274_atzh97f02.s1 Soares fetal liver spleen 1NFLS S1 Homosapiens cDNA clone 429243 3′ similar to contains elementMER22 repetitive element;.RC_AA004415_atzh89b04.s1 Soares fetal liver spleen 1NFLS S1 Homosapiens cDNA clone 428431 3′.RC_AA007160_at13cDNA30A-3, seq Soares infant brain 1NIB Homo sapienscDNA clone HY18-3 3′.RC_AA053660_atzl74e07.s1 Stratagene colon (#937204) Homo sapienscDNA clone 510372 3′ similar to contains Alu repetitiveelement;.RC_AA252603_atzs14a11.s1 NCI_CGAP_GCB1 Homo sapiens cDNAclone IMAGE: 685148 3′.RC_AA411944_atzu03h01.s1 Soares testis NHT Homo sapiens cDNA clone730801 3′.RC_AA412700_atzu12g03.s1 Soares testis NHT Homo sapiens cDNA clone731668 3′.RC_AA430032_atzw65f05.s1 Soares testis NHT Homo sapiens cDNA clone781089 3′.RC_AA430368_atzw20f06.s1 Soares ovary tumor NbHOT Homo sapienscDNA clone 769859 3′.RC_AA434113_atzw24b11.s1 Soares ovary tumor NbHOT Homo sapienscDNA clone 770205 3′ similar to contains element TAR1repetitive element;.RC_AA441791_atzw62c02.s1 Soares total fetus Nb2HF8 9w Homo sapienscDNA clone 774626 3′.RC_AA449419_atzx05b03.s1 Soares total fetus Nb2HF8 9w Homo sapienscDNA clone 785549 3′.RC_AA449914_atzx37g02.s1 Soares total fetus Nb2HF8 9w Homo sapienscDNA clone 788690 3′.RC_D59847_atHuman fetal brain cDNA 3′-end GEN-070G07.T95813_f_atye45f10.r1 Homo sapiens cDNA clone 120715 5′ similarto gb: V00493_rna1 HEMOGLOBIN ALPHA CHAIN (HUMAN);.W80846_atzd83f05.r1 Soares fetal heart NbHH19W Homo sapienscDNA clone 347265 5′ similar to SW: SYB2_XENLAP47193 SYNAPTOBREVIN 2;.RC_AA031360_s_atzk16f07.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 470725 3′.RC_AA063624_atze87h05.s1 Soares fetal heart NbHH19W Homo sapienscDNA clone 366009 3′ similar to TR: G300372 G300372CELL GROWTH REGULATING NUCLEOLAR PROTEIN,;.RC_AA076238_atzm19e04.s1 Stratagene pancreas (#937208) Homo sapienscDNA clone 526110 3′ similar to contains Alu repetitiveelement;.RC_AA076350_atzm91a02.s1 Stratagene ovarian cancer (#937219) Homosapiens cDNA clone 545258 3′.RC_AA101983_atzk87c02.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 489794 3′.RC_AA151245_atzl40f12.s1 Soares pregnant uterus NbHPU Homo sapienscDNA clone 504431 3′.RC_AA164252_f_atzq46f06.s1 Stratagene hNT neuron (#937233) Homosapiens cDNA clone 632771 3′.RC_AA167006_atzo86b08.s1 Stratagene ovarian cancer (#937219) Homosapiens cDNA clone 593751 3′.RC_AA206225_atzq56g08.s1 Stratagene neuroepithelium (#937231) Homosapiens cDNA clone 645662 3′.RC_D62834_atHuman aorta cDNA 3′-end GEN-330D04.RC_D80981_atHuman fetal brain cDNA 3′-end GEN-121E12.RC_H16772_atym34g02.s1 Homo sapiens cDNA clone 50227 3′.RC_N62522_atyz74f08.s1 Homo sapiens cDNA clone 288807 3′.RC_N68222_atyz56e12.s1 Homo sapiens cDNA clone 287086 3′.RC_T10316_s_atseq1014 Homo sapiens cDNA clone b4HB3MA-COT8-HAP-Ft266 3′.RC_W37382_atzc12c07.s1 Soares parathyroid tumor NbHPA Homo sapienscDNA clone 322092 3′.RC_W60582_atzd25e10.s1 Soares fetal heart NbHH19W Homo sapienscDNA clone 341706 3′ similar to gb: M38188 OVARIANGRANULOSA CELL 13.0 KD PROTEIN HGR74 (HUMAN);.RC_W84768_atzh53d03.s1 Soares fetal liver spleen 1NFLS S1 Homosapiens cDNA clone 415781 3′ similar to contains L1, b1L1 repetitive element;.
  • 46. The method according to claim 41, wherein at least one gene from each gene group is expressed in a significantly lower amount in that stage than in one of the other stages.
  • 47. The method according to claim 46, wherein a Ta stage gene is selected individually from any gene comprising a sequence as identified below
  • 48. The method according to claim 46, wherein a Ti stage gene is selected individually from any gene comprising a sequence as identified below
  • 49. The method according to claim 46, wherein a T2 stage gene is selected individually from any gene comprising a sequence as identified below
  • 50. A method of determining an expression pattern of a bladder cell sample, comprising: collecting sample comprising bladder cells and/or expression products from bladder cells, determining the expression level of at least one gene in the sample, wherein at least one gene belongs to a first group of genes, said gene from the first gene group being expressed in a higher amount in normal tissue than in biological condition cells, and/or wherein at least one other gene belongs to a second group of genes, said gene from the second gene group being expressed in a lower amount in normal tissue than in biological condition cells, and the difference between the expression level of the first gene group in normal cells and biological condition cells being at least two-fold, obtaining an expression pattern of the bladder cell sample.
  • 51. The method according to claim 50, wherein the expression level of at least two genes are determined.
  • 52. The method according to claim 50, wherein the expression level of at least three genes are determined.
  • 53. The method according to claim 50, wherein the expression level of at least four genes are determined.
  • 54. The method according to claim 50, wherein the expression level of at least five genes are determined.
  • 55. The method according to claim 50, wherein the expression level of more than six genes are determined.
  • 56. The method of claims 50-55, wherein the genes exclude genes which are expressed in the submucosal, muscle, or connective tissue, whereby a pattern of expression is formed for the sample which is independent of the proportion of submucosal, muscle, or connective tissue cells in the sample.
  • 57. The method of claim 56, comprising determining the expression level of one or more genes in the sample comprising predominantly submucosal, muscle, and connective tissue cells, obtaining a second pattern, subtracting said second pattern from the expression pattern of the bladder cell sample, forming a third pattern of expression, said third pattern of expression reflecting expression of the bladder mucosa or bladder cancer cells independent of the proportion of submucosal, muscle, and connective tissue cells present in the sample.
  • 58. The method of any of the preceding claims 50-55, wherein the sample is a biopsy of the tissue.
  • 59. The method according to any of the preceding claim 50-58, wherein the sample is a cell suspension.
  • 60. The method according to any of the preceding claims 50-59, wherein the sample comprises substantially only cells from said tissue.
  • 61. The method according to claim 60, wherein the sample comprises substantially only cells from mucosa.
  • 62. The method according to any of the claims 50-59, wherein the gene from the first gene group is selected individually from
  • 63. The method according to claim 62 wherein the gene from the first gene group is selected individually from genes comprising a sequence as identified below
  • 64. The method according to claim 63, wherein the gene from the first gene group is selected individually from genes comprising a sequence as identified below
  • 65. The method according to claim 64, wherein the gene from the first gene group is selected individually from genes comprising a sequence as identified below
  • 66. The method according to any of claims 4-14, wherein the second gene group are selected individually from genes comprising a sequence as identified below
  • 67. The method according to any of claims 40-61, wherein the second gene group are selected individually from genes comprising a sequence as identified below
  • 68. The method according to any of claims 40-61; wherein the second gene group are selected individually from genes comprising a sequence as identified below
  • 69. The method according to any of claims 40-61, wherein the second gene group comprises a sequence as identified below
  • 70. The method according to any of the claims 40-69, wherein the expression level of at least one gene from the first gene group are determined.
  • 71. The method according to any of the claims 40-69, wherein the expression level of at least two genes from the first gene group are determined.
  • 72. The method according to any of the claims 40-69, wherein the expression level of at least three genes from the first gene group are determined.
  • 73. The method according to any of the claims 40-69, wherein the expression level of at least four genes from the first gene group are determined.
  • 74. The method according to any of the claims 40-69, wherein the expression level of at least five genes from the first gene group are determined.
  • 75. The method according to any of the claims 40-69, wherein the expression level of more than six genes from the first gene group are determined.
  • 76. The method according to any of the preceding claims 40-75, wherein the expression level of at least one gene from the second gene group are determined.
  • 77. The method according to any of the preceding claims 40-75, wherein the expression level of at least two genes from the second gene group are determined.
  • 78. The method according to any of the preceding claims 40-75, wherein the expression level of at least three genes from the second gene group are determined.
  • 79. The method according to any of the preceding claims 40-75, wherein the expression level of at least four genes from the second gene group are determined.
  • 80. The method according to any of the preceding claims 40-75, wherein the expression level of at least five genes from the second gene group are determined.
  • 81. The method according to any of the preceding claims 40-75, wherein the expression level of more than six genes from the second gene group are determined.
  • 82. A method of determining an expression pattern of a bladder cell sample independent of the proportion of submucosal, muscle, or connective tissue cells present, comprising: determining the expression of one or more genes in a sample comprising cells, wherein the one or more genes exclude genes which are expressed in the submucosal, muscle, or connective tissue, whereby a pattern of expression is formed for the sample which is independent of the proportion of submucosal, muscle, or connective tissue cells in the sample.
  • 83. The method according to claim 57, comprising determining the expression level of one or more genes in the sample comprising predominantly submucosal, muscle, and connective tissue cells, obtaining a second pattern, subtracting said second pattern from the expression pattern of the bladder cell sample, forming a third pattern of expression, said third pattern of expression reflecting expression of the bladder cells independent of the proportion of submucosal, muscle, and connective tissue cells present in the sample.
  • 84. A method of determining the presence or absence of a biological condition in human bladder tissue comprising, collecting a sample comprising cells from the tissue, determining an expression pattern of the cells as defined in any of claims 57-60, correlating the determined expression pattern to a standard pattern, determining the presence or absence of the biological condition of said tissue.
  • 85. A method for determining the stage of a biological condition in animal tissue comprising, collecting a sample comprising cells from the tissue, determining an expression pattern of the cells as defined in any of claims 40-58, correlating the determined expression pattern to a standard pattern, determining the stage of the biological condition is said tissue.
  • 86. A method for reducing cell tumorigenicity or malignancy of a cell, said method comprising contacting a tumor cell with at least one peptide expressed by at least one gene selected from genes being expressed in an at least two-fold higher amount in normal cells than the amount expressed in said tumor cell.
  • 87. The method according to claim 86, wherein the at least one gene is selected individually from genes comprising a sequence as identified below
  • 88. The method according to claim 86 or 87, wherein the tumor cell is contacted with at least two different peptides.
  • 89. A method for reducing cell tumorigenicity of a cell, said method comprising obtaining at least one gene selected from genes being expressed in an at least two-fold higher amount in normal cells than the amount expressed in said tumor cell, introducing said at least one gene into the tumor cell in a manner allowing expression of said gene(s).
  • 90. The method according to claim 89, where the at least one gene is selected individually from genes comprising a sequence as identified below
  • 91. The method according to claim 89 or 01, wherein at least one gene is introduced into the tumor cell.
  • 92. The method according to claim 89 or 90, wherein at least two different genes are introduced into the tumor cell.
  • 93. A method for reducing cell tumorigenicity or malignancy of a cell, said method comprising obtaining at least one nucleotide probe capable of hybridising with at least one gene of a tumor cell, said at least one gene being selected from genes being expressed in an amount at least one-fold lower in normal cells than the amount expressed in said tumor cell, and introducing said at least one nucleotide probe into the tumor cell in a manner allowing the probe to hybridise to the at least one gene, thereby inhibiting expression of said at least one gene.
  • 94. The method according to claim 93, wherein the nucleotide probe is selected from probes capable of hybridising to a nucleotide sequence comprising a sequence as identified below
  • 95. The method according to claim 93 or 94, wherein at least one gene is introduced into the tumor cell.
  • 96. The method according to claim 93 or 94, wherein at least two different genes are introduced into the tumor cell.
  • 97. A method for producing antibodies against an expression product of a cell from a biological tissue, said method comprising the steps of obtaining expression product(s) from at least one gene said gene being expressed as defined in any of claims 36-45, immunising a mammal with said expression product(s) obtaining antibodies against the expression product.
  • 98. A pharmaceutical composition for the treatment of a biological condition comprising at least one antibody produced as described on claim 97.
  • 99. A vaccine for the prophylaxis or treatment of a biological condition comprising at least one expression product from at least one gene said gene being expressed as defined in any of claims 36-45.
  • 100. Use of a method as defined in any of claims 1-85 for producing an assay for diagnosing a biological condition in animal tissue.
  • 101. Use of a peptide as defined in any of claims 86-88 for preparation of a pharmaceutical composition for the treatment of a biological condition in animal tissue.
  • 102. Use of a gene as defined in any of claims 89-91 for preparation of a pharmaceutical composition for the treatment of a biological condition in animal tissue.
  • 103. Use of a probe as defined in any of claims 89-95 for preparation of a pharmaceutical composition for the treatment of a biological condition in animal tissue.
  • 104. An assay for determining the presence or absence of a biological condition in animal tissue, comprising at least one first marker capable of detecting a first expression level of at least one gene from a first gene group, wherein the gene from the first gene group is selected from genes expressed in normal tissue cells in an amount higher than expression in biological condition cells, and/or at least one second marker capable of detecting a second expression level of at least one gene from a second gene group, wherein the second gene group is selected from genes expressed in normal tissue cells in an amount lower than expression in biological condition cells.
  • 105. The assay according to claim 104, wherein the marker is a nucleotide probe.
  • 106. The assay according to claim 104, wherein the marker is an antibody.
  • 107. The assay according to claim 104, wherein the genes are as defined in any of claims 11-18, 43-45, and 47-50.
  • 108. An assay for determining an expression pattern of a bladder cell, comprising at least a first marker and/or a second marker, wherein the first marker is capable of detecting a gene from a first gene group as defined in claim 50, and/or the second marker is capable of detecting a gene from a second gene group as defined in claim 50.
  • 109. The assay according to claim 108, wherein the first marker is capable of detecting one gene as identified in Table 18, and the second marker is capable of detecting another gene as identified in Table 18.
  • 110. The assay according to claim 109, comprising at least one marker for each gene group, correlating the first expression level and/or the second expression level to a standard level of the assessed genes to determine the presence or absence of a biological condition in the animal tissue.
  • 111. The assay according to claim 110, Wherein the marker is a nucleotide probe.
  • 112. The assay according to claim 110, wherein the marker is an antibody.
  • 113. A method for identifying a tissue sample as being from bladder, comprising subjecting the tissue to a method as identified in any of claims 50-83, determining expression patterns and comparing the expression patterns determined with expression patterns from bladder tissue.
Priority Claims (1)
Number Date Country Kind
PA200001020 Jun 2000 DK
PCT Information
Filing Document Filing Date Country Kind
PCT/DK01/00463 7/2/2001 WO